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1 Preamble 
1 Preamble 
Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by the 
homozygous loss of the survival motor neuron gene 1 (SMN1) (Lefebvre et al., 1995). Motor 
neurons, their axons and distal neuromuscular junctions (NMJs) have been demonstrated to 
be severely affected in SMA, resulting in muscle weakness and atrophy. Next to SMN1, a 
nearly identical copy gene is present in all SMA patients, termed SMN2. Importantly, 
however, a silent c.C280T transition is present in exon 7 of SMN2, causing the disruption of 
an exonic splicing enhancer (ESE) (Lorson et al., 1999, Cartegni and Krainer, 2002). Finally, 
this leads to exon 7 skipping in ~90 % of the transcripts and the production of truncated 
Δ7SMN protein with reduced oligomerization capacity and stability (Lorson et al., 1998). Due 
to genetic drift, the SMN2 copy number is highly variable among the population, ranging from  
zero to a maximum of four copies per allele.  Since ~10 % of SMN2 transcripts still code for 
full length (FL) SMN, SMA severity is inversely correlated with SMN2 copy number (Burghes, 
1997, Brahe, 2000, Feldkotter et al., 2002). 
In the past, so called discordant families have been described in which homozygously 
SMN1-deleted individuals are fully asymptomatic despite carrying an identical number of 
SMN2 copies as their affected siblings. From such observations, it has been concluded that 
other SMA-modifying factors must be present in these patients. In 2008, high levels of the 
actin filament bundling protein PLS3 have been shown to act fully protective in SMN1-
deleted unaffected individuals of six discordant SMA families in our group (Oprea et al., 
2008). Further functional analyzes revealed that PLS3 overexpression is able to rescue axon 
outgrowth defects in Smn-depleted PC12 cells as well as motor neurons derived from SMA 
mice. Most strikingly, however, PLS3 overexpression was able to rescue axon outgrowth 
defects in a zebrafish model of SMA in vivo. 
The main goal of the present work was to study the effects of PLS3 overexpression on a 
mouse model of SMA. For this purpose and using the Cre/loxP system, a V5-tagged version 
of human PLS3 was targeted into the murine Rosa26 locus in order to ubiquitously or tissue 
specific overexpress PLS3. PLS3V5 transgenic mice were next crossed on an SMA 
background. As careful morphological analysis revealed, PLS3V5 overexpression led to clear 
improvements of neuromuscular connectivity at the NMJ level (delayed axonal pruning, 
highly arborized axon terminals, highly occupied Acetylcholine receptor (AChR) clusters, 
increase in the size of AChR clusters). Moreover, motor neuron specific expression of PLS3 
in a wt background was sufficient to increase muscle fiber size in P21 mice, indicating that 
the observed changes at NMJ level are indeed functional.  
The following introduction is subdivided into three parts (2.1, 2.2 and 2.3). The first part 
(2.1) starts with a detailed explanation of the clinical picture of SMA and is then leading to the 
underlying molecular causes of the disease. Based on the knowledge from different animal 
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models, the section continues with a description of SMN protein function with particular focus 
on the role of SMN in axons. Although no cure is available yet, the first section will close with 
a brief overview of potential therapeutic strategies for SMA treatment.  
In the second part of the introduction (2.2), the discovery of PLS3 as a fully protective 
modifier of SMA in homozygously SMN1-deleted individuals of discordant families will be 
described. After a short overview on PLS3 gene and protein structure, PLS3 function will be 
explained, again, with particular focus on PLS3 function in the axon. Finally, recent data on 
other potential modifiers of SMA from invertebrate screens will be discussed. 
As PLS3V5 overexpression led to significant improvements of neuromuscular connectivity 
at NMJ level of SMA mice, the third part of the introduction (2.3) deals with the development 
of the neuromuscular system in general. As PLS3V5 overexpression led to delayed axonal 
pruning, an overview about this fundamental developmental process will be given first. 
Moreover, PLS3V5 overexpression resulted in highly arborized nerve terminals as well as 
increased postsynaptic AChR cluster. Therefore, further information will be presented on the 
mechanisms underlying axon growth as well as AChR cluster patterning, with particular focus 
on the role of actin dynamics in both processes. 
  
 
3 Introduction 
2 Introduction 
2.1 Autosomal recessive proximal spinal muscular atrophy (SMA) – 
Symptoms and classification 
First described in the late 19th century by Werdnig and Hoffmann (University of Vienna 
and Heidelberg, respectively), SMA is the leading genetic cause of infant death today 
(Montes et al., 2009). In the western European population, SMA has an incidence of 1 in 
6.000 to 10.000 births with a carrier frequency of 1:35 (Pearn, 1978, Czeizel and Hamula, 
1989, Emery, 1991, Feldkotter et al., 2002). SMA is caused by the homozygous deletion or 
mutation of the survival motor neuron 1 gene (SMN1) located on chromosome 5q13 
(Brzustowicz et al., 1990, Melki et al., 1990) and results in the degeneration of α-motor 
neurons in the anterior ventral horns of the spinal cord as well as their respective efferent 
axons. As a consequence, affected individuals suffer from progressive weakening of 
muscles. In the severe Type I SMA (see below), first signs of muscle weakening are often 
noticed already during the 3rd trimester of pregnancy as fetal movements decrease 
abnormally (MacLeod et al., 1999). Importantly, the decrease of fetal movements has been 
shown to be accompanied by progressive loss of motor neurons (Markowitz et al., 2004). 
Together, these findings suggest that in severely affected SMA patients the onset of disease 
occurs in utero. The first postnatal symptom common to all severity types is weakening of the 
proximal voluntary muscles, e.g. limb or intercostal muscle of the chest. With ongoing 
progression and depending on the severity type of disease, further symptoms include a weak 
cough, dyspnea and even bulbar involvement (Rudnik-Schöneborn et al., 1994). Although 
diaphragmatic strength is usually intact, weakening of intercostal chest muscles can lead to a 
severely restrictive lung deficit and finally to the need of ventilatory support (Markowitz et al., 
2004). Later symptoms, especially in the less affected Type II, III or IV patients (see below), 
typically include progressive weakening of also the distal muscle. Since muscles of the legs 
are affected first, patients will usually be wheelchair bound or suffer major problems in 
climbing stairs or getting up from the floor. Even though a recent study in mouse indicated 
that cellular proliferation, migration and development in hippocampal regions of the brain 
might be affected patient´s sensation and cognitive abilities usually remain intact (D'Angelo 
and Bresolin, 2006, Wishart et al., 2010).  
The denervation of muscle finally results in atrophy, whereby often a few residual motor 
neurons stay connected. The uncontrolled and sporadic firing of such remaining motor 
neurons leads to twitching (fasciculation), particular of the tongue and fingers, a finding often 
used in diagnosis (Markowitz et al., 2004). When there are additional clinical grounds for 
suspecting a diagnosis of SMA in a newborn, e.g. hypotonia or headlag, DNA based tests 
offer quick and reliable sureness. The two most common methods used for the detection of 
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SMN1 deletions are (i) a PCR based approach with subsequent test restriction (Scheffer et 
al., 2001) or (ii) Multiplex Ligation-dependent Probe Amplification (MLPA) (Scarciolla et al., 
2006, Zapletalova et al., 2007). Since in 5 % of all patients the loss of SMN1 function is 
caused by a deletion of one allele and a small intragenic (subtle) deleterious mutation on the 
second allele or, very infrequently, from subtle mutations on both alleles (Alias et al., 2009, 
Vezain et al., 2011), sometimes sequencing must be recruited to determine the exact cause.   
In the following, the classification of SMA into the four Types I, II, III and IV and their 
characteristics will be briefly outlined.  
 
Type I SMA (Werdnig-Hoffmann disease, MIM #253300): 
Type I SMA, also called the infantile acute form, is the most severe type of SMA and 
accounts for ~50 % of all SMA cases (Werdnig, 1891, Pearn, 1978, Markowitz et al., 2004). 
The onset of disease is usually before the age of 6 months, but often around the time of birth. 
Prognosis for type I SMA patients is poor. In different studies, the survival of patients with 
disease onset in the first three months was determined to ~7 months (Rudnik-Schoneborn et 
al., 2009). The proportion of patients surviving more than 2 years is ~6 % (Cobben et al., 
2008, Rudnik-Schoneborn et al., 2009). SMA type I patients will never be able to sit or even 
walk independently. Proximal intercostal muscles (muscle of the chest) are strongly affected, 
resulting in severe breathing problems and increased infection rate.  
 
Type II SMA (Intermediate form, MIM #253550): 
The onset of type II SMA is between 6 months to 18 years, with most patients being 
diagnosed within the first year to 18 months. Affected children are usually able to sit without 
support, but walking is almost impossible. The prognosis is extremely variable in SMA type II 
patients and depends to a large extent on the degree of respiratory muscle involvement and 
the problems associated with the development of kyphoscoliosis (abnormal curvature of the 
spine) (Talbot, 1999). In a comprehensive study with 240 SMA type II patients the survival 
rate was 98.5 % at 5 years and 68.5 % at 25 years (Zerres et al., 1997). 
 
Type III SMA (Kugelberg-Welander, MIM #253400): 
Type III SMA is a very heterogenous form of SMA with first mild symptoms occurring after 
the first 18 months of life (Kugelberg and Welander, 1956). Most patients are diagnosed 
between 2 and 12 years of age. Typically, walking and running as well as climbing stairs are 
possible, but become increasingly difficult with age. The prognosis for SMA type III patients 
is good since life expectancy is almost normal. Type III SMA is further subclassified into type 
IIIa, with onset before the age of 3 years, and type IIIb SMA, with onset after the 3rd year.   
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SMA Type IV  (Adult form, MIM #271150): 
SMA type IV is a very mild form of SMA with late median onset beyond 30 years of age 
(Pearn, 1978, Zerres et al., 1995). As in all SMA forms, weakness is progressive, but affects 
mostly proximal muscle while distal muscle function is preserved. Type IV patients have a 
normal life expectancy. 
2.1.1 SMN1 and SMN2 as SMA determining genes 
In the year 1995 and after a long search, the survival of motor neuron 1 gene (SMN1) has 
been identified as the SMA causing gene (Lefebvre et al., 1995). SMN1 lies within the 
telomeric part of a 500 kb duplicated region on chromosome 5q13 (Brzustowicz et al., 1990) 
(Figure 1). The SMN1 gene spans a 28 kb genomic region and comprises 9 exons (1, 2a, 2b, 
3, 4, 5, 6, 7, 8). The coding sequence of SMN1 is 882 bp and produces a ~1.7 kb transcript 
(together with 5´and 3´ UTR) which is ubiquitously expressed, but particularly high in spinal 
cord. The mRNA codes for a protein of 294 amino acids having a molecular weight of 38 
kDa. Furthermore, SMN1 was found to be highly conserved between all organisms, 
underlining its essential function (Miguel-Aliaga et al., 1999, Paushkin et al., 2000). 
 
Figure 1: 500 kb telomeric and centromeric region containing SMN1 and its duplicated version 
SMN2, respectively. 
In the centromeric region, a nearly identical copy of SMN1 is located, termed SMN2, 
which has been found to be present in all SMA patients. SMN2 differs from SMN1 by only 5 
silent discrepancies: A synonymous mutation in exon 7 (c.C280T in SMN2), exon 8 (nt 27869 
G>A), intron 6 (nt 27092 G>A) and another two in Intron 7 (nt 27289 A>G and 27404 A>G) 
(Lefebvre et al., 1995, Burglen et al., 1996).  
Already at their discovery, it was found that SMN1 and SMN2 have distinct splicing 
patterns. In humans only carrying SMN1, solely the full length transcript (FL-SMN) containing 
exon 7 was present. However, controls carrying both SMN1 and SMN2 additionally showed a 
transcript lacking exon 7 (Δ7SMN2) (Lefebvre et al., 1995). Based on these observations, it 
was found that the c.C280T transition in exon 7 of SMN2 causes the disruption of an exonic 
splicing enhancer (ESE) (Lorson et al., 1999, Cartegni and Krainer, 2002). This in turn 
results in exon 7 skipping in about 90 % of the total transcripts while 10 % of SMN2 
transcripts are still full length. The skipping of exon 7 leads to a frameshift and an alternative 
stop codon in exon 8. Finally, this produces a truncated protein (Δ7SMN2) of reduced 
oligomerization capacity and stability (Lorson et al., 1998). SMN2 lies within a highly 
repetitive genomic region prone to rearrangements. Therefore, the SMN2 copy number is 
variable among the population. Since still about 10 % of the total SMN2 transcript code for 
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fully functional SMN protein, the SMN2 copy number is inversely correlated with the disease 
phenotype and prognosis (Burghes, 1997, Brahe, 2000, Feldkotter et al., 2002).  
Although not absolute, SMN1 deficient SMA type I patients usually carry 1 or 2 SMN2 
copies, SMA type II patients 2 or 3 and SMA type III patients 3 or 4 copies of SMN2. 
Infrequently, patients are observed that develop the relatively mild SMA type III despite 
having only 2 SMN2 copies. The other way around, type I SMA patients were described 
carrying 3 SMN2 copies. This may be because of true variation caused by modifying genes 
or other external factors, intragenic mutations within SMN2, or SMN2 genes partially deleted 
or duplicated as a result of deletions or gene conversions involving either the 5´ or 3´end of 
the SMN genes (Feldkotter et al., 2002). Moreover, up to now three unrelated patients have 
been described who possessed SMN2 copy numbers that did not correlate with the observed 
mild clinical phenotypes and who all carried a c.G859C substitution in the SMN2 gene (Prior 
et al., 2009, Vezain et al., 2010). In their study, the authors were able to demonstrate that 
this mutation creates a new exonic splicing enhancer favoring exon 7 inclusion and 
consequentially increasing SMN levels in the patients. Therefore, not only the number of 
SMN2 copies can affect the disease severity but also sequence variations within SMN2. 
2.1.2 SMN protein  
SMN is a 294 aa protein of about 38 kDa in size and is encoded by 8 exons (Lefebvre et 
al., 1995). SMN has been shown to be ubiquitously expressed with especially high levels in 
the central nervous system (CNS) and the liver (Liu and Dreyfuss, 1996, Carvalho et al., 
1999, Young et al., 2000, Young et al., 2001). While SMN shows diffuse distribution in the 
cytoplasm, it is present in punctate structures in the nucleus termed gemini of Cajal bodies 
(CBs), or gems (Liu and Dreyfuss, 1996). Gems are often located proximal to or overlapping 
with Cajal bodies (CB), structures that are implicated to play an important role in the nuclear 
biogenesis of spliceosomal small nuclear ribonucleoproteins snRNPs (Darzacq et al., 2002, 
Jady et al., 2003). The SMN protein has several functional domains, including an N-terminal 
RNA-binding-domain (RBD, exon 2b and 3), a Tudor domain involved in Sm protein 
interaction (exon 3), a proline-rich stretch (exon 4 and 5), which can interact with profilin as 
well as a C-terminal YG-box (exon 6 and 2) that is important for self-oligomerization (Lorson 
et al., 1998, Bertrandy et al., 1999, Selenko et al., 2001, Bowerman et al., 2007, Bowerman 
et al., 2009). 
2.1.3 SMN function 
After the current model, SMN has multiple roles in a plethora of cellular processes and 
pathways, however, its most recognized and studied function is in the assembly of small 
nuclear ribonucleoproteins (snRNP), important factors within the spliceosome. As will be 
demonstrated in the results part of this thesis, the modifying factor PLS3V5 positively 
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incluences axonal integrity and nerve connectivity in SMA mice at the level of the 
neuromuscular junction (NMJ). Therefore, a particular focus of this chapter is on the function 
of SMN in axonal transport and growth as well as NMJ maturation. Last but not least, recent 
findings about an involvement of muscle and other non-neuronal tissues in SMA disease will 
be outlined.  
 
I. The SMN complex and its function in snRNP assembly: 
SMN has been shown to play an important role in the assembly of small nuclear 
ribonucleoproteins (snRNPs), important factors within the spliceosome (Fischer et al., 1997, 
Meister et al., 2001, Pellizzoni et al., 2002, Gubitz et al., 2004, Eggert et al., 2006, Burghes 
and Beattie, 2009). snRNPs are important in splice site (ss) recognition and catalytic removal 
of introns from pre-mRNA and consist of a U small nuclear RNA (snRNA) (U1, U2,U4, U5, 
U11 or U12) and a heptameric ring of Sm proteins (D1, D2, E, F, G and D3, B) (Raker et al., 
1999). It was demonstrated in the past that Sm proteins can self-assemble on snRNAs in 
vitro, however, in vivo this process requires the SMN complex (Meister et al., 2001, Meister 
et al., 2002, Pellizzoni et al., 2002, Pellizzoni, 2007). In this conformation the SMN complex, 
containing the assembled snRNPs, is then transferred into the nucleus. There, snRNPs are 
further processed and matured in the gems while the SMN complex translocates out of the 
nucleus again (Chari et al., 2009). The SMN complex (approx. 1 mDa) itself is comprised of 
many factors, which are called gemins due to their subcellular localization similar to that of 
SMN (including gems (Carissimi et al., 2006)). SMN is believed to act as the core backbone 
of the complex, however the exact stoichiometry of SMN and its binding partners is still 
unknown.    
Based on these findings, it is assumed that SMN1-deletion impacts on correct splicing. 
Therefore, attempts have been undertaken to investigate the impact of SMN depletion on 
splicing in an SMA mouse model. Indeed, analysis revealed differences in pathways 
associated with neuronal development as well as cellular injury. Nevertheless, it is hard to 
distinguish between splice or expression changes due to secondary stress reactions, and 
changes that are truly caused by SMN depletion (Zhang et al., 2008b, Baumer et al., 2009). 
 
II. SMN function in translational regulation and axonal transport: 
A function of SMN in translational regulation was suggested based on the observation that 
SMN localizes in granules that are transported along the axons of neurons and that show 
colocalization with ribosomal RNAs (Zhang et al., 2003). Local protein synthesis is important 
for axonal integrity, this fact being in line with the observation that SMN deficient neurons 
show defects in axonal outgrowth and pathfinding (McWhorter et al., 2003, Carrel et al., 
2006, van Bergeijk et al., 2007, Oprea et al., 2008, Holt and Bullock, 2009).  
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The effects of Smn deficiency were also studied in primary motor neuron cultures from 
SMA mice (Rossoll et al., 2003). Even though motor neurons derived from SMA mice 
showed the same survival as wt motor neurons, the axon length was significantly reduced. 
Previous electron microscopic (EM) analyses showed that Smn protein is associated with 
axonal microtubules (Bechade et al., 1999, Pagliardini et al., 2000, Rossoll et al., 2003). 
Furthermore, in murine motor neurons Smn protein colocalized with hnRNP R (Rossoll et al., 
2002), which in turn was shown to associates with β-Actin mRNA. Therefore, it was 
speculated that a complex of Smn and hnRNP R might be involved in axonal β-actin mRNA 
transport or processing (Rossoll et al., 2003). Indeed, hnRNP protein was only present in a 
punctuate pattern along motor axons of SMA mice and, presumably due to defects in 
transport, β-actin protein was severely reduced in the growth cones of such. These results 
suggest that the localization of β-actin mRNA and hnRNP R to growth cones depends on the 
presence of Smn and that cytosceletal defects in the growth cones and axons might 
contribute to SMA pathology (Rossoll et al., 2003). 
Besides hnRNP R, many other interaction partners of SMN were identified in the past that 
have important function in RNA binding or translational regulation, e.g.: hnRNP Q, KH-type 
splicing regulatory protein (KSRP), Hu antigen D (HuD) and fragile X mental retardation 
protein (FMRP) (Rossoll and Bassell, 2009, Fallini et al., 2011). Since FMRP associates with 
polyribosomes and has been proven to be a negative regulator of translation by associating 
with mRNAs, SMN might impact on the regulative ability of FMRP through physical 
interaction (Piazzon et al., 2008).  
 
III. The role of SMN in axonal growth and neuromuscular junction (NMJ) maturation: 
SMN has been observed to be expressed at highest levels during embryonic and fetal 
stages compared to the postnatal period (Burlet et al., 1998), indicating essential function of 
SMN during development. Additional expression analyses revealed the presence of SMN in 
vivo in neurites and growth cones of motor neurons in mouse and rat spinal cord, embryonic 
chick forebrain and in vitro in primary rat cortical neurons transfected with recombinant SMN 
as well as in differentiating, neuron-like mouse P 19 cells (Bechade et al., 1999, Pagliardini 
et al., 2000, Dodds et al., 2001, Jablonka et al., 2001, Fan and Simard, 2002, Zhang et al., 
2003, Briese et al., 2005). Using PC12 cells it was found that SMN protein levels increase 
during neuronal differentiation under continuous neuronal growth factor (NGF) treatment (van 
Bergeijk et al., 2007). Furthermore, it was shown in the same study that shRNA-mediated 
knockdown of SMN significantly reduced neurite length in PC12 cells while overexpression of 
SMN led to extensive sprouting. By testing different deletion constructs and transfecting into 
SMN depleted PC12 cells, the growth promoting region could be narrowed to a C-terminal 
fragment comprising amino acid (aa) residues 235-294 of the human SMN. In this construct 
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the tudor domain which is necessary for Sm protein-binding and thus, in turn, essential for 
SMN function in snRNP was completely missing. Therefore, these results could argue for 
distinct functions of SMN in snRNP-assembly / splicing and axons or dendrites (van Bergeijk 
et al., 2007).  
It is well known, that axonal growth and branching strongly depend on actin dynamics 
(Pak et al., 2008, Schmidt and Rathjen, 2010). In this process, a set of actin binding proteins 
such as the main neuronal form of Profilin, Profilin IIa, play an important role. Profilin IIa can 
sequester actin monomers or promote polymerization by desequestering of actin from the 
thymosin/β-actin pool and by adding these monomers to the free barbed ends of 
microfilaments (Pantaloni and Carlier, 1993, Sharma et al., 2005) (see also chapter 2.3.2). It 
has previously been shown that SMN can interact with Profilin IIa and influences the 
sequestering ability of Profilin IIa negatively, thereby triggering polymerization (Rossoll et al., 
2002, Sharma et al., 2005). However, the effect of profilin polymerizing function on the actin 
cytoskeleton and thus on axonal growth is controversially discussed: While in one study the 
knockdown of individual profilin isoforms (I and II) had seemingly no effect and the double 
knockdown clearly inhibited axonal growth (Sharma et al., 2005), it was demonstrated 
elsewhere that the single knockdown of Profilin IIa was sufficient to stimulate neurite 
outgrowth (Da Silva et al., 2003). In combination with the finding of an SMN / hnRNP 
interaction, these observations indicate an involvement of SMN in axonal growth via the 
regulation of actin dynamics.  
Besides observations from cell culture, the findings of axonal growth defects upon SMN 
depletion have been confirmed in a variety of different SMA animal models. In 
Caenorhabditis elegans, a less complete knockdown of smn-1 leads to developmental arrest, 
reduced lifespan and axonal outgrowth defects, which finally results in locomotion deficits 
(Briese et al., 2009). Also in the fly Drosophila melanogaster, developmental and motor 
behavior deficits were observed (Chan et al., 2003). Further electrophysiological combined 
with morphological analysis revealed reduced endplate (Acetyl Choline Receptor (AChR) 
cluster) currents and endplate disorganization (Chan et al., 2003). These findings for the first 
time led to the suggestion of primary defects at the SMA NMJ. Also in the vertebrate 
Xenopus laevis, motor neuron abnormalities with reduced axonal outgrowth and abnormal 
formation of branching extensions have been described (Ymlahi-Ouazzani et al., 2010). 
Similarly, zebrafish deficient for Smn display motor axons with abnormal growth and 
branching, that often do not reach their most distant targets (McWhorter et al., 2003, Carrel 
et al., 2006, Oprea et al., 2008, Hao le et al., 2011).  
While axonal defects have been frequently observed in these models and also in vitro in 
murine motor neurons, in vivo in SMA mouse models no defects in axonal outgrowth were 
detected (McGovern et al., 2008, Torres-Benito et al., 2011). In line with this fact, no changes 
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have been observed in SMA animals with regards to the number of axonal branches 
innervating single muscle fibers. Nevertheless, severe SMA mice have been shown to exhibit 
a significant reduction of axonal inputs per endplate during synapse elimination process, also 
termed axonal pruning (chapter 2.3.1), in proximal TVA muscle (Murray et al., 2008) 
Furthermore, electrophysiological recordings of synaptic activity at the NMJ have shown a 
number of abnormalities in Smn depleted mice (Torres-Benito et al., 2011). In the proximal 
slow twitch Transversus abdominis muscle (TVA), the quantal content (QC, amount of 
neurotransmitter released per action potential) was reduced up to ~50 % in the SMNΔ7 
mouse model (chapter 2.1.4), followed by ~40 % reduction in the distal and fast twitch 
muscles Tibialis anterior (TA), and ~25 % reduction in Extensor digitorum longus (EDL) (Ruiz 
et al., 2010). Since the amount of neurotransmitter per fused vesicle (quantal size) was not 
altered between control and SMA mice, it has been speculated that the reduction in QC was 
due to a decrease in release probability and/or in the number of docked vesicles (Kong et al., 
2009, Ling et al., 2010, Ruiz et al., 2010, Torres-Benito et al., 2011). Indeed, measurements 
in SMA and control mice have confirmed significant changes in vesicle release probability as 
well as in the number of docked vesicles (Kong et al., 2009). Furthermore, also the 
distribution of vesicles in the presynapse appeared abnormal in SMA animals (Kariya et al., 
2008).  
The functional defects observed in NMJs of SMA mice manifest also in altered 
morphological appearance of both pre- and postsynaptic structures. SMA presynapses are 
often characterized by accumulations of Neurofilament (NF) and it is believed that NF 
accumulations participate in motor neuron dysfunction, e.g. by slowing down the transport of 
components required for axonal and synaptic maturation and maintenance (Cifuentes-Diaz et 
al., 2002, Kariya et al., 2008, Kong et al., 2009, Ruiz et al., 2010, Dachs et al., 2011, Torres-
Benito et al., 2011). Further hallmarks of presynaptic defects include tiny nerve terminals that 
are often detached from the postsynaptic membrane, reduced sprouting and concomitantly 
large areas of postsynaptic membrane unoccupied by synaptic terminals. The defects 
observed at SMA postsynapses affect mainly the maturation process of Acetyl Choline 
receptor (AChR) clustering. While in wt ovoid AChR plaques are transformed into complex, 
pretzel-like shapes (characteristic of adult synapses), SMA animals display small and still 
oval shaped endplates with almost no gutters of perforations and postsynaptic membrane 
folds fail to form (Sanes and Lichtman, 1999, Torres-Benito et al., 2011). Postsynaptic 
responses remain slow compared to wildtype, which might in part be attributed to 
predominantly embryonic γ-subunit containing forms of AChR in SMA mice (Kong et al., 
2009). However, the exact mechanisms underlying the maturation defects of NMJs in SMA 
remain elusive. 
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Together, these data suggest that NMJ pathology rather than axonal defects are the 
characteristic disease feature in SMA mice. Since NMJ defects are an early characteristic 
timely preceding motor neuron death, a dying back mechanism was suggested.  
 
IV. SMN function in muscle and other non-neuronal tissues: 
It has previously been shown in different studies that muscle specific overexpression of 
SMN is not sufficient to ameliorate the SMA phenotype in flies and mice in the absence of 
neuronal SMN. In turn, neuron specific expression alone significantly improved survival but 
did not fully rescue the SMA phenotype (Chan et al., 2003, Gavrilina et al., 2008). Therefore, 
it has been speculated that the observed motor defects might be caused by primary 
abnormalities in both muscles and motor neurons, or perhaps due to a failure of 
communication between these two tissues (Walker et al., 2008). There are several further 
hints that SMA is not only caused by defects in motor neurons, axons or at NMJ level. E.g., 
SMN depletion experiments revealed defects in fusion and proliferation of human and mouse 
myoblasts and also the maintenance of stable innervation seems to depend on muscle 
specific expression of SMN (Braun et al., 1995, Guettier-Sigrist et al., 2002, Arnold et al., 
2004, Shafey et al., 2005). In accordance with a muscular involvement of SMN, Smn and its 
complex partners were found to localize to the Z-disc (Divides two Sarcomeres, anchor for 
actin filaments) of  skeletal and cardiac muscle in mouse. Furthermore, Smn was proven to 
be a direct target of calpain, a protease with important function in Z-disc turnover (Walker et 
al., 2008, Fuentes et al., 2010, Anderton et al., 2011). In this context, myofibers from SMA 
mice display morphological defects that are consistent with a Z-disc deficiency (Walker et al., 
2008). Besides the neuronal functions of Smn, these findings point at an additional role of 
Smn in the muscle.  
Apart from muscle, SMN depletion has often been reported to affect also other non 
neuronal tissues, such as heart, bone, blood vessels and liver (Finsterer and Stollberger, 
1999, Kelly et al., 1999, Hsieh-Li et al., 2000, Felderhoff-Mueser et al., 2002, Arai et al., 
2005, Hachiya et al., 2005, Bach, 2007, Shanmugarajan et al., 2007, Khatri et al., 2008, 
Rudnik-Schoneborn et al., 2008, Araujo Ade et al., 2009, Meyer et al., 2009, Shanmugarajan 
et al., 2009, Bevan et al., 2010, Gogliotti et al., 2010, Heier et al., 2010, Hua et al., 2010, 
Michaud et al., 2010, Riessland et al., 2010, Shababi et al., 2010). These observations have 
led to the development of the so called threshold theory, which proposes different 
susceptibility of certain cells to SMN depletion: While motor neurons are affected at weakly 
reduced SMN levels, other tissues such as heart, bone and finally all tissue types get 
affected as SMN levels further decrease or are even completely absent (Sleigh et al., 2011). 
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2.1.4 SMA mouse models 
In contrast to humans, where a second copy of SMN1 is present, the SMN1 orthologue in 
mouse, Smn, has been shown to exist as a single copy gene (DiDonato et al., 1997). The 
homozygous knockout of Smn is embryonically lethal, providing evidence that Smn is 
indispensable for cell survival (Schrank et al., 1997, Hsieh-Li et al., 2000, Park et al., 2010). 
Due to its early embryonic lethality, however, this SMA model was not useful to adequately 
study disease mechanisms. For this reason and to more accurately mimic the human 
situation, the aberrantly spliced human SMN2 (hSMN2) gene was introduced into the Smn-/- 
background as a genomic fragment (Hsieh-Li et al., 2000, Monani et al., 2000, Park et al., 
2010).  
In the SMA mice generated by Monani, the hSMN2 transgene is present as one copy per 
transgenic allele. Homozygous Smn-/-;hSMN2tg/tg mice (2 hSMN2 copies) are viable but 
develop severe symptoms including motor neuron loss and motoric disability by P2 and die 
by P4 (Monani et al., 2000). Heterozygous Smn-/-;hSMN2tg/wt with a total of 1 hSMN2 copy, 
however, are embryonically lethal. Importantly, 8 copies of hSMN2 have been shown to be 
sufficient to fully rescue the lethal SMA phenotype of the Monani mice, providing the first 
proof-of-concept study of the feasibility of modulating the SMN2 gene for therapeutic 
purposes (Monani et al., 2000, Park et al., 2010).  
The most commonly used SMA model today is the so called SMNΔ7-mouse (Le et al., 
2005). This line carries the Monani-hSMN2 transgene (1 hSMN2 copy per allele) and 
additionally Δ7hSMN2 (an SMN cDNA lacking exon 7), each homozygously, on the Smn null 
background. In Smn-/-;hSMN2tg/tg;Δ7hSMN2tg/tg mice a modest attenuation of the SMA 
phenotype was observed with a mean survival of 13.3±0.3 d., demonstrating that also 
Δ7SMN2 is at least partially functional and does not, as was previously alleged, act 
deleterious through dominant-negative effects (Kerr et al., 2000, Le et al., 2005).  
Further SMA mouse models include the Smn2B/- mouse line with a 3 bp substitution in the 
exon 7 exonic splicing enhancer (ESE) (mean survival ~P30) (Bowerman et al., 2009) or the 
Smn-/-;hSMN2tg/tg;A2Gtg/wt with an A2G missense mutation in the first exon of the SMN1 
transgene (mean survival ~8 mo)  (Monani et al., 2003).  
Recently, a stably integrated Cre-inducible SMA mouse was generated in which 
expression of full length hSMN2 occurs after tamoxifen administration (Bebee et al., 2011). 
Many approaches today aim at the successful restoration of SMN levels in motor neurons. 
Using self-complementary adeno-associated virus 9 (scAAV9) mediated SMN1 gene 
transfer, researchers were able to fully rescue the SMA phenotype when treating early P1, 
but not P10 SMA animals (Foust et al., 2010). Such findings indicate a certain timing 
requirement for SMN inductive or delivery therapy. Therefore, inducible SMA models will be 
of great help in defining the optimum therapeutic window in SMA therapy.   
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In the year 2000, Hsieh-Li et al. generated another SMA mouse model, also termed Hung 
mice, by crossing an integrate carrying 2 hSMN2 copies onto the Smn-/- background. 
Heterozygous Smn-/-;hSMN2tg/wt animals (2 hSMN2 copies) show a background-dependent 
survival of ~10 (FVB) (Riessland et al., 2010) to ~14 d (C57BL/6N, this thesis) while 
homozygous mice of the genotype Smn-/-;hSMN2tg/tg (4 hSMN2 copies) are fully viable and 
fertile but show necrosis of the ears and tail. The Hung mouse model offers the big 
advantage of producing 50 % of SMA and 50 % of control mice in one litter. Since the Hung 
mouse model was in this study used to analyze the effect of PLS3 overexpression on the 
SMA phenotype, this model including the breeding scheme for the production of SMA mice is 
described in chapter 5.4.2.1. 
2.1.5 Therapeutic strategies in SMA treatment 
Currently, a number of therapeutic strategies are investigated for their potential in SMA 
therapy, however, to date no cure is available.  
Several approaches aim at the stimulation of SMN2 transcription, since still around ~10% 
of FL-SMN transcript are produced by this locus. Drugs of the so called Histone deacetylase 
inhibitor (HDACi) class of substances have turned out promising candidates for the 
development of an SMA therapy. As the name suggests, HDACi block the activity of histone 
deacetylases (HDAC). Therefore, these drugs activate gene transcription by shifting the 
modification of histones towards an increased acetylation state. In several studies using 
different substances (e.g. Sodium butyrate, valproic acid (VPA), phenylbutyrate, Trichostatin 
A, suberoylanilide hydroxamic acid (SAHA), M344 and LBH589), HDAC inhibition was 
proven to activate SMN2 expression when tested in cell culture or murine SMA models 
(Chang et al., 2001, Brichta et al., 2003, Sumner et al., 2003, Andreassi et al., 2004, Brahe 
et al., 2005, Brichta et al., 2006, Riessland et al., 2006, Avila et al., 2007, Mercuri et al., 
2007, Tsai et al., 2008, Garbes et al., 2009, Hauke et al., 2009).  
Another strategy aims at the correction of the SMN2 splicing pattern towards increased 
levels of FL-SMN transcripts. Although attempts using antisense oligonucleotides (ASOs) 
such as morpholinos or RNAs (Lim and Hertel, 2001, Cartegni and Krainer, 2003, Dickson et 
al., 2008) have been proven successful in elevating SMN levels in cell culture and even 
when injected into the brain of SMA mice (Passini et al., 2011), delivery into the human CNS 
remains challenging.  
An additional way to increase SMN levels in SMA patients might be to stabilize remaining 
FL-SMN protein. In 2004, it was discovered that SMN is degraded via the 
ubiquitin/proteasome pathway (Chang et al., 2004, Garbes et al., 2009). In line with this, 
treatment of SMA patient`s cell lines with the proteasome inhibitor MG132 led to an increase 
in SMN protein. These results raise the possibility that proteasome inhibitors may be useful 
for the treatment of SMA. 
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Also stem cell therapy has been suggested as a potential treatment form of SMA. Indeed, 
when transplanted into the spinal cord of the SMNΔ7 mouse model, neural stem cells 
differentiated into motor neuron like cells, protected host motor neurons from degeneration 
and significantly improved motoric ability as well as survival (Corti et al., 2010). However, it is 
unlikely that transplanted motor neurons form axons that reach their targets in the respective 
muscle tissue. Therefore, any positive effect is likely to be mediated through neuroprotection 
of host motor neurons by numerous factors released from the donor cells, such as brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), neurotrophin-4/5 (NT4/5) and 
nerve growth factor (NGF) (Ebert et al., 2009, Corti et al., 2010, Wyatt and Keirstead, 2010). 
Last but not least, outstanding progress has been achieved in the development of a gene 
therapeutic approach to treat SMA in the last two years. In three independent studies, 
researchers used the self-complementary adeno-associated virus 9 (scAAV9) for gene 
delivery into motor neurons of SMA mice by intravenous injection (Foust et al., 2010, Valori 
et al., 2010, Dominguez et al., 2011). Most strikingly, scAAV9-SMN was able to cross the 
blood brain barrier (BBB), highly efficiently transduced motor neurons in the lumbar region of 
the spinal cord as well as muscle tissue and rescued the survival phenotype.  
2.2 PLS3 - a fully protective modifier of SMA 
Typically, genetically caused diseases display a broad phenotypic variability among 
patients. The reasons for such variability include environmental as well as intrinsic genetic 
factors that might influence the severity. Genetic factors with impact on a certain disease 
phenotype are referred to as genetic modifying genes, or short modifiers. In multifactorial 
genetic diseases, modifications may comprise complex genetic networks which are often 
hard to dissect. Therefore, “monogenic” diseases provide unique opportunities to dissect 
components as they each have a single etiology, relatively uniform treatments, and the 
contribution of the disease-causing gene is usually known to some degree (Antonarakis and 
Beckmann, 2006, Cutting, 2010). Often, different mutations in one single gene account for a 
broad spectrum of disease variability. E.g., in one of the most prevalent genes causing 
deafness, connexin 26 (CNX26), different mutations can result in either a recessive or a 
dominant inheritance mode (Rabionet et al., 2000). The finding, however, that patients with 
one and the same mutations often strongly vary in their phenotypic appearance suggests the 
existence of other modifying genes or variants.  
For a long time, SMN2 was the only known SMA-modifying gene with a strongly inverse 
correlation of SMN2 copy number and SMA severity (Feldkotter et al., 2002). Interestingly, 
however, homozygously SMN1-deleted patients and parents have been reported who are 
completely healthy, whereas members of the same family carrying the identical genotype 
show SMA symptoms according to the SMN2 copy number (Brahe et al., 1995, Cobben et 
al., 1995, Hahnen et al., 1995, Wang et al., 1996). The observation that siblings with identical 
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SMN2 copy number and homozygous absence of SMN1 can show variable phenotypes has 
suggested that SMA is also modified by other unknown factors (Helmken and Wirth, 2000).  
In 2008, the actin filament bundling protein PLS3 was identified as the first SMA modifying 
protein besides SMN2 in a total of six discordant families (Oprea et al., 2008). In these 
discordant families, a small proportion of individuals homozygous for the absence of SMN1 
are fully asymptomatic despite carrying an identical number of SMN2 copies as their affected 
siblings (mostly 3 – 4, reflecting SMA type III). Via differential gene expression (micro-array) 
analysis and as confirmed by qRT-PCR as well as protein analysis, PLS3/PLS3 was then 
found to be highly upregulated in Epstein-Barr-virus (EBV)-transformed lymphoblastoid (LB) 
cell lines of unaffected individuals compared with their affected siblings. Expression of PLS3 
in blood is very rare, as it could be shown only in ~5 % of healthy controls. Furthermore, by 
detecting high PLS3 levels in native blood of an unaffected individual, it was ruled out that 
PLS3 expression in LBs was induced by Epstein-Barr virus transformation. Further 
expression analysis showed, that PLS3 is highly expressed in fetal and adult human spinal 
cord, as well as brain and muscle.  
To functionally dissect the working mechanism underlying PLS3 protection, PLS3 
overexpression analysis was performed in Smn-depleted neuronal PC12 cells and primary 
mouse motor neuron cultures derived from SMA mice. In both cases, PLS3 was able to 
rescue axon outgrowth defects typically observed in the absence of Smn. Most strikingly, 
however, PLS3 overexpression led to a full rescue of axon defects in smn depleted zebrafish 
(Danio rerio) embryos. Since PLS3 mainly functions in actin bundling, G- to F-actin ratios 
were determined in LB cells of affected and unaffected siblings. Here, it has been found that 
unaffected SMN1-deleted siblings who highly expressed PLS3 had significantly increased F-
actin levels in LBs, as compared with their affected siblings who lack PLS3 expression. Also 
when overexpressed in HEK cells, PLS3 activity resulted in a highly significant increase in F-
actin levels. These findings, together with the observed rescue of axonal outgrowth defects in 
vitro and in vivo, suggest a model by which PLS3 might exert its rescuing effect through a 
stabilization of the actin cytoskeleton in motor neurons.  
As revealed by 2 dimensional blue-native–polyacrylamide gel electrophoresis (2D-BN-
PAGE), Pls3 has been observed to be present in one ~500 and another ~200 kDa complex 
together with Smn in murine spinal cord. These observations have further been supported by 
the finding of indirect PLS3/SMN interaction as demonstrated in co-immunoprecipitation (Co-
IP) experiments. Based on their findings, the authors have speculated that PLS3, apart from 
the actin filament stabilizing effect, might exert additional functions in cooperation with Smn 
within the complex. Interestingly, only females seem to be protected by high PLS3 
expression, since Oprea et al. (2008) observed that males highly expressing PLS3 displayed 
a phenotype as expected based on SMN2 copy number.  
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Most strikingly, the Drosophila melanogaster and Caenorhabditis elegans orthologues of 
PLS3, Fim and plst-1, have been demonstrated to ameliorate disease severity also in these 
organisms, suggesting that PLS3 is a cross species SMA modifier (Dimitriadi et al., 2010) 
(see also chapter 2.2.4).  
After PLS3 had been shown to act as a gender specific modifier of SMA by Oprea et al. in 
2008, three more studies focusing on the aspect of PLS3 protection were published in the 
following years. In 2009, Bowerman et al. presented a study investigating the role of profilin 
IIa, an actin binding protein, in SMA pathology (Bowerman et al., 2009). As it has been 
demonstrated before also by others, the knockdown of profilin IIa alone results in stimulation 
of neurite outgrowth, while overexpression of profilin IIa reduces neurite number and size (Da 
Silva et al., 2003). Furthermore, SMN and profilin IIa directly interact, whereby SMN has 
been shown to moderate and restrict profilin IIa negative function on actin polymerization 
(Sharma et al., 2005). Interestingly, Bowerman et al. have detected increased profilin IIa 
levels in motor neurons of SMA mice and therefore speculated that negatively acting profilin 
IIa might be causative for axonal defects in SMA. Moreover, the researchers detected lower 
PLS3 protein levels in brain and spinal cord of the Smn2B/- SMA mouse model, this finding 
being in line with the idea of a Pls3/Smn complex formation in mouse. To investigate a 
possible negative effect of profilin IIa on axon development in vivo, Bowerman et al. crossed 
the profilin IIa knockout (pfn2-/-) into the Smn2B/- SMA background, hoping to see an 
amelioration of the SMA phenotype. Interestingly, the authors have been able to show that 
Pls3 levels were restored in Smn2B/-;pfn2-/- animals compared to Smn2B/-;pfn2+/+ mice, 
suggesting a modulation of plastin 3 levels by profilin IIa. Unfortunately, however, despite the 
restoration of Pls3 levels in pfn2-/-;Smn2B/- animals, this did not result in an amelioration of the 
SMA phenotype. Therefore, Bowerman et al. speculate that in addition to profilin IIa and 
plastin 3, other components of actin dynamics are also affected in SMA, which would explain 
why the simple downregulation of profilin IIa or upregulation of Pls3 is not sufficient on its 
own to ameliorate the SMA phenotype (Bowerman et al., 2009). 
In another study, it has been investigated whether PLS3 might serve more broadly as a 
biomarker for SMA severity (Stratigopoulos et al., 2010). To investigate this question, PLS3 
expression was measured in whole blood from 88 types I, II, and III SMA patients. A clear 
correlation between PLS3 expression and SMA phenotype was detected in postpubertal 
females, whereas in prepubertal females as well as age matched male patients no such 
coincidence was observable. Therefore, the authors conclude that it is unlikely that PLS3 
expression alone will be a generalizable biomarker for SMA in most clinical trials.  
A third study assessed PLS expression in EBV-transformed lymphoblastoid and  fibroblast 
cell lines from four SMA discordant families (Bernal et al., 2011). Based on expression 
analysis using LB cell lines, PLS3 has been excluded as the protective factor for two of the 
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four families investigated. In contrast, in the other two families, PLS3 levels were 8-9 fold 
increased in unaffected siblings when compared to affected siblings. When investigating 
PLS3 levels in fibroblasts of discordant siblings, Bernal et al. found that the PLS3 expression 
levels exceeded those of blood ~12-200-fold. Based on this observation, they pointed out 
that the subtle positive changes obtained in LBs of the asymptomatic individuals may reflect 
a similar situation in their motor neurons and nerves and should therefore be considered 
cautiously. To exclude that higher PLS3 levels in LB cells of unaffected siblings resulted from 
immortalization, Oprea et al. in their study investigated native blood of an unaffected sibling 
and found a similar increase as in the respective LB sample. Likewise, Bernal et al. used 
native blood as a control for all of their discordant families. Interestingly, PLS3 expression 
levels were different when comparing LB cell lines with native blood of the same patient`s 
cell lines. Therefore, the authors speculated that at least in their study immortalization or 
another unknown factor may influence the regulation of PLS3 expression (Bernal et al., 
2011). In summary, the results of this study only partially confirm the data presented in 
Oprea et al., 2008.  
2.2.1 PLS3 gene 
Human PLS3 (NP_001129497), also called T-plastin, fimbrin  or plastin 3, was first cloned 
in 1988 and is located on Xq23 spanning a region of ~90 kb (Lin et al., 1988). PLS3 
comprises 16 exons and produces three mRNA transcript variants (1,2 and 3). Despite 
differences in the 5`UTR, Splice variants 1 and 2 encode exactly the same 1893 bp 
transcript. Splice variant 3, however, uses an alternate in-frame splice site in the coding 
region, producing an 81 bp shorter mRNA of 1812 bp in size. Plastins are highly conserved 
from lower eukaryotes to humans, reflecting their important role in the cell (Klein et al., 2004, 
Delanote et al., 2005). Next to PLS3, two homologues genes exist in humans, I-plastin and 
L-plastin, which are encoded by distinct genes on chromosomes 3 and 13, respectively (Lin 
et al., 1993a, Lin et al., 1993b, Lin et al., 1994). Additionally, analyses of intron/exon borders 
revealed that all three human Plastins have emerged from one ancestral gene (Lin et al., 
1993b). 
2.2.2 PLS3 protein 
PLS3 consists of 630 aminoacids (aa) and has a predicted size of ~70 kDa. The original 
name for PLS3, fimbrin, derives from its first described association with surface structures 
such as membrane ruffles, microvilli, microspikes and focal adhesions in chicken embryo 
fibroblasts and cultured rat mammary cells (Bretscher and Weber, 1980, Delanote et al., 
2005). PLS3, L- and I-Plastin show 70 % similarity on aa level. While PLS3 is expressed in 
almost all solid tissue (including human brain, spinal cord and muscle (Oprea et al., 2008)) 
and usually not in the hematopoietic system, L-plastin is mainly found in cells of the 
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hematopoietic lineage. The expression of I-plastin, in contrast, is restricted to intestinal 
tissues only, as was demonstrated by expression analysis including humans and rat (Lin et 
al., 1994). PLS3 has a modular structure consisting of two N-terminal EF-hand domains 
(helix-loop-helix structural domains) and two actin binding domains (ABD1 and ABD2), each 
comprising two calponin-homology (CH) domains (Figure 2). 
 
Figure 2:  PLS3 protein structure: The 630 aa long protein has two N-terminal EF-hand domains   
followed by two actin binding domains (ABD1 and ABD2), each consisting of two 
calponin homology domains.  
The EF-hand motif has a structure much like the spread thumb and forefinger of a hand, 
in which Ca2+ ions are coordinated by ligands within the loop. The CH domains are each 
composed of four α-helical segments. Three of the four helices form a loose bundle, while 
the fourth is oriented perpendicular to the major bundle.  
The crystal structure of the complete PLS3 protein has not been determined yet, however, 
the fragmented parts including the N-terminal human ABD1 domain as well as the 
crosslinking core of Schizosaccharomyces pombe (S.pombe) and Arabidopsis thaliana 
(A.thaliana) have been resolved (Goldsmith et al., 1997, Klein et al., 2004). Recently, another 
study has been published in which the authors used cryo electron-microscopy (EM) and a 
single-particle approach to generate a 12-Å-resolution map of F-actin alone and F-actin 
decorated with the ABD2 domain of human L-plastin containing tandem CH-domains (Galkin 
et al., 2008). In their study the authors propose a working mechanism of PLS3 actin-bundling 
activity: Based on their findings, they propose that first ABD2 binds to one actin filament, 
which in turn “activates” ABD1 so that it may bind in a more ordered manner than that 
observed for free ABD1 to another actin filament with high affinity. 
Based on crystallization experiments, it has been proposed that calcium binding to the N-
terminal EF-hand domains of PLS3 might regulate its activity in actin bundling (Hanein et al., 
1998). Based on calculations, the authors supposed that the EF-hand domains are needed 
for PLS/actin binding, however, calcium acts as a negative regulator in this interaction. 
Furthermore, by a digestion approach it was shown that a hot spot for proteolysis, between 
the putative EF-hands and the ABD1, becomes protease-resistant in the presence of 
calcium. Therefore, the authors followed that the observed calcium induced conformational 
change might be the mechanism behind the inhibition of PLS3/actin interaction (Hanein et 
al., 1998). In several studies the role of calcium in the regulation of plastin isoforms was 
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examined by studying the actin bundling activity of plastins at variable calcium 
concentrations. All three plastin isoforms show a rather weak homology regarding their 
calcium binding domains and this may suggest that their actin binding activities are 
differentially regulated by calcium (de Arruda et al., 1990, Delanote et al., 2005). L-plastin 
possesses all conserved and essential aa required for calcium binding and is indeed 
negatively regulated by calcium (Namba et al., 1992). Also I-plastin has been demonstrated 
to be negatively regulated by calcium. Despite above mentioned findings, however, a calcium 
dependent regulation of PLS3 is controversially discussed. Even though Hanein et al. 
showed conformational changes occurring in the ABD1-containing fragment of PLS3 in the 
presence of calcium, a regulatory influence of the calcium concentration on PLS3 activity 
was neither proven in vitro, nor in vivo. Moreover, another group showed that co-
sedimentation of actin with T-plastin was not affected by free calcium concentrations of up to 
2,2 μmol/l (Giganti et al., 2005). Furthermore, in a depolymerization assay of the same study, 
calcium concentrations in the range of 4.6 nmol/L–1.6 μmol/L had no impact on PLS3 
activity. Also phosphorylation by protein kinase A (PKA) has been shown to influence L-
plastin activity (Janji et al., 2006). However, although conserved, Ser7, has never been 
demonstrated to become phosphorylated in PLS3. Additionally, L-plastin binding activity to 
actin seems to be negatively regulated by increasing amounts of phospholipids, e.g. 
Phosphatidylinositol 4,5-bisphosphate (PIP2) (Lebart et al., 2004). For I-plastin and PLS3, 
however, no such studies have been performed so far. 
2.2.3 PLS3 function 
PLS3 is an actin binding protein with its main function in actin filament cross-linking. 
Generally, plastins are located in focal adhesions, ruffling membranes, lamellipodia, 
filopodia, or in specialized surface structures with highly ordered microfilament bundles such 
as microvilli and stereocilia. Sometimes they co-localize with stress fibers (Bretscher and 
Weber, 1980, Delanote et al., 2005). PLS3 function in actin bundling and the consequences 
of overexpression have nicely been demonstrated in vitro in fibroblast–like CV-1 and 
epithelial LLC-PK1 cells (Arpin et al., 1994). In CV-1 cells, PLS3 overexpression resulted in a 
rounding-up of cells, concomitantly with a significant reorganization of the actin cytoskeleton. 
In this regard, actin filaments became organized into polygonal networks in the cortical 
region of the cells. In LLC-PK1 epithelial cells, PLS3 overexpression led to a high increase in 
length and density of brush border microvilli, particularly at the periphery of the cells. 
Furthermore, PLS3 overexpression resulted in a significant diminution of focal contacts, 
presumably due to extensive remodeling of the actin cytoskeleton, implying a possible 
involvement of PLS3 in cell movement processes. Another study focused on the mechanism 
underlying PLS3 induced cytoskeletal rearrangements (Giganti et al., 2005). Here, beads 
were coated with the VCA domain of Wiskott/Aldrich-syndrome protein (WASP) to recruit the 
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actin-branching and polymerizing complex Arp2/3. This alone resulted in actin polymerization 
at the surface of the beads and movements of such when placed in cell-free extracts. 
Importantly, it was shown that PLS3 increased the velocity of VCA beads movement, 
stabilized actin comets and concomitantly displaced cofilin, an actin-depolymerizing protein. 
Since a mutated form of the ABD1 domain unable in cross-linking was sufficient to induce the 
above described effects, Giganti et al. propose a novel mechanism of action for PLS3 in 
which this protein might contribute to Arp2/3 mediated actin assembly independently of 
cross-link formation. In other words: PLS3 on the one hand stabilizes actin filaments through 
cross-linking and additionally triggers Arp2/3-mediated actin polymerization. Since the Arp2/3 
complex nucleates a branched actin network found, e.g., in the lamellipodium at the leading 
edge of migrating cells, this fact highlights the significance of PLS3 function for protrusive 
membrane-outgrowth and more generally, cell motility. A role of PLS3 in cell motility was 
further confirmed in studies by Serio et al., who found that T-plastin is important for actin tail 
formation in the pathogenic bacteria Rickettsia parkeri (R. parkeri) and for its actin-based 
motility in mammalian cells (Serio et al., 2010). In line with this, PLS3 was shown to play an 
important role in invasion of the bacteria Shigella flexneri and Salmonella typhimurium 
(Prevost et al., 1992, Adam et al., 1995, Zhou et al., 1999a). In both cases, PLS3 causes 
actin cytoskeleton rearrangements in the host cells that lead to the formation of actin 
protrusions engulfing the bacteria and finally resulting in phagocytosis and uptake of the 
pathogen.  
PLS3 was furthermore implicated to play a role in DNA repair and cell cycle control and 
consequentially also in cancer. By differential mRNA display, it has been demonstrated that 
PLS3 is 12-fold more abundant in cisplatin-resistant cell lines from bladder, prostatic, head 
and neck cancer (Hisano et al., 1996). In this regard, cisplatin is an anti-cancer drug 
intercalating with DNA and interfering with DNA-repair. Accordingly, the downregulation of 
PLS3 was found to be associated with higher cisplatin sensitivity. Additionally, the increased 
sensitivity of cancer cells to DNA interfering drugs as caused by plastin3 downregulation, has 
also been shown for the Topoisomerase II-blocking agent VP-16 (Ikeda et al., 2005). In line 
with these findings, higher PLS3 levels were also detected in UV-radiation resistant cell lines 
(Higuchi et al., 1998). Also in Sézary syndrom, the most common form of cutaneous T-cell 
lymphoma, the presence of sézary cells was correlated with high levels of PLS3 in peripheral 
blood mononuclear cells (PBMCs) (Capriotti et al., 2008, Tang et al., 2010). Vice versa, 
PLS3 levels dropped upon chemotherapeutic treatment and completely disappeared after 
bone marrow transplantation in a patient. In another study, higher levels of PLS3 were 
correlated with G2-phase arrest upon X-radiation in Chinese hamster ovary (CHO) cells 
(Sasaki et al., 2002). However, when PLS3 was downregulated via antisense knockdown, 
radiation-induced G2 arrest was short and decreased in transfected cells. The authors have 
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therefore speculated that downregulation of PLS3 may be involved in cancer development 
through G2/M cell-cycle control in mammalian cells. These results highlight low levels of 
PLS3 as possibly causative for cancer development, different from the before mentioned 
findings, where high PLS3 levels were associated with cancerous state. Possibly, species- or 
cell type specific differences might explain these opposite observations. In this line, it is also 
unclear whether up- or downregulation of PLS3 in the various cancer forms is causative for, 
or is a result from cancer development. Next to PLS3, the L-plastin isoform is an even more 
prevalent cancer marker, since it is expressed in a high percentage of tumor-derived cells, 
but never in normal diploid cells of solid tissues (Leavitt and Kakunaga, 1980, Leavitt, 1994).  
Apart from cancer, PLS3 is also involved in the human autoimmune disease systemic 
lupus erythematosus (SLE). In an animal model for this disease as well as in human patients, 
antibodies against L- and T-plastin were found in serum (De Mendonca Neto et al., 1992, 
Mine et al., 1998, Shinomiya et al., 2003, Delanote et al., 2005). However, it has to be 
determined in how far these antibodies contribute to the loss of cell function or other aspects 
of SLE.  
Due to interaction with ataxin-2 (ATX2) in yeast and also murine brain, PLS3 has 
additionally been implicated in the regulation of RNA metabolism and translational pathway. 
In this context, ATX2 is known to interact with cytoplasmic poly(A)-binding protein (PABP) 
that functions in translation initiation and mRNA decay regulation and forms part of stress 
granules (Ralser et al., 2005a). The finding of an interaction of PLS3 and ATX2 has been 
further underlined by the observation of a stabilizing effect of ATX2 on PLS3 when 
overexpressed (Ralser et al., 2005b). 
2.2.4 Other potential SMA modifiers – knowledge from invertebrates 
There are several examples, where invertebrate modifier screens have identified 
conserved human disease-related genes and/or functional pathways (Kim, 2007, Schlegel 
and Stainier, 2007, Silverman et al., 2009). In this context, SMN orthologs are also present in 
Drosophila melanogaster (D.m., DmSmn) and Caenorhabditis elegans (C.e., Cesmn-1) and 
loss of function studies have revealed growth and neuromuscular defects as well as larval 
lethality in both organisms (Miguel-Aliaga et al., 1999, Chan et al., 2003, Rajendra et al., 
2007, Chang et al., 2008, Briese et al., 2009).  
In 2008, a study was set out to find modifying factors of SMA in the invertebrate model 
D.m. (Chang et al., 2008). In this screen, a total of 27 modifiers were identified able to rescue 
the lethal SMA phenotype. Surprisingly, despite the essential role of SMN in snRNP 
assembly, none of the modifying factors identified function in RNA processing. Moreover, 
three of the identified genes were orthologous to human BMP type II receptor (BMPRII), 
Fragile X relative protein 2 (FXR2) and dynein light chain LC8-type 2 (DYNLL2), all of which 
have been associated with functions at the NMJ (Aberle et al., 2002, Marques et al., 2002, 
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Pan et al., 2004). Interestingly, also high levels of the actin bundling protein α-actinin were 
associated with an enhancement of the SMA phenotype in this screen. In another study, 
RNAi knockdown of α-actinin was able to rescue the growth defects observed in Cesmn-1 
depleted C.e. (Dimitriadi et al., 2010). Therefore, the identification of α-actinin as another 
actin bundling protein with impact on SMA severity highlights the importance of cytoskeletal 
organization in SMA pathology.  
In a second screen using C.e. as SMA model, 4 more modifiers were identified (Dimitriadi 
et al., 2010): nuclear cap binding protein 2 (ncbp-2), the predicted protein T02G5.3, G-protein 
coupled receptor kinase 2 (grk-2), and FMRF-like peptide family member (flp-4). Apart from 
T02G5.3, the other 3 genes are present as orthologs also in human. Since these candidates 
represent potential new targets for SMA therapy, their function should be further analyzed in 
the disease context in vertebrates. Furthermore, the D.m. and C.e. orthologs of PLS3, Fim 
and plst-1, were in the same study tested for their potential to modify the SMA phenotype. 
Most strikingly, Fim and plst-1 were confirmed as SMA modifiers in both organisms, verifying 
the previous findings by Oprea et al. and suggesting that PLS3 is a cross species modifier of 
SMA.  
2.3 Development of the neuromuscular system 
NMJ pathology is one of the striking disease features in SMA mice and chronologically 
precedes motor neuron loss in the ventral horns of the spinal cord (Kariya et al., 2008, 
Murray et al., 2008, Kong et al., 2009). In the context of SMA, NMJ abnormalities include 
both pre- and postsynaptic defects, among these abnormal neurofilament (NF) accumulation 
in the nerve terminals, poor terminal arborization, immature plaque-like AChRs and 
embryonic γ-subunit containing forms of the receptor (Wyatt and Keirstead, 2010). In the 
present work, PLS3 was overexpressed in SMA mice to test whether high levels of PLS3 are 
able to rescue the SMA phenotype, similar to the situation in humans (chapter 2.2). PLS3 
overexpression was shown to result in significant pre as well as postsynaptic changes at the 
NMJ of SMA mice. Therefore, an overview about fundamental processes driving axon growth 
and specification (axonal pruning) as well as NMJ development and refinement will be given 
in the following chapters. 
2.3.1 The process of axonal pruning in NMJ refinement 
In the present thesis, overexpression of PLS3 has been shown to delay axon withdrawal 
from the NMJ during the process of axonal pruning. How is axonal pruning defined and what 
is the mechanism underlying this developmental process? 
Per definition, axonal pruning is a strategy to selectively remove exuberant neuronal 
branches and connections in the immature nervous system to ensure the proper formation of 
functional circuitry (Low and Cheng, 2006). Perinatally, individual AChR cluster are 
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innervated by numerous nerve terminals. During the axonal pruning process, all but one 
presynaptic connections are removed, so that finally one endplate gets innervated by one 
single motor nerve ending (Lichtman and Colman, 2000, Luo and O'Leary, 2005). It is 
assumed that 50 % of the postmitotic neurons of the vertebrate nervous system do not 
survive until adulthood. However, it is important to note that controlled apoptotic events in the 
context of neuronal plasticity are a phenomenon highly distinct from axonal pruning. Namely, 
axon pruning enables removal of exuberant or misguided axon branches in the absence of 
cell death, whereas other appropriate connections of the same neuron are maintained 
(Vanderhaeghen and Cheng, 2010).  
Historically, the two most popular mechanisms to explain how these axons disappear 
were axon retraction and Wallerian-type degeneration. During axon retraction, axonal 
contents are believed to be shuttled to other axon branches, however, axon retraction has 
never been directly documented at the neuromuscular junction (NMJ) (Riley, 1981, Bishop et 
al., 2004). Alternatively, it was believed that axons might undergo a classical Wallerian-type 
degeneration, as has been suggested by ultrastructural data (Rosenthal and Taraskevich, 
1977, Bishop et al., 2004). However, what speaks against this last mentioned possibility is 
that Wallerian-type degeneration usually removes entire axon arbors rather than a subset of 
axon`s branches. As new tools with better spatial and temporal resolution have become 
available, these opportunities revealed a new and unexpected mechanism termed axosome 
shedding (Bishop et al., 2004). In the process of axon shedding, retreating axons leave 
behind dismantled bulbs at their tips. These bulbs are removed over time as they get 
subdivided into smaller remnants, termed axosomes. Most importantly, by fluorescent 
confocal microscopy it could be proven that engulfing Schwann cells incorporated axosome 
material, therefore actively driving axonal recycling (Bishop et al., 2004).  
The molecular factors driving axonal pruning at the NMJ (small scale pruning) are largely 
unknown (Vanderhaeghen and Cheng, 2010). However, some molecules driving large scale 
axonal pruning (E.g. of neurons in the corticospinal tract (CST) or in the central nervous 
system (CNS)) have been identified. These molecules are subdivided into intrinsic and 
extrinsic proteins. As for intrinsic factors, e.g. the homeodomain transcription factor Otx1 has 
been identified (Weimann et al., 1999). As major extrinsic factors hormones and trophic 
factors have been suggested, however, their effects are often broad and nonspecific 
(Vanderhaeghen and Cheng, 2010). 
2.3.2 Actin dynamics in axon growth 
It was demonstrated in the present work, that PLS3 overexpression results in an increase 
of presynaptic nerve arborization and occupancy of AChR clusters at the NMJ. Furthermore, 
PLS3 led to a delay in the axonal pruning process (chapter 2.3.1), indicating that PLS3 might 
exert a positive effect on axonal integrity. To understand how PLS3 accomplishes 
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“stabilizing” function on axons, a basic knowledge about fundamental mechanisms driving 
axonal growth and the involvement of the actin cytoskeleton in this process is required.  
Axons grow out from the tip region of neurites, the so called growth cones. Growth cones 
are highly complex structures subdivided into three distinct zones (Figure 3): (i) The central 
zone (C domain), (ii) the intermediary transition zone (T domain) and (iii) the  peripheral zone 
(P domain). In the central zone, microtubules enter from the axon shaft and polymerize. 
These filaments act mainly as transport system for organelles and vesicles into the growth 
cone. The P domain represents the 
cortex of the growth cone and consists of 
actin filaments. Such filaments are crucial 
for the formation of filiopodia (finger like 
protrusions containing bundled actin 
filaments) and lamellipodia (flattened, 
veil-like membrane extensions containing 
an unbundled actin network) (Stiess and 
Bradke, 2011). The T domain contains 
both, microtubules and actin filaments 
and the interplay between both systems 
leads to neurite extension (Schaefer et 
al., 2008, Stiess and Bradke, 2011). The process of axonal extension can be seen as a 
continuous repetition of the three phases protrusion, engorgement, and consolidation 
(Goldberg and Burmeister, 1986). During the protrusion phase, actin polymerizes in the P 
domain and filopodial/lamellipodial structures are formed and progress in the direction of 
outgrowth. The following engorgement phase is characterized by a disassembly of actin 
filaments in the T domain, which previously inhibited microtubules from entering the P 
domain. Finally, in the consolidation phase an actin free corridor is formed in the T domain so 
that microtubules can invade the P domain. Thereupon, vesicles and organelles can be 
transported into the newly formed area (Stiess and Bradke, 2011).  
Today, a whole plethora of factors is known that act on actin dynamics and modulate axon 
growth. One important actin destabilizing factor (ADF) is Cofilin. Cofilin is present in the T 
zone of the growth cone and localizes to the pointed (-) end of actin filaments, where it 
severs and depolymerizes actin (Pak et al., 2008). This way, Cofilin regenerates the 
available globular actin (G-actin) pool, a necessary prerequisite for axon outgrowth. In line 
with this, it could be shown that overexpression of the active form of Cofilin triggered axon 
growth while depletion impaired axon formation (Garvalov et al., 2007). As it was mentioned 
earlier in this thesis (chapter 2.1.3), profilin IIa is another key component regulating axon 
dynamics and has even been proven to interact with SMN (Rossoll et al., 2002, Sharma et 
Figure 3 Structure of a growth cone at the 
distal tip  of a neurite (Taken from 
(Lowery and Van Vactor, 2009)).  
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al., 2005). Profilin IIa accelerates the ADP/ATP exchange in G-actin monomers. This way, 
profilin IIa is able to trigger the polymerization of Actin filaments. Against intuition, the 
polymerization of Actin per se does not account for enhanced axonal growth. Moreover, 
overexpression of profilin IIa resulted in reduced neurite outgrowth while the knockdown had 
the opposite effect (Da Silva et al., 2003). In this context, it has been demonstrated, indeed, 
that a more dynamic and less condensed actin cytoskeleton in the growth cone defines the 
future axon, whereas growth cones of designated neurites remain rather static and retain a 
rigid actin cytoskeleton (Bradke and Dotti, 1999, Kunda et al., 2001). Profilin IIa is activated 
by the Rho/Rock cascade. This pathway, in turn, is negatively controlled by plasma 
ganglioside sialidase (PMGS). The fact that profilin IIa is a negative regulator of axonal 
growth was further supported by the finding of high levels of PMGS in the designated axon 
during axon specification (Da Silva et al., 2005). While the described consequences of 
profilin IIa function suggest that actin polymerization acts negatively on axon growth, other 
examples exist where controlled actin polymerization is supportive for axon formation and 
elongation. The Wiskott-Aldrich syndrom protein (WASP) family is known to transduce 
signals from membrane receptors to the actin cytoskeleton. Through complex formation 
together with verprolin-homologous protein (VE), WASP and VE (WAVE) mediate actin 
polymerization via recruitment of the actin-related protein 2/3 (Arp2/3) complex (Takenawa 
and Suetsugu, 2007). In this context, the Arp2/3 complex closely resembles the structure of 
G-actin and serves as nucleation site for new actin filaments. In fact, the knockdown of 
Arp2/3 complex results in axonal growth defects (Takenawa and Suetsugu, 2007). Together, 
these results highlight the importance of actin dynamics (actin severing and polymerization) 
for correct axonal growth.  
Next to actin polymerization or depolymerization, also the connections between actin 
filaments, as mediated by actin-crosslinking as well as branching proteins, are important for 
cytoskeleton dynamics and thus for axonal growth. Bundling proteins typically found in 
filopodia of growth cones e.g. include α-actinin, fascin, CamKII, Myosin, AbLIM, Filamin as 
well as PLS3 (Letourneau and Shattuck, 1989, Lundquist et al., 1998, Cohan et al., 2001, 
Dent and Gertler, 2003, Okamoto et al., 2007, Oprea et al., 2008). The formation of filopodial 
structures requires the presence of parallel actin bundles, however, in lamellipodia actin is 
predominantly organized into a branched dendritic network. Therefore, actin branching 
proteins such as Arp2/3 complex are dominating in lamellipodia while actin bundling proteins 
are predominantly present in filopodia.  
As it was indicated above, also the microtubule network has important function in axonal 
growth. Microtubules consist of alternating α/β-tubulin heterodimers and have a dynamic 
plus-end (+) and a less dynamic minus-end (-). At the (+)-end, microtubules polymerize 
(rescue) or shrink (catastrophe). Disturbance of proper microtubule function has in the past 
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been associated with defects in axonal growth and the other way around, the stabilization of 
microtubules in dendrites can initiate axon specification (Baas, 2002, Hoogenraad and 
Bradke, 2009).  
Taken together, the Actin and microtubule network and their respective regulators are the 
key cellular systems in defining axon specification, growth and maintenance. 
2.3.3 Acetylcholine receptor (AChR) prepatterning 
Neuromuscular junctions (NMJ) are the contacts formed by a motor neuron´s axon and a 
muscle target cell. The communication between nerve and muscle is established through 
neurotransmitter release from the presynaptic nerve terminal and receptor mediated signal 
perception and transduction at the postsynapse. The excitatory signals secreted by the 
presynapse vary between organisms. E.g., in Drosophila glutamate acts as the excitatory 
neurotransmitter, while in the vertebrate system Acetyl Choline (ACh) is presynaptically 
released and bound by ACh receptors (AChR) at the postsynaptic site. In vivo studies have 
shown that prior axon arrival AChRs cluster along the central region of muscle fibers in a 
process termed AChR-prepatterning (Lin et al., 2001, Yang et al., 2001). Supporting the idea 
of prepatterning, aneural AChR clustering was also observed in mice that lack phrenic or 
motor nerves (Yang et al., 2000, Wu et al., 2010). The muscle-specific receptor tyrosine 
kinase MuSK is required for both, aneural and neural clustering (Zhang et al., 2004, Wu et 
al., 2010). Interestingly, in MuSK-/- mice the absence of aneural clusters is associated with 
nerve terminals straying from the central regions of muscle fibers (DeChiara et al., 1996, Lin 
et al., 2001, Yang et al., 2001, Zhang et al., 2004, Jing et al., 2009). These findings indicate 
an important role of AChR clustering in guiding axons to their distinct muscle targets. 
Regarding AChR prepatterning, it is important to mention that fundamental differences exist 
between species. While AChR prepatterning in mice and zebrafish seems to confine axonal 
guidance along the central muscle fiber region, there is no evidence for aneural clustering in 
Drosophila melanogaster Caenorhabditis elegans so far. In Drosophila melanogaster, motor 
neurons seek out target regions independently of the target cell while in Caenorhabditis 
elegans, motor neurons form so called “en passant” interactions with muscle arms actively 
searching for presynaptic terminals (Keshishian et al., 1996, Wu et al., 2010).  
With ongoing development, axons innervate some but not all clusters, whereby the size of 
innervated clusters increases and primitive clusters will finally disappear.  
2.3.4 The role of presynaptic signaling in AChR clustering and refinement 
During the process of axonal pruning, all but one remaining nerve connection will 
disappear with ongoing development so that endplates become innervated by one single 
motor axon only. Also at postsynaptic level, clear morphological changes can be observed as 
axons are specified. As the NMJ matures, the size of innervated AChR cluster slowly 
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increases. Furthermore, the postsynaptic membrane invaginates to form junctional folds, and 
AChRs are concentrated only at the crests of the junctional folds, giving the synapse a 
characteristic pretzel-like appearance (Sanes and Lichtman, 2001, Wu et al., 2010). The 
process of NMJ assembly is orchestrated by positively and negatively acting factors, most 
important to mention here Agrin and Acetylcholine (Ach), respectively (Figure 4).  
 
Figure 4: Circuitry in AChR clustering at the NMJ. Positive signals, such as Agrin-MuSK 
signaling, postsynaptically activate certain pathways that trigger AChR clustering, 
expression and stabilization. Counteracting negative signals, such as ACh stimulate 
the serine/threonine kinases cyclin-dependent kinase 5 (Cdk5) and Ca
2+
/calmodulin-
dependent kinase II (CaMKII) to inhibit AChR clustering, to suppress AChR expression 
and to destabilize AChR clusters in entire muscle fibers. Positive and negative signals 
together refine AChR clustering to sites of axonal innervation. (Taken from (Wu et al., 
2010). 
The most central pathway in NMJ assembly is the Agrin/Lrp4/MuSK pathway. Agrin is a 
glycoprotein synthesized in motor neurons and is transported along the axons to the nerve 
terminals where it is synaptically released. Agrin is the essential key player in the induction of 
AChR clustering and postsynaptic differentiation, a fact that has been proven by several 
different observations. In mice deficient for Agrin (Agrin-/-), NMJs do not form with several 
postsynaptic marker proteins being absent and AChR dispersed throughout the mutant 
muscle fiber (Gautam et al., 1996). Interestingly, however, prepatterning of AChR still occurs 
indicating that this process is Agrin independent (Lin et al., 2001, Yang et al., 2001). 
Furthermore, Agrin is able to induce ectopic AChR clustering in adult muscle and elicits the 
formation of the postsynaptic apparatus in denervated muscle (Gesemann et al., 1995, 
Jones et al., 1997, Bezakova et al., 2001, Wu et al., 2010).  
MuSK is a receptor tyrosine kinase and has been identified as a protein stringently 
colocalizing with AChR at NMJs (Valenzuela et al., 1995). In MuSK-/- mice, NMJs do not 
form, no prepatterning of AChR is observeable and also upon innervation AChR are evenly 
distributed throughout the muscle fiber (DeChiara et al., 1996, Lin et al., 2001, Yang et al., 
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2001). Moreover, Agrin is not able to induce AChR clustering in MuSK-/- mice, however, 
MuSK can restore Agrin sensitivity (Glass et al., 1996, Zhou et al., 1999b, Herbst and 
Burden, 2000). Together, these findings underline the necessity of interplay of both Agrin and 
MuSK in the formation of nerve-induced AChR clustering (Wu et al., 2010). Most 
interestingly, MuSK seems to represent an important factor for retrograde signaling from the 
post- to the presynapse. This assumption is based on the observation that MuSK-/- mice 
exhibit highly branched and arborized motor neuron terminals, which is indicative for a role of 
MuSK in presynaptic differentiation (Wu et al., 2010).  
As has been described, both Agrin and MuSK mediate AChR clustering in vertebrate NMJ 
formation. Nevertheless, a direct interaction between Agrin and MuSK has never been 
observed. Recently, Lrp4 was identified as a coreceptor of MuSK that can directly interact 
with Agrin (Kim et al., 2008). Lrp4-/- exhibit NMJ defects closely similar to that observed in 
MuSK-/- mice (Weatherbee et al., 2006). That Lrp4 is the long searched linker in Agrin 
mediated MuSK signaling was confirmed by studies demonstrating that Lrp4 is necessary for 
Agrin-induced MuSK activation and AChR clustering in cultured muscle cells (Kim et al., 
2008, Zhang et al., 2008a, Wu et al., 2010). The downstream functions of MuSK signaling 
will be outlined in chapter 2.3.5. 
Presynaptically released ACh is the main excitatory signal inducing muscle contraction in 
vertebrates and at the same time the most important negatively acting factor in NMJ 
assembly. The first evidence for ACh being a negative regulator of AChR clustering came 
from the observation that AChR grow faster and larger in mice deficient for choline 
acetyltransferase (ChAT), an enzyme essential for ACh biosynthesize (Misgeld et al., 2002, 
Brandon et al., 2003). Further functional analyses revealed that ACh activates the 
serine/threonine kinase cyclin dependent kinase 5 (Cdk5) or Ca2+/calmodulin-dependent 
protein kinase II (CaMKII) (Tang et al., 2001, Fu et al., 2005, Lin et al., 2005). These 
pathways have been connected with negative regulatory roles in AChR assembly, 
expression and stabilization. Importantly, the negative effect of ACh is global affecting the 
entire muscle fiber. Therefore, positive and negative outcome of Agrin-MuSK and ACh 
signaling, respectively, together accounts for the correct refinement of AChR clusters to 
positions of axonal innervation.   
2.3.5 MuSK downstream signaling and the importance of cytoskeletal dynamics in 
AChR clustering 
As it will be outlined in chapter 5.4.3.3, PLS3 overexpression resulted in an increase in 
AChR cluster size when ubiquitously overexpressed in SMA mice. Importantly, motor neuron 
specific overexpression of PLS3 was sufficient to increase endplate size, suggesting that 
increased presynaptic arborization and occupancy contribute to the endplate size increase. 
Nevertheless, based on the experiments performed in this work a muscle specific effect of 
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PLS3V5 cannot be entirely excluded. Indeed, cytoskeletal rearrangements in the muscle are 
a prerequisite for proper AChR clustering, suggesting that also muscle specific PLS3V5 
might account for the observed increase in AChR size.   
As it was explained in chapter 2.3.4, MuSK is indirectly activated by Agrin binding to its 
coreceptor Lrp4. Upon interaction and as a prerequisite for AChR clustering, MuSK is rapidly 
internalized via endocytosis (Zhu et al., 2008). One consequence of MuSK activation is the 
rearrangement of cytoskelletal structures. Such rearrangements are assumed to be pre-
conditional for AChR anchorage and redistribution, as well as shaping postsynaptic 
membrane into folds opposed to presynaptic active zones (Dobbins et al., 2006). Upon Lrp4 
mediated Agrin-MuSK interaction, tyrosine kinase Abl and the metalloenzyme geranylgeranyl 
transferase I (GGT) get activated. Both proteins in turn activate small GTPases of the Rho 
family (Weston et al., 2000, Weston et al., 2003). One target of Rho GTPases is p21 
activated kinase (Pak1), a serine/threonine kinase that has been shown to phosphorylate 
and hence activate the actin binding protein Cortactin. Cortactin is located in the cytoplasm 
and promotes actin polymerization and rearrangements through interaction with the (Arp2/3) 
complex (see also chapter 2.2.3). The finding that Cortactin might act in Agrin-MuSK 
mediated cytoskelletal rearrangements is in line with previous reports showing an 
involvement of Cortactin in promoting lamellipodia formation, invadopodia formation, cell 
migration, and endocytosis (Kelley et al., 2010, Astro et al., 2011, Zhu et al., 2011). 
Moreover, it has been demonstrated that AChR clustering is directly regulated via Cofilin- 
directed vesicular trafficing (Lee et al., 2009). Next to Pak1, other targets of Rho GTPases 
have been identified that are actively involved in cytoskeletal rearrangements, among these 
Wiskott-Aldrich syndrome protein (WASP) family proteins, which activate the Arp2/3 complex 
and Rho-associated protein kinase (ROCK). ROCK is a key regulator of actin organization 
since it can phosphorylate a variety of effectors assumed in the regulation of the actin 
cytoskeleton, including LIM kinase, myosin light chain (MLC) and MLC phosphatase (Riento 
and Ridley, 2003).  
Another important factor for neural and aneural AChR clustering is Rapsyn. Rapsyn has 
been shown to interact with AChR as well as the actin bundling protein α-Actinin in an Agrin-
MuSK signaling dependent manner (Moransard et al., 2003, Dobbins et al., 2008). Therefore, 
it is assumed that Rapsyn anchors AChR to the Actin cytoskeleton and hence stabilizes 
AChR clusters. Furthermore, Agrin-MuSK signaling intensifies the interaction between 
Rapsyn and the chaperone heat shock protein 90β (HSP90β). Rapsyn is a very unstable 
protein, however, bound to HSP90β the AChR/Actin linking function of Rapsyn might be 
preserved. Furthermore, also HSP90β itself has been demonstrated to exert actin filament 
cross-linking activity. Additionally, Agrin binding strengthens the interaction of Rapsyn with 
the protease Calpain, resulting in a suppression of Calpain activity. Calpain, in turn, is 
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involved in the activation of Cdk5, a negative regulator of AChR clustering acting on 
cytoskeletal dynamics. Therefore, Rapsyn/Calpain interaction establishes another link 
between AChR clustering and cytoskeletal dynamics. Interestingly in this context is the 
finding, that Smn is a direct target of Calpain in muscle cells (Walker et al., 2008). Defects in 
synaptic release are a hallmark of SMA. Therefore, reduced Agrin amounts might indirectly 
account for an increased Smn turnover in muscle cells and contribute to the known muscular 
SMA phenotype. In other studies, Agrin was shown to induce the association of AChR with 
the tumor suppressor adenomatous polyposis coli (Apc) (Wang et al., 2003). Furthermore, 
this interaction turned out to be a necessary pre-requisite for AChR clustering. Apc itself is 
able to directly interact with Actin filaments and microtubules or to recruit further 
cytoskeleton-associated proteins (E.g. Asef, Iqgap1) to AChR, contributing to cytoskeletal 
rearrangement (Kawasaki et al., 2000, Watanabe et al., 2004, Wu et al., 2010).  
The above mentioned downstream cascades following Agrin-mediated MuSK activation 
highlight the importance of cytoskeletal dynamics in the process of AChR clustering.  
2.3.6 Mutations in NMJ genes cause myasthenic syndromes  
In many of the above mentioned genes, mutations have been identified which are 
causative for the development of the neuromuscular disorder congenic myasthenic syndrome 
(CMS). Depending on the mutated gene, CMS are subdivided into three categories: 
Presynaptic (e.g. Choline acetyltransferase (CHAT), synaptic (Acetylcholinesterase 
collagenic tail peptide (COLQ)) and postsynaptic (e.g. Acetylcholine receptor (ACHR)). For 
all categories, different subtypes of CMS exist displaying highly variable phenotypic severity 
(Table  1). General clinical features of variable phenotypic strength and time of onset 
common to many CMS forms comprise muscle weakness accompanied by reduced mobility 
as well as swallowing and often respiratory problems (Barisic et al., 2011). The symptoms 
are often similar to Myasthenia Gravis (MG), with the difference that MG is an autoimmune 
disease with circulating antibodies mostly against the ACHR (~85 – 90 % of patients, (Guptill 
and Sanders, 2010)) and sometimes against the MUSK receptor(~8 %, (Sanders et al., 
2003)) .  
MG therapy includes treatment with Acetylcholinesterase (ACHE) inhibitors or 
immunosuppressants (Angelini, 2011). In CMS, immunotherapy is not useful. Instead, AChE 
inhibitors and/or the potassium channel blocker 3,4-diaminopyridine (3,4-DAP), quinidine, 
fluoxetine or ephedrine have been shown to improve disease symptoms (Abicht and 
Lochmuller, 1993, Argov, 2009). 
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Table  1: Congenital myasthenic syndromes (CMS) with associated NMJ genes and clinical picture of the different types. White background: Presynaptic 
genes, light gray: synaptic genes, dark gray: postsynaptic genes (Abbreviations: mNE = mainly Northern European, n.d. = not determined)  
 
Gene / OMIM Name 
 
Type of CMS 
 
Detection frequency 
 
Population 
 
Literature (exemplary) 
Choline 
Acetyltransferase / 
CHAT 
CMS-EA < 3 %1 Diverse origin (mNE) (Ohno et al., 2001) 
Acetylcholinesterase 
collagenic tail peptide / 
COLQ 
EAD < 7,5 %1 Diverse origin (mNE) 
(Donger et al., 1998, Ohno et al., 
1998, Shapira et al., 2002, Yeung et 
al., 2010) 
Acetylcholine receptor 
(AChR) subunits (α, β, 
δ, γ, ε) / CHRNA1, 
CHRNB1, CHRND, 
CHRNG, CHRNE 
CHRNA1: FC/SCCMS, MPS (lethal 
type)  
CHRNB1: SCCMS, CMS ass. with 
ACHR deficiency 
CHRND: FC/SCCMS; MPS (lethal 
type) 
CHRNG: MPS, MPS (lethal type) 
CHRNE: MG, FC/SCCMS, CMS ass. 
with ACHR deficiency 
CHRNA11:  < 0,5 %  
CHRNB11:  < 0,5 % 
CHRND1  :  < 0,5 % 
CHRNG  :  < very rare, 
(<2X105 in the US) 
CHRNE1  :  10 – 30 % 
CHRNA1: Diverse origin 
(mNE) 
CHRNB1: Diverse origin 
(mNE) 
CHRND: Diverse origin 
(mNE) 
CHRNG: US citizens 
CHRNE: Roma/  
southeastern European 
individuals, The Maghreb 
(especially Algeria and 
Tunisia), Diverse origin 
(mNE) 
CHRNA1: (Garchon et al., 1994, 
Engel et al., 1996, Wang et al., 1999, 
Michalk et al., 2008)  
CHRNB1: (Engel et al., 1996, Quiram 
et al., 1999) 
CHRND: (Gomez et al., 2002, Shen et 
al., 2002, Michalk et al., 2008) 
CHRNG: (Hoffmann et al., 2006, 
Morgan et al., 2006, Amalnath et al., 
2011) 
CHRNE: (Uchitel et al., 1993, Ohno et 
al., 1995, Engel et al., 1996, Croxen 
et al., 2002) 
Muscle-specific tyrosine 
kinase / MUSK 
CMS ass. with ACHR deficiency < 1 %1 Diverse origin (mNE) 
(Chevessier et al., 2004, Mihaylova et 
al., 2009, Maselli et al., 2010) 
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Gene / OMIM Name 
 
Type of CMS 
 
Detection frequency
1 
 
Population 
 
Literature (exemplary) 
43 kDa receptor-
associated protein of 
the synapse (Rapsyn) / 
RAPSN 
CMS ass. with ACHR deficiency < 10 %1 Diverse origin (mNE) 
(Ohno et al., 2002, Muller et al., 2006, 
Gaudon et al., 2010) 
Downstream of tyrosine 
kinase 7 / DOK-7 
LGM ~ 1 %1 n.d. 
(Rodolico et al., 2002, Beeson et al., 
2006, Srour et al., 2010) 
Sodium channel, 
voltage gated, type IV, 
alpha polypeptide / 
SCN4A 
HYPP, PMC, HOKPP2 < 0,5 %1 Diverse origin (mNE) 
(Ptacek et al., 1991, Bulman et al., 
1999) 
Type of CMS Clinical picture2 
CMS-EA (Congenital 
myasthenic syndrome 
with episodic apnoea) 
Sudden and recurrent episodes of apnoea, bulbar weakness precipitated by infection, fever, either neonatal onset respiratory 
distress with progressive improvement over time but then further respiratory relapses in adulthood, or late onset (during 
infancy or childhood) respiratory crises with a more unpredictable course of disease  
EAD (COLQ) 
(Endplate 
Acetylcholinesterase 
(AChE) deficiency) 
Broad clinical heterogeneity (often severe) with early onset with progressive disability or later onset with much milder progression 
over the years,  
onset of symptoms in the neonatal period, evidence of delayed motor milestones, frequent early respiratory complications, 
sometimes needing ventilator support, ocular involvement, ptosis, ophthalmoparesis, pupillary reactions  
 
FCCMS 
(Fast channel 
congenital myasthenia 
gravis) 
Caused by mutations in various ACHR subunits and reduced ACh responsiveness, sometimes decreased neonatal movements, 
contractures of both hands, neonatal hypotonia, weak cry, respiratory difficulties, poor feeding, fatigue, ptosis, ophthalmoplegia, facial 
weakness, weakness of the neck flexor muscles, high-arched palate, micrognathia, large ears  
HOKPP2 
(Hypokalemic periodic 
paralysis type 2) 
Onset in childhood to adolescence, hypokalemia, paralytic episodes of all limbs, infrequent but severe attacks, myotonia (sometimes 
temperature depending), muscle weakness 
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Type of CMS Clinical picture2 
HYPP 
(Hyperkalemic periodic paralysis) 
 
Hyperkalemia, muscle weakness (periodic), myotonia (sometimes ocular), bidirectional cardiac dysrhythmia, 
facial dysmorphism, muscle hypertrophy, severe constipation, psychomotor delay, progressive myopathy 
LGM 
(Limb-girdle myasthenia) 
 
Often early onset, weakness within first 5 years of life, difficulty in walking, in adulthood proximal weakness 
in upper and lower limbs as well as neck and trunk, fatigue, ptosis, facial weakness, bulbar symptoms, 
respiratory difficulties  
SCCM 
(Slow channel congenital 
myasthenia symptom) 
Caused by mutations in various AChR subunits and, selective severe neck, wrist, finger extensor weakness 
Onset varies from childhood to adult, varies from mild to severe progressive, ventilatory insufficiency may 
require assisted ventilation 
MPS 
(Multiple pterygium syndrome 
(prenatally lethal and Escobar)) 
 
Pterygia of the neck, elbows, and/or knees and joint contractures (arthrogryposis), small stature, scoliosis, 
flexion contraction of fingers, facial dysmorphism 
PMC 
(Paramyotonia congenita) 
Early childhood to adolescence onset, myotonia (increased by exposure to cold), intermittent flaccid paresis, 
not necessarily dependent on cold or myotonia, lability of serum potassium, nonprogressive nature, lack of 
atrophy or hypertrophy of muscles 
1: Detection frequency based on individuals with CMS investigated in (Abicht and Lochmuller, 1993, Beeson et al., 2005, Engel and Sine, 2005, Amalnath et al., 
2011)  
2: Clinical manifestations of the different CMS types are very heterogenously and thus not exhaustively listed in this table. Taken from OMIM and (Lajoie, 1961, 
Gamstorp, 1963, Bradley et al., 1990, Abicht and Lochmuller, 1993, Bulman et al., 1999, Sugiura et al., 2000, Ohno et al., 2001, Miller et al., 2004, Barisic et al., 
2005, Beeson et al., 2006, Hoffmann et al., 2006, Morgan et al., 2006, Gay et al., 2008, Mihaylova et al., 2008, Schara and Lochmuller, 2008, Selcen et al., 2008, 
Huze et al., 2009, Schara et al., 2010, Barisic et al., 2011) 
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3 Study Aims 
Spinal muscular atrophy (SMA) is the leading genetic cause of infant death and caused by 
the homozygous loss of the survival of motor neuron 1 (SMN1) gene. A nearly identical copy 
gene, SMN2, possesses a C to T transition in exon 7, resulting in the disruption of an exonic 
splicing enhancer (ESE) and consequentially skipping of exon 7 in 90 % of the total 
transcript. However, SMN2 still produces around 10 % full length (FL) transcript. Although 
SMN2 does not fully compensate the SMN1 loss, residual FL-SMN2 is able to ameliorate 
SMA symptoms. Since SMN2 copy number is variable in the population ranging from zero to 
a maximum of four per allele, SMA severity is inversely correlated with SMN2 copy number. 
For a long time SMN2 was the only known modifying gene of SMA. However, in 2008, the 
actin bundling protein PLS3 was identified as another SMA modifying gene showing high 
upregulation in SMN1-deleted unaffected siblings of discordant SMA families. In a detailed 
functional study, PLS3 has been found to rescue axonal outgrowth defects in neuronal cell 
cultures as well as in a zebrafish SMA model. 
The main aim of the present study was to investigate whether PLS3 overexpression is 
able to rescue the disease phenotype in an SMA mouse model. Using the Cre/loxP system, 
a V5-tagged version of human PLS3 (PLS3V5) should be targeted into the Rosa26 locus in 
order to motor neuron (MN) specifically or ubiquitously express the transgene. Prior to further 
analysis, expression of PLS3V5 on mRNA and protein level as well as the subcellular 
localization of the transgene should be analyzed in detail. 
Since PLS3 has been demonstrated to be unexpectedly overexpressed in the 
hematopoietic system of discordant SMA siblings, it was next planned to ubiquitously 
overexpress PLS3V5 in the Hung SMA mouse model. In unaffected SMN1-deleted siblings 
of discordant families, PLS3 overexpression fully compensates SMA symptomatic. To study 
the effects of PLS3V5 overexpression on the clinical picture of SMA mice, motoric tests (tube 
test, righting reflex test) as well as weight and survival measurements should be performed.  
It has been shown in the past that MN death and defects at the neuromuscular junction 
(NMJ) are a hallmark of SMA, finally resulting in atrophy of the muscles. To study the effects 
of PLS3 overexpression on MN, NMJ and muscle development, detailed immuno-
/histological analysis should be performed on these tissues (MN size, presynaptic 
connectivity, Acetylcholine receptor (AChR) cluster size, muscle fiber size). Furthermore, 
possible cell autonomous effects of PLS3V5 overexpression should be studied by motor 
neuron specific activation of the transgene using the Hb9-Cre line. 
The findings presented in this thesis provide new insights into the mechanisms underlying 
PLS3-mediated protection in unaffected SMA patients of discordant families. Furthermore, 
understanding PLS3V5 function in the disease context might ultimately reveal new cellular 
pathways and potential candidate genes for the development of therapeutic strategies. 
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4 Materials and methods  
4.1 Equipment  
 Analytical balance ARJ 120-4M Sartorius 
 Autoradiography cassette Developer Cassettes Siemens 
 Avanti J-20XPI Beckman Coulter 
 Bacterial incubators 
 Standard Kelvitron T Heraeus 
 Shaking Innova 44 New B.scientific 
 FACS FACS Vantage SE BD 
 Cell counting chamber Neubauer chamber Optik Labor 
 Cell incubator Hera Cell 150 Hereaus 
 Centrifuges Allegra X22-R Beckman Coulter 
 5415 D Eppendorf  
 5415 R Eppendorf 
 Avanti J-20XPI Beckman Coulter 
 Concentrator 5301 Eppendorf 
 Developer machines Curix 60  Agfa 
 DNA engine Tetrad 2 MJ research 
 Electrophoresis chambers 
 Agarose gels SGE-020-02 CBS-scientific 
 SDS-PAA gels Mini-Protean 3 cell Biorad 
 Protean II xi Biorad 
 Electroporation cuvettes  GP cuvettes, 0.4 cm Biorad 
 Electroporation system Gene pulser Xcell Biorad 
 Embedding apparatus EG 1150c Leica 
 Flattening table HI 1220 Leica 
 Floating water bath FBC 620 FischerBrand 
 Geiger counter LB 1210B Berthold 
 Glass staining chamber 
 Glaskasten  Roth 
 Färbegestell  Roth 
 Drahtbügel  Roth 
 Heating block HTMR-133 HLC 
 Hot plate magn. stirrer MR 3000 Heidolph 
 Imaging system ChemiDoc XRS Biorad 
 Microplate reader Safire2 Tecan 
 Microscopes  
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 Fluorescent microscope Axioplan 2 Zeiss 
 Inverted microscope DMIL Leica 
 Confocal microscope TCS-SP Leica 
 Confocal microscope META 510 Zeiss 
 Stereo microscope S8 APO Leica 
 Microwave Micro combi Bosch 
 Multi channel pipettes  
 12 channel pipette Finpipette 
 8 channel pipette 4780 Eppendorf 
 pH-meter pH Level 1 Inolab 
 Photometer cuvettes UV-Vette Eppendorf 
 Pipettes 0.5-10  µl Eppendorf 
 2-20  µl Eppendorf 
 10-100  µl Eppendorf 
 20-200  µl Eppendorf 
 100-1000  µl Eppendorf 
 Power supplies PowerPac 1000 Biorad 
  PowerPac HC Biorad 
  Protean II xi Biorad 
 Real time thermocycler Light cycler 1.5 Roche 
 Rotary Microtome RM2255 Leica  
 Shaker 3015 GFL 
 VS.R23 Grant BOEKEL 
 Spectrophotometer BioPhotometer Eppendorf 
 Nanodrop ND-1000 Peqlab 
 Staining chamber Rotilabo® Roth 
 Thermocycler GeneAmp 9700 Applied Biosystems 
 DNA engine Tetrad 2 MJ research 
 Tissue culture hood Hera Safe Hereaus 
 Tissue processor TP 1020 Leica 
 Vacuum pump BVC 21 Vacuubrand 
 Vibratomes Vibratome Series® 1000 Pelco 
 VT 1200 S Leica 
 Water bath par. sections HI 1210 Leica 
 Western blot chambers Mini-Protean 3 cell Biorad 
  Protean II xi Biorad 
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4.2 Chemicals 
If available, chemicals used in this work were purchased as purity grade “pro analysis”. 
For RNA isolation and analysis only RNase-free chemicals were used. Most chemicals and 
reagents were purchased from the following companies: 
 Applichem Darmstadt Germany 
 GE Healthcare Freiburg Germany 
 Life science (formerly Invitrogen) Leek Netherlands 
 Merck Darmstadt Germany 
 Perkin Elmer Rodgau-Jügesheim Germany 
 Promega Mannheim Germany 
 Qiagen Hilden Germany 
 Roche Molecular Biochem. Mannheim Germany 
 Roth Karlsruhe Germany 
 Sigma Aldrich Taufkirchen Germany 
 
Frequently used chemicals include: 
 2-Propanol Applichem 
 Acetic acid  Applichem 
 Chloroform : Isoamyl alcohol 24:1 Applichem 
 Ethanol (EtOH) Applichem 
 Glycerol Applichem 
 Hydrochloric acid (37 %, HCL) Applichem 
 Methanol (MeOH) Applichem 
 Phenol Applichem  
 Potassium acetate (KAc) Applichem 
 Sodium acetate, anhydrous (NaAc) Sigma  
 Sodium Chloride (NaCl) Applichem 
 Sodium hydroxide (NaOH) Applichem 
 Tris (hydroxymethyl)-aminomethane (TRIS) Applichem 
 TRIZMA-base Sigma 
 Xylol Applichem 
4.3 Reagents for molecular biology 
4.3.1 Reagents for DNA work 
 100 bp & 1 kb DNA ladder Applichem 
 Agarose Sigma 
 dNTPs Peqlab 
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 Ethidiumbromide Applichem 
 Oligo d(T) primers 0.5 µg/µl Fermentas 
 Proteinase K Sigma 
 10 x PCR buffer (from Taq kit) Invitrogen 
 50 mM MgCl2 
 TBE-10x-buffer Applichem 
4.3.2 Reagents for radioactive DNA work 
 Hybond XL membrane GE-Healthcare 
 Probe Quant G50 micro columns GE-Healthcare 
 Salm sperm DNA Merck 
 α-[32P]-dCTP radioisotope Perkin Elmer 
4.3.3  Reagents for protein work 
 Ammoniumpersulfate (APS) Applichem 
 Aqua plus (29:1) Acrylamide Applichem 
 Bromphenolblue Applichem 
 Complete Mini Protease Inhibitor Roche 
 Glycin Applichem 
 Nitrocellulose membrane Protran 
 Non fat dried milk powder Applichem 
 Page Ruler Plus Fermentas 
 Ponceau S Sigma 
 Restore Western Blot Stripping Buffer Pierce  
 RIPA-buffer Sigma   
 SuperSignal West Pico ECL Substrate Pierce 
 Tetramethylethylenediamine (TEMED) Applichem 
 Whatman paper Hartenstein 
4.3.4 Reagents for work with bacteria 
 Ampicilin 
 Bacto tryptone 
 Bacto yeast extract 
4.3.5 Reagents for cell culture 
 1x PBS Dulbecco w/o Ca2+, Mg2+, low endotoxin  Biochrom  
 Amphotericin B  Gibco 
 Bacillol®  Bode 
 Dimethylsulfoxide (DMSO) Sigma 
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 Disposable Filter Unit 0.2 μm FP30/0.2 CA-S  Whatman  
 DMEM (+D-Glucose, +L-Glutamine, #41966) Gibco 
 DMEM (+D-Glucose, +Sodiumpyruvate, #10829-018) Gibco 
 DMEM high Glucose (4.5 g/l ) – Glutamine (E15-009) PAA 
 DMEM high Glucose (4.5 g/l) + stable Glutamine PAA 
(E15-883) 
 Fetal Calf Serum (FCS, S0115)  Biochrom AG 
 Gelatine (2 %) Sigma 
 Geneticin (G418-Sulfate) Gibco   
 Leukemia inhibitory factor 1000x (LIF)  Embl 
 L-Glutamin (100 x), 200 mM Invitrogen 
 Mitomycin C (MMC) Sigma 
 Non essential amino acids 100x (NEA) Invitrogen 
 PenStrep (Penicillin Streptomycin)  Invitrogen 
 RPMI transfection-buffer (w/o Phenol red) Gibco 
 Sodiumpyruvate 100mM (1000x) Invitrogen 
 Trypsin-EDTA-Solution  Sigma  
 β-Mercaptoethanol 1000x (ME)  Merck 
4.3.6 Reagents for histo- and immunohistochemical methods 
 Acidic Eosin Y Sigma 
 Bovine serum albumine (BSA) Invitrogen 
 Cresyl violet acetate (Nissl)  Sigma 
 Hard set mounting media (w/o DAPI) Vectashield 
 Hematoxylin  Sigma 
 Horse serum (HS) Invitrogen 
 Mowiol® mounting media Polysciences, Inc. 
 Normal goat serum (NGS) Invitrogen 
 Paraformaldehyde (PFA) Riedel de Haen 
 Triton X-100 Applichem 
 Tween-20 Applichem 
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4.3.7 Kits 
 BCA Protein Assay Reagent  Pierce  
 EndoFree Plasmid Maxi Kit  Qiagen 
 LightCycler FastStar DNA Master SYBR green I  Roche  
 Qiagen MiniPrep Kit  Qiagen  
 QIAquick Gel Extraction Kit  Qiagen 
 QiaQuick PCR Purification Kit  Qiagen   
 QIAshredder  Qiagen  
 Quant-iT RiboGreen RNA assay Kit  Invitrogen 
 QuantiTect Reverse Transcription Kit  Qiagen  
 RediprimeTMII Random Prime Labeling System Ge Healthcare 
 RNase-free DNase I Set  Qiagen  
 RNeasy Mini Kit  Qiagen  
 SuperSignal West Pico ECL Substrate  Pierce  
 QIAEX II gel extraction system Qiagen 
 BigDye Terminator V1.1 Sequencing Kit  Applied Biosystems 
 pcDNA3.1/V5-His Topo TA Expression kit  Invitrogen  
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4.4 Enzymes 
All enzymes were used with buffers recommended by the respective company 
4.4.1 Restriction enzymes 
 Asc I NEB 
 Bam HI NEB 
 Eco RI NEB 
 Eco RV NEB 
 Hind III NEB 
 Kpn I NEB 
 Nco I NEB 
 Not I NEB 
 Not I NEB 
 Pst I NEB 
 Xho I NEB 
4.4.2 Other enzymes 
 Platinum® Taq DNA Polymerase High Fidelity Invitrogen 
 RNase A Qiagen (19101) 
 RNase-free DNase I  Qiagen (79254)  
 Shrimp alkaline phosphatase I (SAP I)  NEB (R0569)  
 T4 DNA-ligase Roche (481220) 
 Taq DNA Polymerase Recombinant  Invitrogen  
4.5 Material for the work with mice 
4.5.1 Mouse dissection equipment 
 Cutfix Sterile Scalpel (5518040) Aesculap 
 Dissecting forceps (BD047R) Aesculap 
 Ear tags (1005-1) National Band & Tag Co. 
 Iris and ligature scissors (BC 100R) Aesculap 
 Micro forceps (FM002R) Aesculap 
 Micro scissors, Spring type (FD012R) Aesculap 
 Operating scissors (BC 321R) Aesculap 
 Splinter forceps (BD302) Aesculap 
 Splinter forceps curved (BD312) Aesculap 
 Surgical scissors (BC 341R) Aesculap 
 Tag applicator (1005-s1) National Band & Tag Co. 
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4.5.2 Reagents for Embryo transfers / Cryoconservation 
 100 Sterican Braun 
 Gonadotropin from pregnant mare serum (PMSG) Sigma 
 Human Chorionic Gonadotropin (hCG) Sigma 
 Omnifix®-F 1 ml Braun 
4.6 Antibodies 
4.6.1 Primary antibodies and staining reagents 
 α-bungarotoxin labeled with rhodamine (B35451) Invitrogen 
 α-Choline Acetyltransferase (ChAt), goat  Millipore 
 (Ab144, Ab144P) 
 α-GAPDH, monoclonal IgG1 (50A19A-1) Imgenex 
 α-Neurofilament M (160kDa, MAB5254), rabbit Millipore 
 α-Neurofilament, monoclonal (2H3-c) Hybridoma Bank  
 α-RPL13a1, goat (sc-160039) Santa Cruz  
 α-SMN, monoclonal IgG1 (S55920) BD Transduction Lab. 
 α-Synaptic vesicle 2, monoclonal (SV2-c) Hybridoma Bank  
 α-V5, monoclonal (R960CUS) Invitrogen 
 α-V5, rabbit (ab9116) Abcam 
 α-V5-HRP, monoclonal (R96125) Invitrogen 
 α-β-actin, monoclonal IgG2a (A2228) Sigma 
 α-β-tubulin, monoclonal IgG1 (T4026) Sigma 
4.6.2 Secondary antibodies 
 HRP-conjugated goat α-mouse IgG (115035000) Dianova 
 HRP-conjugated goat α-rabbit IgG (31460) Pierce 
 Donkey α-goat Alexa 568 IgG (H+L) (A11057) Invitrogen 
 Donkey α-rabbit Alexa 568 IgG (H+L) (A10042) Invitrogen 
 Donkey α-goat Alexa 488 IgG (H+L) (A11055) Invitrogen 
 Goat α-mouse Alexa 488 IgG (H+L) (A10667) Invitrogen 
 Donkey α-rabbit Alexa 350 IgG (H+L) (A10039) Invitrogen 
 Goat α-rabbit Alexa 488 IgG (H+L) (11034) Invitrogen 
 Goat α-mouse Alexa 568 IgG (H+L) (A11004) Invitrogen 
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4.7 Solutions and media 
4.7.1 Frequently used solutions 
Diethylpyrocarbonate (DEPC) treated H2O (for 1 l): 
DEPC  1 ml 
Deionized H2O  to a final volume of 1 l 
 Mix overnight and autoclave 
 
Phosphate buffered saline (PBS, 10 x, for 1 l): 
NaCl  80.0 g 
KCl  2.0 g 
Na2HPO4  14.4 g 
KH2PO4 (pH 7.3)  2.4 g 
deionized H2O  to a volume of 800 ml 
 adjust pH to 7.4 
deionized H2O to a final volume of 1 l 
 autoclave 
 
Sodium Dodecyl Sulfate (SDS) solution 10 % (for 100 ml): 
SDS  10.0 g 
deionized H2O  to a final volume of 100 ml 
 dilute at 65°C, store at room temperature 
 
Tris-HCl (1 M, pH 6.8, for 400 ml): 
Tris-HCl  60.0 g 
deionized H2O  to a final volume of 400 ml 
adjust pH to 8.5 with concentrated HCl 
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4.7.2 Cell culture media 
All cell culture media were stored at 4°C. Freezing-media was used immediately. MMC-
solution was aliquoted and frozen at -20°C. MEF- and ES cell culture was performed using 
media without addition of antimicrobial substances. 
 
Murine embryonic fibroblast (MEF) media (Feeder for ES cell culture): 
DMEM (E15-883, PAA) 500 ml 
FCS (S0115, Biochrom) 70ml 
Sodium pyruvate (100 x) 6 ml 
 
Embryonic stem cell (ES) media (free of antibiotics and fungicides): 
DMEM (E15-009, PAA) 500 ml 
FCS (S0115, Biochrom) 90 ml 
L Glutamine (100 x) 6 ml 
LIF (1000 x) 1.2 ml 
NEA (100 x) 6 ml 
Sodium pyruvate (100 mM) 6 ml 
β-mercaptoethanol 1.2 ml 
 
Common Murine embryonic fibroblast (MEF) media: 
DMEM (41966, Invitrogen) 500 ml 
Amphotericin B (250 µg/ml) 1.4 ml 
FCS (S0115) 50 ml 
PenStrep (10 U/ml) 7 ml 
 
Freezing media for MEF cells (for 1 ml): 
DMSO 0.1 ml 
FCS (S0115) 0.9 ml 
 
Freezing media for ES cells (for 1 ml): 
DMSO 0.2 ml 
FCS (S0115) 0.8 ml 
 
Mitomycin C (MMC) solution: 
MEF media (w/o antimicrobials) 100 ml 
MMC 1.0 g 
 
45 Materials and methods 
 
4.7.3 Solutions for bacterial work 
LB-Media (pH 7.5, for 2 l): 
Bacto Trypton 20 g 
Bacto yeast extract 10 g 
NaCl 10 g 
 adjust pH to 7.5, autoclave and store at 4°C 
 
LB-Agar (for 500 ml): 
LB Media 500 ml 
Agar 7.5 g 
 autoclave and store at 4°C  
4.7.4 Solutions for the work with DNA 
DNA loading buffer (10 x, for 50 ml): 
0.1 % Brom phenol Blue  0.05 g 
1% SDS 2.5 ml 20 % SDS 
100 mM EDTA (pH 7.2-8.5)  10 ml 0.5 M EDTA (pH 7.2-8.5) 
50 % Glycerol 28.7 ml 87 % Glycerol 
Deionized H2O  to a final volume of 50 ml 
 
dNTP mix (for 1 ml): 
dNTP (100 mM)  12.5 μl of each dNTP  
Deionized H2O  to a final volume of 1000 μl 
 
Tail-tip lysis buffer (pH 7.4) (for 500 ml): 
EDTA (0,5 M) 5ml 
NaCl (5 M) 20 ml 
SDS (20 %) 5 ml 
Tris/HCl (1 M, pH 8.5) 50 ml 
Deionized H2O to a final volume of 500 ml 
Proteinase K (200µg/ml)  separately added to each approach 
TBE buffer (5 x): for 1 l: 
Tris base (445 mM)  54 g Tris base 
Borate (445 mM)  27.5 g Boric acid 
EDTA (10 mM)  20 ml 0.5 M EDTA (pH 8.0) 
deionized H2O  to a final volume of 1000 ml 
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TE-4 buffer (for 100 ml): 
Tris (1 M, pH 8.0)  1 ml 
EDTA (0.5 M, pH 8.0)  20 μl 
deionized H2O  to a final volume of 100 ml 
RNAse A (50 µg/ml) separately added to each approach 
 
4.7.5 Solutions for Southern blotting 
Prehybridization mix (for 20 ml): 
deionized H2O 2 ml 
EDTA (0.5 M, pH8) 40 µl  
NaH2PO4 (1 M) 10 ml  
Sonicated and denatured Salm sperm DNA 1 ml add freshly (10 mg/ml) 
SDS (20 %) 7 ml  
 
Salm sperm DNA (10 mg/ml, for 100 ml): 
Salm sperm (sonicated) 1 g 
TE buffer (pH 8.0) 99 ml 
 Solve over night, store at 4°C 
 
TE buffer (for 100 ml): 
Tris/HCl (1 M, pH 8) 1 ml 
EDTA (pH 8, 0.5 M) 0.2 ml 
deionized H2O to a final volume of 100 ml 
 autoclave 
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Wash buffer: 
Wash I:  
SSC (20 x) 100 ml 
SDS (10 %) 10 ml 
deionized H2O to a final volume of 1 l 
 
Wash II: 
SSC (20 x) 10 ml 
SDS (10 %) 10 ml 
deionized H2O to a final volume of 1 l 
 
 Heat buffers to 68°C prior use 
4.7.6 Solutions for Western blotting 
Ammonium Persulfate (APS) solution (10 %, for 10 ml): 
APS  1.0 g 
deionized H2O  to a final volume of 10 ml 
 
Blocking solution (6 %, for 100 ml): 
Nonfat dry milk  6 g 
TBS Tween buffer  to a final volume of 100 ml 
 
Bradford solution (for 1l): 
Coomassie Brilliant Blue G250  100 mg 
H3PO4 (85 %)  100 ml 
Ethanol (95 %)  50 ml 
deionized H2O  to a final volume of 
 
Electrophoresis buffer (10 x, for 1 l): 
Tris-Base  30.29 g 
Glycine  144.13 g 
SDS  10.0 g 
deionized H2O  to a final volume of 1 l 
 
Laemmli buffer for SDS PAGE (2x, for 100 ml): 
Tris-Base  0.757 g 
Glycerol  20 ml 
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Brom phenol Blue  10 mg 
SDS  6 g 
deionized H2O  to a final volume of 90  
β-Mercaptoethanol (prior to use)  10 ml  
 
Ponceau solution (for 100 ml): 
0.5 % Ponceau S  0.5 g 
1 % Acetic acid glacial  1 ml 
deionized H2O  to a final volume of 100 ml 
 
RIPA buffer (for 50 ml): 
NaCl (150 mM)  1.5 ml 5 M NaCl 
IGEPAL (1 %) 5 ml 10 % IGEPAL 
Deoxycholic acid (DOC) (0.5 %)  2.5 ml 10 % DOC 
SDS (0.1 %)  0.5 ml 10 % SDS 
50 mM Tris (pH 8.6)  2.5 ml 1 M Tris (pH 8.6) 
deionized H2O  to a final volume of 50 ml 
 
Separation gel for SDS PAGE (12 %, for 1 gel): 
deionized H2O  1.7 ml 
acrylamide-bisacrylamide mix (29:1, 30 %)  2.0 ml 
Tris (1.5M, pH 8.8)  1.3 ml 
SDS 0.05 ml of 10 % SDS 
APS 0.05 ml of 10 % APS 
TEMED  0.002 ml 
 
Stacking gel for SDS PAGE (for 1 gel): 
deionized H2O  0.68 ml 
acrylamide-bisacrylamide mix (29:1, 30 %)  0.17 ml 
Tris (1 M, pH 6.8)  0.13 ml 
SDS (10 %) 0.01 ml  
APS (10 %) 0.01 ml  
TEMED  0.001 ml 
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TBS Tween buffer (for 5 l): 
Tris (20 mM)  12.1 g  
NaCl (137 mM)  40.0 g 
Tween 20 (0.5 %)  25 ml  
deionized H2O  to a final volume of 5 l 
 adjust to pH 7.56 
 
Transfer buffer (for 5 l): 
Tris-Base  12.1 g 
Glycine  56.3 g 
Methanol  1000 ml 
deionized H2O  to a final volume of 5 l 
 
Tris-HCl (1 M, pH 6.8, for 400 ml): 
Tris-HCl  60.0 g 
deionized H2O  to a final volume of 400 ml 
 adjust pH to 6.8 with concentrated HCl 
 
Tris-HCl (1.5 M, pH 8.8, for 400 ml): 
Tris-HCl  90.5 g 
deionized H2O  to a final volume of 400 ml 
 adjust pH to 8.8 with concentrated HCl 
 
4.7.7 Solutions for histo- and immunohistochemical work 
Blocking (cell-stainings, for 20 ml): 
NGS  1 ml 
BSA 1 g 
PBS to a final volume of 20 ml 
 
Blocking (paraffin sections, for 20 ml): 
NGS (5 %) 1 ml 
BSA (5 %) 1 ml 
TBS to a final volume of 20 ml 
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Blocking (Vibratome sections, for 200 ml): 
Triton X 100 (20 %) 7 ml  
DMSO (1 %) 2 ml 
BSA (2 %) 4 g 
PBS to a final volume of 200 ml 
 
Citrate buffer (0.01 M, pH 6.0, for 1 l): 
Citrate monohydrate 2.1 g 
deionized H2O to a final volume of 900 ml 
 adjust pH to 6.0 
deionized H2O to a final volume of 1 l 
 store at 4°C 
 
Cresyl violet acetate (Nissl) solution (for 1 l): 
Cresyl violet acetate  5 g 
deionized H2O to a final volume of 1 l 
 
4 % Paraformaldehyde (PFA) in PBS (pH 7,3, for 1 l): 
PFA 40 g 
deionized H2O  to a volume of 900 ml 
 adjust pH to 7.3 
deionized H2O to a final volume of 1 l 
 Aliquot and store at -20°C 
TBS (pH 7.5, 10 x, for 1 l): 
NaCl 87.66 g  
Tris 12.11 g 
deionized H2O  to a volume of 900 ml 
 adjust pH to 7.5 
deionized H2O to a final volume of 1 l 
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4.8 Primer 
Primers were individually designed and purchased by Metabion in lyophilized form. Upon 
arrival, lyophilized primers were diluted to 100 pmol/μl stock solutions using deionized 
autoclaved water. Working solutions were obtained by diluting stock solutions to a final 
concentration of 10 pmol/µl. 
Table 2: Primers for cloning a V5-tagged version of PLS3 into the Rosa26 targeting vector 
Transcript / 
Description 
Sequence  
(5´ - 3´) 
ID# Name 
Annealing / 
Amplicon 
length 
PLS3 / 
Amplification of 
PLS3-coding 
sequence (cds) 
for GAGGTGCAGAAGTTGTCTGA 2454 Plst.3T_ex.1-2_fw 
55°C / 
1968 bp rev CACTCTCTTCATTCCCCTGC 2586 Pl_NO_stop_rev 
PLS3V5 / 
Colony PCR 
for TAATACGACTCACTATAGGG 1840 T7 55°C / 
721 bp 
 
rev GTTGATTGCTCTTTCATCAATG 2457 
Plst.3T_ex.3-
4_rev 
PLS3V5 / 
Amplification of 
PLS3V5 with 
Asc I - overhang 
primers 
for 
GGCGCGCCACCATGGATGAGA
TGGCTACCACTC 
3289 AscI-PLS3 For 
55°C / 
2047 bp 
rev 
GGCGCGCCTCAATGGTGATGG
TGATGATGACCGGTA 
3290 AscI-PLS3 REV 
PLS3V5 with 
Asc I restriction 
overhangs / 
colony PCR 
for TGGTGACAGGAATAAAGATG 2456 Plst.3T_ex.3-4_fw 
55°C / 
1112 bp rev ACTGTAAGATTACCAGGGCATC 2463 
Plst.3T_ex.9-
10_rev 
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Table 3:  PLS3V5-sequencing primer 
Transcript 
Sequence 
(5´ - 3´) 
ID# Name Annealing  
PLS3V5 
for GAGGTGCAGAAGTTGTCTGA 2454 Plst.3T_ex.1-2_fw 
55°C for TGGTGACAGGAATAAAGATG 2456 Plst.3T_ex.3-4_fw 
for TGACCTGTTCAAAGCTGTTG 2458 Plst.3T_ex.5-6_fw 
for ATCATTAAGATCGGTTTGTTCG 2460 Plst.3T_ex.7-8_fw 
55°C 
for GGACAAAAGGAAGGTGAACC 2462 
Plst.3T_ex.9-
10_fw  
for TGAAGAAAGAACCTTCCGTAAC 2464 
Plst.3T_ex.11-
12_fw  
for ACTTTAGCTTTAGTCTGGCAGC 2466 
Plst.3T_ex.13-
14_fw  
rev CCTTCTTTCCTGTTGATTGC 2455 
Plst.3T_ex.1-
2_rev  
rev GTTGATTGCTCTTTCATCAATG 2457 
Plst.3T_ex.3-
4_rev  
rev TAAGTTCCTCCAAAGTCTCACC 2459 
Plst.3T_ex.5-
6_rev 
rev TGCAACCTAATTTATCTGCTTG 2461 
Plst.3T_ex.7-
8_rev  
rev ACTGTAAGATTACCAGGGCATC 2463 
Plst.3T_ex.9-
10_rev 
rev GTCGTCATTGGCTTTCTGAC 2465 
Plst.3T_ex.11-
12_rev 
rev AGAGCATACACTCTGGCTCC 2467 
Plst.3T_ex.13-
14_rev  
 
Table 4:  Primers used in qRT-PCR 
Transcript / 
Description 
Sequence  
(5´ - 3´) 
ID# Name 
Annealing / 
Amplicon 
length 
Hprt1 
for TCAGTCAACGGGGGACATAAA 4118 musHprt1F1 63°C / 
142 bp rev GGGGCTGTACTGCTTAACCAG 4119 musHprt1R1 
Murine / 
human PLS3 
for ATGAGCTTGATGAACTCAAA 4092 PLS3olFor1 66°C / 
107 bp rev TGGCATATTAGCTTCCTTGA 4093 PLS3olRev1 
murine Pls3 
for AGCTGATCTGTTCAGCACACC 3301 
Pls3_Mus_3_cDN
A_for 63°C / 
95 bp rev ATACAAAGCAAGCCGGAATG 3302 
Pls3_Mus_3_cDN
A_rev 
PLS3V5 
for GCCAAGTATGCAGTGTCAATG 3913 PLS3 RT For1.2 
66°C / 
230 bp rev 
CCGAGGAGAGGGTTAGGGATA
GG 
3911 PLS3 RT Rev1 
Rpl13a1 
for TTCGGCTGAAGCCTACCAGA 4116 musRpl13aF3  63°C /  
146 bp rev CAAGATCTGCTTCTTCTTCC 4117 musRpl13aR3  
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Table  5:  Genotyping-primers 
Inbred 
strain 
Gene/ 
Transcript 
Sequence  
(5´ - 3´) 
ID# Name 
Annealing/ 
Amplicon 
length 
SMA-Hung 
WT Smn 
for 
ATAACACCACCACTC 
TTA CTC  
3370 
HungSMA_mouse
_wt/Mut_fw_S1 59°C / 
1050 bp 
rev 
GTAGCCGTGATGCCATT
GTCA  
3372 
HungSMA_mouse
_wt_rev_H1 
Hung KO 
for 
AGCCTGAAGAACGAGAT
CAGC  
3371 
HungSMA_mouse
_wt_rev_S2 59°C / 
950 bp 
rev 
ATAACACCACCACTCTTA
CTC  
3370 
HungSMA_mouse
_wt/Mut_fw_S1 
hSMN2 tg 
for 
CGAATCACTTGAGGGCA
GGAGTTTG 
3375 
HungSMA_mouse
_tghSMN2_fw_2F 
59°C / 
479 bp 
rev 
AACTGGTGGACATGGCT
GTTCATTG 
3376 
HungSMA_mouse
_tghSMN2_rev_2
B 
PLS3V5 
PLS3V5 rec 
for 
AAAGTCGCTCTGAGTTG
TTATC 
3650 Typ_forw 
56°C / 
380 bp 
rev 
GATATGAAGTACTGGGC
TCTT 
3649 TYP_rev_wt 
PLS3V5 wt 
for 
AAAGTCGCTCTGAGTTG
TTATC 
3650 Typ_forw 
56°C / 
576 bp 
rev 
TGTCGCAAATTAACTGTG
AATC 
3648 TYP_rev_CAGS 
Stop-
cassette 
Stop-in 
for 
AGGGTTTCCTTGATGAT
GTCA 
3988 Rosa1 Stop for1 59°C / 
505 bp 
rev CATCAGGGGCTCGCGCC 3989 NeoStatRev 
Stop-out 
for 
AGGGTTTCCTTGATGAT
GTCA 
3988 Rosa1 Stop for1 
59°C / 
412 bp 
rev 
CCTTCTTTCCTGTTGATT
GC 
2455 
Plst.3T_ex.1-
2_rev 
CMV-Cre 
Cre for 
CGCATAACCAGTGAAAC
AGCAT 
3104 Credel_fw 
60°C / 
600 bp 
Cre rev 
GAAAGTCGAGTAGGCGT
GTACG 
3105 Credel_rev 
Hb9-Cre 
Cre for 
GTCCAATTTACTGACCGT
ACACC 
3140 Hb9Cre_fw 
60°C / 
704 bp 
Cre rev 
GTTATTCGGATCATCAGC
TACACC 
3141 Hb9Cre_rev 
60°C / 
704 bp 
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4.9 Generated plasmids / GVOs 
The following Plasmids have been generated and were used in the context of this work. 
All insert sequences have been verified by sequencing. 
Table 6:  Plasmids generated and used in this study 
Name 
Vector 
backbone 
GVO # /  
Description 
Antibiotic 
Colony 
PCR 
primer # 
Product 
size (bp) 
PLS3 in 
Topo3.1V5/His, 
correct orientation 
pcDNA3.1V5   
/ His Topo 
500 / 
PLS3 in 
pcDNA3.1V5/His in 
frame with tags 
Amp 
Neo 
1840 
and 
2457 
721 
PLS3V5 Asc I in 
Topo zero blunt 
K2 180807 
Zero blunt 
Topo 
 
502 / PLS3V5 with 
Asc I restriction 
overhangs in Zero 
blunt Topo 
Kan 
Zeocin 
 
2456 
and 
2463 
1106 
PLS3V5 Asc I in 
Rosa26 K1 
20.09.07 
 
Rosa26 CAGS 
targeting 
vector 
503 / PLS3V5 cloned 
into Rosa26 CAGS 
targeting vector 
Amp 
Neo 
 
2533 
and 
2459 
864 
Rosa26 Sonde 
cut EcoRI BamHI 
KII 
pCR Topo 
 
501 / Neo probe 
cloned into pCR Topo 
Amp 
Kan 
 
no 
primers 
- 
 
4.10 Software, internet programs and databases 
 AxioVision Rel.4.7 (fluorescence imaging)  Zeiss 
 CellQuest BD 
 Chromas 2.22 Technelysium Ltd 
 EndNote9/X2 (reference organization)  Thomson Research  
 Lasergene Package (Sequence analysis)  DNAstar Inc. 
 Leica LCS confocal software Leica 
 LightCycler Software (qRT-PCR analysis)  Roche 
 LSM 510 confocal working software Zeiss 
 Office 2003/2007 (word processing etc.)  Microsoft 
 Photoshop CS (image editing)  Adobe 
 Quantity One 4.5.1 (densitometric analysis)  Biorad  
 Sequence Detection Software (qRT-PCR analysis)  ABI 
 SigmaPlot 9/10 (creation of graphs)  Systat Software Inc 
 Vector NTI Invitrogen 
 XFluor4Safire² software (platereader)  Tecan 
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Ensembl  http://www.ensembl.org/  
Gene Expression Atlas database  http://www.ebi.ac.uk/gxa/  
Genecards  http://www.genecards.org/  
Medline  https://www.ncbi.nlm.nih.gov/pubmed  
NCBI  http://www.ncbi.nlm.nih.gov/  
OMIM  http://www.ncbi.nlm.nih.gov/omim  
UCSC  http://genome.ucsc.edu/  
4.11  Molecular biology methods 
4.11.1 Working with DNA 
4.11.1.1 Isolation of genomic DNA from tissue 
To isolate DNA from tissue, the respective tissue (mostly tail tips) was incubated in 493 µl 
lysis buffer + 7 µl Proteinase K (200µg/ml) at 55°C o.n. until the tissue was completely 
resolved. Next, the samples were centrifuged for 5 min at 13.200 rpm. to sediment residual 
hair. The supernatant was transferred into a fresh 1.5 ml tube and 500 µl of RT isopropanole 
were added to precipitate DNA. Tubes were then centrifuged for 10 min at 13.200 rpm to 
pellet the DNA. The supernatant was again discarded and the pellet was rinsed with 700 µl 
70 % EtOH to remove residual salts. After another centrifugation step for 10 min at 13.200 
rpm, the EtOH was removed and the pellet was air-dried in a sterile incubator for 30 min. 
Finally, the pellet was resuspended in an adequate volume of TE-4/RNase (e.g. 70 µl). 1 µl of 
the DNA solution was used for subsequent genotyping PCR reactions. To obtain highly 
purified DNA, as it was needed for Southern blotting, phenol/chloroform extraction was 
performed (chapter 4.11.1.4). 
4.11.1.2 Isolation of genomic DNA from cells 
Attaching cells were first washed with PBS and then trypsinized using 1 x Trypsin solution 
for 5 min at 37°C in a sterile incubator. After trypsinization, the cells were transferred into an 
adequate collection tube and centrifuged for 5 min at 1200 rpm. Another washing step with 1 
x PBS was added and the resulting pellet resolved in 493 µl lysis buffer + 7µl Proteinase K. 
All subsequent steps were performed as in chapter 4.11.1.1. 
4.11.1.3 Determination of DNA concentration 
To determine DNA concentrations, the respective DNA solution was measured using the 
NanoDrop ND-1000 spectrophotometer (Peqlab). After blank with solvent, 1.5 µl of DNA 
solution were applied. Absorptions at wavelengths of 260 and 280 nm were measured 
utilizing a path length of 0.2 mm. Next to the concentration, purity grade was automatically 
determined as the ratio of measured absorption at the wavelength of 260 nm and 280 nm. 
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The optimum range was between 1.8 and 2.0 whereby higher ratios indicate RNA 
contamination and lower ratios indicate protein- or EtOH contamination.  
4.11.1.4 Phenol/chloroform extraction 
Genomic DNA isolated from tissues is highly enriched with proteins. Since protein content 
can interfere with subsequent reactions, e.g. restriction digestions or sequencing, 
phenol/chloroform extraction was applied after DNA isolation. By building hydrogen bonds 
and via hydrophobic interactions, phenol is able to bind to denatured proteins. This property 
makes it possible to separate the organic from the aqueous solution. In brief, the protocol 
included the following steps: First, the supernatant of the cell lysate was mixed with an equal 
volume of phenol/chloroform (1:1) in a Phase Lock Gel™ Heavy tube. The tube was incubated 
for 5 min on a rotator, centrifuged for 5 min at 13.200 rpm and the aqueous supernatant 
transferred into a fresh Phase Lock Gel™ Heavy tube. An equal amount of chloroform was 
added to the solution to extract remaining phenol and another centrifugation step for 5 min at 
13.200 rpm was performed. The purified DNA solution was transferred into a fresh 1.5 ml 
tube. Next, 3 Vol. of ice-cold 100 % EtOH together with 1/10 Vol. of 3 M NaAc (pH 5.2) were 
added to precipitate the solution o.n. at -20°C. The next day, tubes were centrifuged for 20 
min at 13.200 rpm and the resulting pellet was washed once in 70 % EtOH. After another 
centrifugation step the pellet was air-dried and resuspended in an appropriate Vol. of TE-
4/RNase. Phenol/chloroform extraction was also applied to linearized plasmid prior to ligation 
and transfection of ES cells.  
4.11.1.5 Agarose gel electrophoresis 
The principle of gel electrophoresis is the size dependent separation of DNA fragments in 
a gel matrix applying an electric field. Since the ribose-phosphate backbone of DNA is 
negatively charged the DNA migrates towards the cathode (+ pole) in the electric field.  
1 % standard gels were prepared by solving 2.0 g of agarose in 200 ml of 1 x TBE buffer 
under constant heating in a microwave. After cooling of the clear solution to about 50-60°C, 
ethidiumbromide was added to a final concentration of 1 µg/ml.  
The solution was then poured into an appropriate gel tray with a well comb fixed properly and 
placed in the 4°C room. After solidifying, the gel tray was transferred into an electrophoresis 
chamber and covered with 1 x TBE. The comb was removed and PCR samples were 
supplemented with 5 µl of loading dye. The DNA solution was carefully pipetted into the slots 
and the gel was run at 120 V. When the respective bands were nicely separated, as 
controlled by using a UV hand lamp, the gel was documented using the ChemiDoc XRS 
Imaging system (Biorad). 
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4.11.1.6 Purification of DNA fragments out of agarose gels 
To purify DNA fragments out of an agarose gel, the respective DNA band was cut out 
using a scalpel and transferred into a 1.5 ml tube. Normally, the QIAEX II gel extraction- and 
the QIAquick Gel Extraction Kit were used following the manufacturer`s instructions. This 
method was used for the purification of PCR amplified fragments, probes for Southern 
blotting or vectors prior to cloning.  
4.11.1.7 Polymerase chain reaction (PCR) 
The polymerase chain reaction is an enzymatic method to specifically amplify certain 
regions of single-stranded DNA using sequence specific oligonucleotides (primers) (Mullis 
KB, 1986). For DNA amplification the thermostable and so called Thermophilus aquaticus 
(Taq) DNA polymerase was used. Starting from the 3´- end, Taq polymerase is able to 
synthesize complementary DNA sequences from-single stranded template DNA. The 
PCR reaction consists of a series of the three steps denaturation, primer-annealing and 
elongation, termed cycles. An example of a typical cycling sequence is given in Table 7. 
Annealing temperatures of primers depend on the CG/AT content of the individual primer and 
the elongation time on the amplicon size, whereby Taq has an amplification speed of ~1 kb 
/1 min. 
Table 7:  Example of a typical thermocycler program  
Step Temperature [°C] Duration  
1.) Initial denaturation 95 10 min 
2.) Denaturation 94 30 sec 
3.) Annealing XX (depending on primers  
4.) Elongation 72 XX (depending on amplicon size) 
Cycle to step 2 for 35 repetitions 
5.) Final extension 72 10 min 
 
Typically, amplification volumes had a size of 25 µl for genotyping reactions and up to 80 
µl for amplification of fragments to be cloned. An example for a standard 25 µl genotyping 
PCR reaction is given in Table 8. 
Table 8:  Example of a typical 25 µl genotyping PCR reaction 
Component Amount 
dNTPs (200 µM of each, dATP, dCTP, dGTP, dTTP) 4 µl 
MgCl2 0.75 µl 
Forward primer (10 pmol) 1 µl 
Reversed primer (10 pmol) 1 µl 
10 x reaction buffer 2.5 µl 
Taq polymerase (1 U) 0.2 µl 
DNA 1 µl (or minimum 100 – 200 ng) 
H2O to a final volume of 25 µl 
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4.11.1.8 Sanger sequencing 
Underlying the Sanger method of DNA sequencing (Sanger F, 1977) is the use of 
dideoxynucleotide triphosphates (ddNTPs). When incorporated into an elongating DNA 
strand, ddNTPs terminate the PCR amplification reaction. In principle, a PCR reaction is 
performed with a mixture of DNA primer, a Taq DNA polymerase, normal 
deoxynucleotidephosphates (dNTPs), and modified ddNTPs. Each of the four ddNTPs is 
labeled with a different fluorescent dye allowing the identification of the final nucleotide by 
capillary electrophoresis. In this work, the BigDye Terminator V1.1 Sequencing Kit (Applied 
Biosystems) was used strictly following the manufacturer`s instructions.  
4.11.1.9 Enzymatic restriction digestion 
Enzymatic restriction digestion was frequently used in site specific cloning reactions, for 
test restrictions of cloned plasmids or for restriction of genomic DNA prior to Southern 
blotting. Restriction endonucleases cut double- or single stranded DNA by hydrolyzing 
phosphodiester bonds between two nucleotides. The recognition nucleotide sequences 
specific for each of the different enzymes are termed restriction sites. For digestion of 
plasmids 2-5 µg and for genomic DNA 5-20 µg of DNA were restricted o.n. in a water bath at 
37°C. To increase efficiency, a three-fold enzymatic excess was used for plasmid restriction. 
For genomic DNA restriction, an even 5-fold enzymatic excess was used in the reaction. 
Additionally, spermidin and DTT were added to the reaction when genomic DNA was 
digested. A typical example of a restriction reaction for plasmid and genomic DNA is given in 
Table  9. 
 
Table  9:  Exemplary restriction digestion reactions for 1.) plasmid and 2.) genomic DNA 
Component Amount  
1.) Plasmid restriction (total Volume = 30 µl) 
Plasmid  2-5 µg 
10 x buffer 3 µl 
100 x BSA (if necessary)  0.3 µl 
Enzyme  3 U / 1 µg of plasmid DNA 
H2O to a final volume of 30 µl 
2.) Genomic DNA restriction (total Volume = 50 µl) 
DNA 5-20 µg 
10 x buffer 5 µl 
100 x BSA 0.5 µl 
DTT (1 M) 0.05 µl 
Spermidine (1 M) 0.05 µl 
Enzyme 5 U / 1 µg of genomic DNA 
H2O to a final volume of 50 µl 
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4.11.1.10 Ligation of DNA fragments 
Ligation reactions were carried out using T4-DNA ligase (Roche). This enzyme catalyzes 
the joining of two DNA strands between the 5´-phosphate and the 3´-hydroxyl groups of 
adjacent nucleotides in either a cohesive-ended or blunt-ended configuration. For ligation 
reactions, 5 U of T4-DNA ligase were mixed together with the respective vector and insert 
(molar ratio of 1:3, 200 ng of vector standard amount) as well as 1.5 µl of 10 x ligase buffer 
provided by the company and added to a total volume of 15 µl. The approach was incubated 
in a thermocycler o.n. at 16°C. Typically, 5 µl of the ligation reaction was used for the 
transformation of 1 vial TOP 10 cells. 
4.11.1.11 Southern blotting  
Via Southern blot technique, enzymatically restricted DNA is transferred to a nylon 
membrane and target fragments are detected via radioactively labeled DNA probes 
(Southern, 1975) . In this work, Southern blotting was employed for the verification of correct 
insertion of the Rosa26 targeting vector into its destined genomic region in ES cell clones 
and transgenic animals. Following preceding digestion of genomic DNA using EcoR I, two 
different probes were used to prove correct insertion of the Rosa26 targeting construct: 1.) 
An external probe, termed Rosa probe, which binds 5´ of the targeting construct in the 
intrinsic genomic region. This probe allows the detection of correct insertion into the Rosa26 
locus. 2.) An internal probe, called Neo probe, which binds in the Neomycin cassette of the 
targeting construct. Using this probe, random integration of the targeting construct into the 
genome could be detected. The phenomenon of random integration is strictly to avoid since 
insertion into other genes or their promoter regions can disrupt correct gene function. 
4.11.1.12 Restriction and transfer of genomic DNA on a nylon membrane 
Before genomic DNA of ES cells or tail tips was transferred to the nylon membrane it was 
digested with EcoR I o.n. (chapter 4.11.1.9) and separated on a 0.7 % agarose gel o.n. at 
20-30 V. Prior to the transfer, a picture of the gel was taken using the ChemiDoc XRS 
Imaging system. The DNA standard was delineated by stitching through the gel using a 200 
µl pipette tip. Before the transfer, the gel was carefully placed in 0.125 M HCl on a swinging 
incubator for 10 min to depurinate and break DNA into smaller pieces. In the next step, the 
gel was transferred to 0.4 M NaOH and incubated on a swinging incubator for another 20 
min. This step is important for the denaturation of double stranded DNA. The Southern blot 
was assembled avoiding bubbles between the different layers. Before the membrane was 
placed on the Whatman papers, both were briefly preincubated in 0.4 M NaOH. Transfer was 
conducted for 16 h o.n.. The next day, the blot was disassembled and attaching gel rests 
were removed by a short wash in 2 x SSC. For fixing of the DNA, the membrane was 
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incubated for 2 h at 80°C in an incubator. The membrane was either directly used for 
subsequent steps or could be stored at RT for a longer time.  
4.11.1.13 Radioactive labeling of probes and hybridization of the blot  
Prior to hybridization of the nylon membrane with the radioactively labeled DNA probe, 
prehybridization was carried out by incubating the membrane in prehybridization mix (chapter 
4.7.5) for 2-4 h at 65°C on a rolling incubator.  
The sequence of the external Rosa26 probe was subcloned into pCR Topo and was 
generated by enzymatic digestion of the vector with EcoR I and BamH I. The Neo probe was 
PCR-amplified directly from the Rosa26 targeting vector (primer #3849 and 3850). Both 
probes were purified as described in 4.11.1.6. Radioactive labeling of the probes was 
performed using RediprimeTMII Random Prime Labeling kit following the manufacturer`s 
instructions and α-[32P]-dCTP as radioisotope (25µCi). To remove excess nucleotides, the 
probe was purified by centrifugation of the solution in a Probe Quant G50 micro column for 5 
min. After a denaturation step at 95°C and cooling on ice, the labeled DNA probe was given 
to the membrane directly into the prehybridization mix. The membrane was incubated for 16 
h o.n. on a rolling incubator at 65°C. The following day, hybridization mix containing the 
labeled probe was removed and unbound probe was washed off the membrane by stepwise 
20 min incubation in prewarmed washing buffer I and II. Between the washing steps, 
radioactivity was monitored with a Geiger counter to avoid complete removal of the probe. 
When the value of measured radioactivity reached approx. 30-80 Becquerel, the membrane 
was shrink-wrapped in plastic foil and fixed in an autoradiography cassette. An X-ray film 
was placed upon the membrane and incubated, depending on the intensity of the signal, o.n. 
or longer at -80°C. For incubation of the same membrane with a different probe, the 
membrane was stripped by boiling in Southern stripping solution for 20 min. The membrane 
was then incubated with a different radioactively labeled probe. An overview about probes 
and expected fragment sizes is given in Table 10. 
Table 10:  DNA probes for Southern blotting and expected sizes 
Name Detection Enzyme Fragment sizes 
Rosa probe 
Correct insertion of the construct into 
the Rosa26 locus of ES cells and 
transgenic mice 
EcoR I 
wt = 16 kb 
rec = 6.8 kb 
Neo probe 
Random insertion of the construct 
into the genome of ES cells and 
transgenic mice 
EcoR I 
rec = 6.8 kb 
in case of random 
integration: 
additional bands of 
undefined size 
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4.11.2 Working with RNA 
All RNA work was performed using RNAse free substances and material. Since RNA is 
less stabile compared to DNA, samples were always thawed and kept on ice or otherwise 
stored at -80°C.  
4.11.2.1 Isolation of total RNA from mouse tissues 
Isolation of total RNA from mouse tissues was performed using the RNeasy Kit (Qiagen) 
and the QIAshredder (Qiagen) kit according to the manufacturer`s instructions. Since the 
isolation of RNA from fatty tissues like brain and spinal cord can be problematic, an 
additional Qiazol® step was included prior use of the RNeasy Kit. The optional DNase I 
digestion in the RNeasy kit protocol was always conducted.  
4.11.2.2 Determination of RNA concentration 
Total RNA isolated from mouse tissues was used for quantitative real time PCR analysis 
(qRT-PCR). Since the photometric measurement of total RNA is rather imprecise, the Quant-
iT™ RiboGreen® RNA Assay Kit (Invitrogen) was conducted following the manufacturer`s 
instructions. The kit is based on RiboGreen, a dye that is only fluorescent when bound to 
RNA. Therefore, the fluorescence intensity is directly correlated to the RNA concentration 
present in a sample. The assays were performed as triplicates in 96 well plates (Black, flat 
bottom, medium binding, #655076, Greiner bio-one) and analyzed with the TECAN Safire2 
monochromator-based microplate reader (Tecan). 
4.11.2.3 Reverse transcription of RNA into cDNA 
Since RNA cannot be used as template in quantitative real time PCR (qRT-PCR) 
analyses, RNA was first reversely transcribed into cDNA. For this purpose, the QuantiTect 
Reverse Transcription Kit (Qiagen) was used following the manufacturer`s protocol. To avoid 
contamination with genomic DNA, a DNase digestion step was included in the kit. 
Furthermore, oligo-dT primers (Fermentas) binding to the mRNA-specific poly-A tail were 
used to specifically transcribe mRNA only. For the individual samples 300 ng of total RNA 
were transcribed in a volume of 20 µl. Of the defined standard 600 ng of total RNA were 
transcribed in a volume of 20 µl. 
4.11.2.4 Quantitative real time PCR (qRT-PCR) 
Total RNA was isolated from tissues and reversely transcribed as explained in chapters 
4.11.2.1 and 4.11.2.3. When used for qRT-PCR, cDNAs of the samples were diluted in a 
ratio of 1:5 in TE-4. For the standard, 16 µl were mixed with 24 µl of TE-4, properly mixed and 
diluted 8 times in a ratio of 1:2 to obtain all in all 9 dilutions. 3 µl of the diluted sample as well 
as the standard were used in a standard qRT-PCR reaction. An example of a standard 
reaction is given in Table 11. qRT-PCR was performed on a LightCycler 1.5 instrument using 
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Fast Start DNA Master SYBR Green I (Roche). To analyze measurements, the second 
derivative maximum method of the LightCycler software was recruited. Experiments were 
always conducted in triplicates. All primer combinations used in qRT-PCR including 
annealing temperature and amplicon size are given in Table 4.  
Table 11:  Example of a standard qRT-PCR reaction 
Component Amount [ul] 
V[sample] 3 
H2O 2.7 
MgCl2 1.2 
Forward primer 1 
Reversed primer 1 
Fast start DNA Master mix 0.83 
Polymerase 0.27 
 
4.11.3 Working with bacteria 
All cloning steps in this thesis were performed using TOP10 chemocompetent cells 
(Invitrogen). Only for the cloning of PLS3V5 into the targeting vector, XL1-Blue 
chemocompetent cells (Agilent Biotechnology) were used.  
4.11.3.1 Topo TA cloning 
Transformation of Plasmids into TOP 10 cells was performed using the Topo TA cloning 
technology (Invitrogen). This technique makes use of the vaccinia virus derived enzyme 
topoisomerase I that can function as both, a restriction enzyme and as a ligase. The Topo-
vectors are provided linearized and carry topoisomerase I covalently bound to each 3´ 
phosphate of the extending thymine of the pentameric sequence 5´-(C/T)CCTT-3´. If a Taq-
amplified PCR product is added to the buffered reaction solution, topoisomerase I ligates the 
overhanging adenosine rests of  the PCR-fragment to the complementary 3´ thymine of the 
vector. The Topo vectors used in this work were pcDNA3.1/V5-His Topo and Zero blunt 
Topo. 
To clone a certain DNA fragment into a Topo cloning vector, the DNA fragment was first 
amplified using the Taq High Fidelity system (Invitrogen). The PCR product was purified 
using the QIAquick PCR purification system and eluted in TE-4-buffer. To ensure the 
specificity of the PCR reaction, a small aliquot of 5 µl of the PCR product was always tested 
on an agarose gel. If the expected size was detected on the gel, ligation into the respective 
Topo vector was performed as follows: 4 µl of PCR product was mixed with 1 µl of salt 
solution provided by the manufacturer. 1 µl of Topo vector was added and the solution was 
incubated for 10 min at RT. 2 µl of the cloning reaction were given to a vial of freshly thawed 
TOP10 chemocompetent cells. The vial was finger-flipped and incubated for 30 min on ice. 
Following incubation on ice, the heat shock was performed for 30 sec at 42°C. The tube was 
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transferred on ice and 250 µl of RT S.O.C. medium was added. Next, the tube was shaken 
horizontally (200 rpm) for 1 h at 37°C. Different volumes of bacteria (e.g. 30 µl and 70 µl) 
were dispersed on agar-plates containing Ampicillin or Kanamycin in a final concentration of 
50 µg/ml. Plates were incubated o.n. in a sterile incubator at 37°C.  
4.11.3.2 Cloning of PLS3V5 into the Rosa targeting vector 
Before PLS3V5 was inserted into the Rosa targeting vector, 5´ and 3´ Asc I restriction 
overhangs were added via HiFi-Taq PCR and the construct was subcloned into the Zero 
blunt Topo vector. For the final cloning step into the Rosa 26 targeting vector, 5 µg of the 
Zero blunt vector containing PLS3V5 and the empty Rosa26 targeting vector were digested 
with Asc I (chapter 4.11.1.9). To prevent self ligation, the targeting vector was alkaline 
phosphatase treated prior ligation by addition of the respective buffer and enzyme directly to 
the restriction reaction. The complete restrictions were then separated on a 1 % agarose gel. 
The restricted Rosa targeting vector as well as the 2 kb PLS3V5 fragment were cut out and 
purified from the gel using QIAEX II gel extraction kit for the targeting vector and the 
QIAquick Gel Extraction Kit for the PLS3V5 fragment. After elution in an adequate volume of 
H2O (e.g. 20 – 50 µl) the concentration of the eluates was determined and the ligation 
reaction performed  using a vector:insert ratio of 1:3 o.n. at 13°C (chapter 4.11.1.10).The 
next morning, transformation of XL1-Blue chemocompetent cells was performed according to 
the protocol described for TOP10 cells under 4.11.3.1. 
4.11.3.3 Picking and colony PCR for the identification of correct clones 
The agar plates containing the respective antibiotic were kept at 37°C o.n. and usually 10 
colonies were picked per construct the next morning. For colony PCR, clones were lysed by 
osmotic shock in 20 µl dH2O. 5 µl of the clone were used for colony PCR, while the other 15 
µl were used to inoculate an 8 ml o.n. culture.  
The next morning, 0.5 ml of the culture were mixed with 0.4 ml of 50 % glycerol, snap-
frozen and then stored as glycerol stocks at -80°C. The rest of the culture (7.5 ml) was used 
for the isolation of plasmids with the Qiagen MiniPrep Kit after the manufacturer`s 
instructions. After elution of plasmids in dH2O, the concentrations were photometrically 
determined and 150 ng used for sequencing (chapter 4.11.1.8).  
4.11.3.4 Maxi preparation of plasmids 
To isolate up to 500 µg of plasmid, the EndoFree Plasmid Maxi Kit (Qiagen) was used 
following the manufacturer`s instructions. Usually 250 ml of o.n. culture were used for the 
experiments. The kit is specifically designed to eliminate any bacterial contaminations, e.g. 
lipopolysaccharides (LPS) that might interfere with subsequent transfection reactions.  
The plasmids generated and used in this work are listed in Table 6. 
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4.12  Protein biochemical and immunological methods 
4.12.1 Working with proteins 
Since proteins are highly temperature-sensitive, all protein work including thawing was 
performed on ice. Since proteins can furthermore degrade through protease activity, 
protease inhibitor was added to the RIPA buffer. 
4.12.1.1 Isolation of proteins from mouse tissues 
For protein isolation from mouse tissue, a small part of the respective tissue was lysed in 
350-600 µl RIPA buffer, depending on the size of the sample. Prior use, complete mini 
protease inhibitor (1 pill per 7 ml of RIPA buffer) was added to the RIPA buffer to block 
protease activity. Soft tissues like spinal cord or brain were homogenized with help of an 
EPPI-pestle. For compact tissues like muscle, the T 10 basic ULTRA-TURRAX homogenizer 
was used. Next, protein solutions were centrifuged for 30 min at 13.200 rpm at 4°C. The 
supernatant containing the dissolved proteins was transferred to a fresh tube and the protein 
concentration was determined (chapter 4.12.1.3). 
4.12.1.2 Isolation of proteins from cells 
To harvest proteins, cells were first washed two times in 1 x PBS. Lysis of the cells was 
performed by adding 50 µl RIPA buffer containing protease inhibitor (chapter 4.12.1.1) 
directly on a 10 cm Petri dish (30 µl per 1 well of a 6 well plate). The dishes were kept on ice 
for 20 min before a cell scraper was used to collect the solution which was then transferred 
into a fresh 1.5 ml tube. Following another 20 min of incubation on ice, the tubes were 
centrifuged for 20 min at 13.200 rpm at 4°C. The supernatant was transferred into a new 1.5 
ml tube and the concentration was determined (chapter 4.12.1.3) before it was frozen at -
80°C.  
4.12.1.3 Determination of protein concentration 
The protein concentration was determined using the Bradford method (Bradford, 1976). 
Bradford dye is able to bind to proteins whereupon it shifts its absorption maximum from 470 
to 595 nm. To determine the protein concentration of a sample, 2 µl of protein lysate were 
mixed in 498 µl of Bradford solution and incubated for 20 min at RT. After blank with Bradford 
dye, the absorption of the sample was measured at a wavelength of 595 nm. The protein 
concentration of the unknown sample was determined by the mashine comparing the 
measurements to a bovine serum albumin (BSA) standard curve.  
4.12.1.4 SDS polyacrylamide gel electrophoresis (SDS PAGE) 
When separated by SDS PAGE, proteins need to be denatured in Laemmli buffer and 
under the influence of heat (95°C). The SDS of the Laemmli buffer and the PAA gel applies a 
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negative charge to the protein which by far exceeds the intrinsic charge of the protein. This 
way, SDS page allows the separation of all proteins of a sample by size (Laemmli, 1970). 
For SDS PAGE, a 12 % PAA separation gel (chapter 4.7.6) was prepared between two 
glass plates (0.5 mm thickness). Isopropanole was pipetted on top to cover the gel. After 
polymerization, the isopropanole was removed and a stacking gel (chapter 4.7.6)  was 
poured on top of the separation gel. A suitable comb was fixed between the glass slides and 
adjusted using two clamps. Stacking- and separation gel differ by their PAA content and pH. 
Since the stacking gel contains less PAA it forms bigger pores through which the denatured 
proteins can migrate easily in between a front of dipolar glycine and Cl- ions. Therefore, the 
function of a stacking gel is to concentrate the proteins along the border of stacking and 
separation gel. Once the proteins migrate into the separation gel, the glycine dissociates due 
to the increased pH. The separation gel contains a bigger amount of PAA and therefore 
smaller pores are formed. Thus, bigger proteins are slowed while small proteins can easily 
migrate through the pores. Due to their overall negative net charge, proteins are separated 
only by size. Protein samples to be separated (typically 7.5 µg) were supplied with 5 µl of 2x 
Laemmli buffer to which β-Mercaptoethanol had been added in a ratio of 1:10. After mixing 
and a short spin to collect the solution at the bottom of the tube, the proteins were heated to 
95°C for 5 min for complete denaturation. The heating step was followed by a short 
centrifugation step at 4°C to collect condensed fluid from the tube seam. Proteins were kept 
on 4°C until loaded on the gel. Protein size was estimated loading the PAGE Ruler Plus 
(Fermentas) protein ladder in a separate lane. Gel electrophoresis was performed using the 
Mini-Protean 3 cell or Protean II xi system (Biorad). The proteins were run at 40 V in 1 x 
electrophoresis buffer (4.7.6) until reaching the separation gel. From this point on, the 
applied current was increased to 80-120 V. 
4.12.1.5 Transfer of proteins to a nitrocellulose membrane (Western blotting) 
To transfer proteins on a nitrocellulose membrane by wet blotting, the separation gel was 
removed from the glass plates and the remaining stacking gel was discarded. Two sponge 
pads, two filters, the nitrocellulose membrane as well as the gel were equilibrated in transfer 
buffer (4.7.6) and arranged on top of each other in the following order: Sponge pad, filter, gel, 
membrane, filter, sponge pad. Possible air bubbles in the sandwich were removed by 
carefully rolling a small glass pipette over the filter paper. The gel sandwich was then 
inserted into a transfer cell and a cooling module was added. The transfer cell was placed in 
a 4°C room and a current of 30 V was applied o.n..Caused by the negative charge, the 
proteins migrate in the electric field and finally adhere to the membrane due to hydrophobic 
interactions, at the same time keeping the separation pattern present in the gel. The next 
morning, the wet blot was disassembled and the membrane was briefly rinsed in TBST. 
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Protein transfer was either monitored via reversible Ponceau staining or the membrane was 
immediately used for subsequent immunological detection. 
4.12.1.6 Ponceau staining of proteins on nitrocellulose membranes 
To control the protein transfer to the nitrocellulose membrane staining with Ponceau 
solution is commonly used. Ponceau interacts with positively charged amino acid side chains 
and since the staining is reversible the membrane can afterwards be used for subsequent 
immunological detection using antibodies. For Ponceau staining, the membrane was 
incubated in Ponceau solution for 30 sec. The arising band pattern could be clarified rinsing 
the membrane in fresh TBST. For further analysis, the membrane was simply washed in 
TBST until no red signal was present on the membrane any longer.  
4.12.1.7 Immunological detection of proteins on nitrocellulose membranes 
To detect proteins on a nitrocellulose membrane, primary antibodies are used that 
specifically recognize the protein of interest. The staining procedure was performed as 
follows: After wet blotting, the membrane was washed 5 times in TBST to remove any 
residual MeOH from the transfer buffer. To avoid background, the membrane was next 
blocked using 6 % non-fat milk powder in TBST for 3 h. The 6 % non-fat milk was discarded 
and exchanged with 3 % non-fat milk in which the primary antibody had been diluted. After 
incubation with the primary antibody, the membrane was washed 5 x for 5 min in TBST to 
remove unbound primary antibody. Following washing, the membrane was incubated with an 
HRP-conjugated secondary antibody in 3 % non-fat milk that was directed against the 
species from which the primary antibody was derived. After incubation with the secondary 
antibody, the membrane was washed again 5 x for 5 min in TBST to remove unspecifically or 
unbound secondary antibody. To chemiluminescently detect the protein bands, the 
membrane was incubated for another 5 min in SuperSignal® West Pico Chemiluminescent 
Substrate (Pierce). Lastly, the membrane was carefully wrapped in plastic foil, placed into an 
developing cassette and exposed to Hyperfilm ECL (Amersham). Densitometric analysis of 
the films was performed using ChemiDOC XRS analysis software. 
For a summary of primary and secondary antibodies used in this study and respective 
dilutions and incubation times see Table 12. For order numbers of the respective antibodies 
refer to chapter 4.6. 
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Table 12:  Antibodies used in Western blotting 
Primary antibodies Dilution Incubation time 
Rabbit-α-PLS3 
(custom made, Eurogentech) 
1: 4,000 o.n. 
α-SMN (monoclonal) 1:2,000 2 h, alt. o.n. 
α-V5 (monoclonal) 1:3,500 o.n. 
α-V5-HRP conjugated 1:1,500 2 h 
α-Actin (monoclonal) 1:80,000 0.5 h 
α-GAPDH (monoclonal) 1:4,000 o.n. 
Rabbit-α-β-Tubulin (polyclonal) 1:80,000 0.5 h 
Secondary antibodies Dilution incubation time 
Goat-α-mouse-HRP 1:10,000 1 h 
Donkey-α-rabbit-HRP 1:10,000 1 h 
4.12.2 Immuno- and histochemical staining procedures 
Histochemical stainings were performed to visualize cells of the spinal cord (Nissl 
stainings) as well as muscle fibers (Hematoxylin and eosin stainings, H&E). While 
histochemistry describes the staining of tissues using structure specific dyes (e.g. 
hematoxylin staining nuclei and eosin delineating the cytoplasm), immunohistochemical 
stainings are based on the use of primary- and secondary antibodies to detect a protein of 
interest. In a first step, the fixed section is incubated with the primary antibody. After washing 
steps, the fluorophore-conjugated secondary antibody is applied to indirectly detect the 
protein. Analysis is then performed under UV light excitation using a microscope equipped 
with respective filter sets. Alternatively, HRP-conjugated secondary antibodies can be used, 
whereby HRP converts the substrate 3,3'-Diaminobenzidine (DAB) into an insoluble brown 
reaction product in the presence of H2O2. The signal can then be detected using a common 
transmission filter. 
4.12.2.1 Nissl stainings 
For Nissl stainings the basophilic organic compound Cresyl violet is used to outline 
nucleic and ribosomal structures of nerve tissue. In this work, Nissl stainings were 
exclusively performed on 7 µm thick spinal cord sections. First, spinal cord sections were 
deparaffinized by incubation in Xylol for 3 min. Via incubation in decreasing EtOH 
concentrations (100 %, 96 %, 70 %, 50 %, 3 min each) and subsequent incubation for 5 min 
in PBS, the sections were rehydrated before they were stained in Cresyl violet acetate for 10 
min. Following a short wash in H2O, sections were washed in highly diluted acetic acid (2-3 
drops in 100 ml H2O), dehydrated via increasing EtOH concentrations (50 %, 70 %, 96 %, 
100 %, 3 min each), air-dried and embedded in Entellan mounting media.  
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4.12.2.2 Hematoxylin and eosin (H&E) stainings of muscle fibers 
H&E stainings were in this study performed to counter-stain mouse muscle tissue for 
subsequent fiber size measurements. In order to stain with H&E, muscle sections of 7 µm 
thickness were deparaffinized by incubation in Xylol for 30 min. Following incubation in 
decreasing EtOH concentrations (100 %, 96 %, 70 %, 50 %, 3 min each), the sections were 
quickly washed once in PBS and then incubated in H2O for 1 min. Next, sections were 
incubated in Hematoxylin for 6 min and afterwards washed in H2O for 15 min. The sections 
were rinsed quickly in H2O once to remove excess dye and then placed into Eosin solution 
for 1 min. To clarify the stainings, sections were rinsed in H2O 6-7 times and then dehydrated 
in increasing EtOH concentrations. Finally, sections were air dried and embedded in 
Entellan. 
4.12.2.3 Immunohistological stainings of motor neurons 
In order to stain motor neurons, 7 µm thick spinal cord sections were deparaffinized for 2 
h in Xylol and subsequently rehydrated in decreasing EtOH concentrations (100 % I, 100 % 
II, 96 %, 70 %, 1 min each). Following an incubation in H2O for 10 min, antigen retrieval was 
performed by boiling the sections in citrate buffer for 3 x 5 min at 600 W in a microwave. 
After boiling, the sections were left in citrate buffer and cooled down to RT for 45 min. To 
remove citrate buffer, sections were washed once in TBS for 5 min. Blocking of the sections 
was carried out in 5 % of the secondary antibody`s host serum plus 5 % BSA in TBS by 
directly pipetting the solution on the sections and incubating for 45 min at RT in a wet 
chamber.  Subsequently, sections were washed for 3 x 5 min using TBS in a glass tray. After 
that, the sections were incubated with primary antibodies diluted in blocking media o.n. at 
4°C in a wet chamber (Rabbit α-PLS3 1:40; rabbit α-V5 1:40, goat α-Chat 1:40). The next 
day, unbound primary antibody was removed from the sections by 3 x 5 min washing steps in 
TBS. The secondary antibodies were diluted in freshly made blocking solution (Donkey α-
goat Alexa 488 1:200, donkey α-rabbit Alexa 568 1:200) and directly pipetted on the 
sections. Incubation with the secondary antibodies was carried out for 3-4 h at 4°C in a wet 
chamber. To get rid of unbound secondary antibody, sections underwent 3 more washes for 
5 min each. To remove residual salt, sections were briefly rinsed in H2O and then embedded 
in Mowiol® mounting media. 
4.12.2.4 Immunohistological stainings of neuromuscular junctions (NMJ) 
Neuromuscular junction (NMJ) stainings were either performed on proximal- (Transversus 
abdominis, TA) or distal muscle tissue (Gastrocnemius). The isolation of TA- and 
Gastrocnemius muscle is described in chapter 4.14.2.2. All washing and incubation steps 
were performed in 24 well plates.  
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First, the tissue derived from TA muscle was fixed for 10 min and such from 
Gastrocnemius muscle for 20 min in 4 % PFA at RT. After fixing, the TA muscle could 
directly be used for stainings. Different from that Gastrocnemius was embedded in 4 % low 
melting agarose and sliced into 150 µm thick sections prior the actual staining protocol. From 
this point on, the staining protocol was the same for TA- and Gastrocnemius muscle. To 
remove excess PFA, the muscles were washed in 1 x PBS 3 x for 10 min on a rocking 
platform at RT. To permeabilize the tissue, muscles were incubated in PBS containing 2 % of 
Triton X for 30 min on a rocking platform. Following permeabilization, blocking was 
performed in PBS containing 4 % BSA and 1 % Triton. Finally, the antibodies were prepared 
in blocking solution (Mouse-α-2H3 1:100, mouse-α-SV2 1:100, mouse-α-neurofilament 
1:250) and pipetted on the tissue samples. To obtain the best results, incubation with the first 
antibody was always performed o.n.. To reduce background, the samples were 6 x washed 
in 1 x PBS for 10 min under constant shaking on a rocking platform. At this point of the 
protocol, a Bungarotoxin (BTX, labeled with Rhodamine) staining step was included into the 
protocol. For that, 10 µl of BTX stock solution (1 M) was diluted in 7 ml of PBS and the 
samples incubated for 10 min under shaking at RT. In the meanwhile, the secondary 
antibody (goat α-mouse Alexa 488 1:250) was diluted in PBS. After the BTX staining had 
completed, the media was exchanged with the secondary antibody in PBS without any 
intermediate washing step and incubated for 2 h at RT on a rocking platform and wrapped in 
tin foil.  
4.12.2.5 Immunohistological stainings of murine embryonic fibroblasts (MEF)  
For staining of murine embryonic fibroblasts, cells were trypsinized and replated in 12 
wells provided with sterile cover slips. After settling o.n., MEFs were rinsed in PBS once and 
afterwards fixed in 4 % PFA for 15 min at RT. Following fixation, the cells were washed once 
in 1 x PBS for 5 min. To make the epitope better accessible for the antibody, antigen retrieval 
was conducted by adding 80°C hot citrate buffer (pH 6.0) to the cells and incubating them 
under constant cooling to RT for 20 min. After another washing step in 1 x PBS, cells were 
permeabilized in 0.2 % Triton X (alternatively Tween20) in PBS for 5 min. For blocking, cells 
were incubated in 5 % of the secondary antibody`s host serum plus 5 % BSA in PBS for 2 h 
at RT. Next, the primary antibodies (Rabbit α-PLS3 1:40, mouse α-V5, rabbit α-V5 1:40, 
mouse α-Vinculin 1:150) were diluted in 5 % BSA in PBS and given to the cells for o.n. 
incubation. The next day, unbound antibody was removed in 3 washing steps in 1 x PBS for 
15 min each. The secondary antibodies (Donkey α-rabbit Alexa 350 1:250, goat α-mouse 
Alexa 488 1:250) were codiluted with Phalloidin (1:40) in PBS containing 5 % BSA. For an 
optimum result, the cells were incubated in secondary antibody/phalloidin for 4 h, however, if 
shorter incubation times were necessary, the time could be reduced to a minimum time of 1 
h. To remove residual salt, cover slips were repeatedly dunked in dH2O before they were 
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mounted in Vectashield mounting media containing DAPI. Especially when an Alexa 350 
conjugated antibody was used, the DAPI of the mounting media could mask all upcoming 
signals. In this case, DAPI-free Mowiol was used as mounting media. 
To save antibodies, in all experiments a 40 µl droplet of the respective antibody solution 
was pipetted on parafilm and the cover slips placed on the drop with the cells facing the 
solution. For washing steps, the cover slips could easily be transferred into 12 wells again. 
4.13  Eukaryotic cell culture procedures 
To avoid microbial contamination, all cell culture work was performed under sterile 
conditions in a laminar flow tissue culture hood. Additionally, all equipment was sterilized with 
Bacillol or 70 % Ethanol. All ES cell work was conducted under antibiotic- as well as 
fungicide-free conditions, whereas amphotericin B and PenStrep were added to the media 
used for the work with isolated primary murine fibroblasts (chapter 4.7.2). All cell cultures 
were stored in sterile cell incubators at normal cultivation growing conditions in an 
atmosphere with 5 % CO2 at 37°C.  
4.13.1 Common cell-culture techniques 
4.13.1.1 Thawing of cells 
All cell types used in this work were long-term stored in 2 ml Nunc cryo-tubes at either –
80°C or in liquid nitrogen. To thaw eukaryotic cells, 1 ml of the respective media was added 
to the cells and carefully pipetted up and down to slowly resuspend the cells. To dilute toxic 
DMSO the media containing the cells was then transferred into a 15 ml Falcon tube 
containing 8 ml of media. Subsequently, cells were pelleted at 1,200 rpm for 5 min and then 
resuspended in an appropriate volume for further cultivation. 
4.13.1.2 Freezing of cells 
For freezing, the cells were once rinsed with PBS, then trypsin was added and cells were 
incubated at 37°C in a sterile incubator for 5 min. The detachment-process was monitored 
using an inverse microscope since extensive trypsin-treatment might harm the cells. When 
all cells were detached from the surface, the trypsinization-reaction was stopped adding the 
equivalent amount of culture media. Cells were harvested into a collection tube of 
appropriate size and centrifuged at 1,200 rpm for 5 min. The pellet was resuspended in 
freezing media (chapter 4.7.2) and resuspended cells were distributed into cryo-tubes. Cells 
were frozen and stored at -80°C for the first 24 h and then transferred to liquid nitrogen. 
4.13.1.3 Passaging of cells and cell number estimation 
For passaging, cells were first rinsed in PBS and then trypsinized at 37°C in a sterile 
incubator for 5 min. The trypsinization reaction was interrupted by addition of an equivalent 
amount of culture media and resuspended cells were transferred into appropriate collection 
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tubes. The collection tubes were centrifuged at 1200 rpm for 5 min and the pellet was 
reconstituted in an adequate volume of culture media. The resuspended cells where then 
split onto fresh cell plates.  
Estimation of cell number was a frequently used method, e.g. for plating constant 
numbers of cells for immunohistochemical stainings (as performed with MEF cells) but also 
for the transfection procedure of ES cells. To estimate cell number, the cell pellet was 
resuspended in 10 ml of the respective media. 10 µl of the suspension were taken and 
dispersed between a cover slip and a Neubauer counting chamber. The mean value of cells 
of four squares was determined and multiplied by 104 to obtain the total amount of cells per 1 
ml of media.  
4.13.2 Murine embryonic fibroblasts 
Mitotically inactive murine embryonic fibroblasts (MEFs) are commonly used in the 
culturing of murine embryonic stem cells (ES cells). Since transgenic ES cells are eventually 
transplanted into host-blastocysts to finally develop the germline of the chimeric animal, it is 
absolutely necessary to keep them undifferentiated while in culture. In ES cell culturing, 
MEFs serve as monolayer cell matrix to promote ES cell growth. At the same time, MEFs 
secrete leukemia inhibitory factor (LIF), a protein needed to maintain the undifferentiated 
state of ES cells. To further inhibit unwanted differentiation, ES cell media was additionally 
supplied with recombinant LIF (Smith et al., 1988, Williams et al., 1988). 
4.13.2.1 Isolation of murine embryonic fibroblasts 
Murine embryonic fibroblasts (MEFs) for ES cell culture were isolated from E13.5 animals. 
Since ES cells were selected against Neomycin during the transgenesis-procedure, it was 
important to obtain fibroblasts from Neomycin resistant embryos. For that purpose, 
Neomycin-resistant male mice of the line IL-4 (Muller et al., 1991) were bred with wt female 
animals of clean C57BL/6N background. To determine the exact time point of fertilization, 
females were routinely plug-checked early in the morning. If plug positive, the day of 
fertilization was considered as day E0.5 of embryonic development. At E13.5, mothers were 
sacrificed and the embryos carefully prepared from the surrounding uterine tissue. Heart and 
liver were removed while the head of the embryo was used for subsequent genotyping. The 
remaining tissue was transferred to a Petri dish where it was rinsed in PBS 2 times. After the 
washing steps, the embryonic tissue was incubated in 50 ml trypsin/EDTA solution at 37°C 
for 30 min before the reaction was stopped using MEF media. Cells were then centrifuged at 
1,200 rpm for 5 min and the cell pellet was resuspended in MEF media. Finally, the cell-
number was determined as described in chapter 4.13.1.3 and 2.5x106 cells were plated per 
15 cm Petri dish. Cells were grown to confluence under standard cell culture conditions and 
frozen as aliquots containing 5x106 cells. Whenever needed, one aliquot of MEF cells could 
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be thawed and afterwards plated on three 15 cm Petri dishes. At this stage, MEF cells were 
considered as so called EF1 cells, the name indicating that they had been passaged once. 
EF1 cells were then grown to confluence and again split in a 1:3 ratio on three more 15 cm 
Petri dishes resulting in nine 15 cm Petri dishes of EF2 cells. In a last round, EF2 cells were 
passaged to another three 15 cm dishes. Via this way, all in all 27 15 cm dishes of EF3 cells 
could be obtained from one single MEF cell aliquot.  EF3 cells could then be mitotically 
inactivated by MMC treatment for usage in ES cell culture. If not directly needed for ES cell 
culture, EF2 cells were frozen instead and thawed as EF3 cells, inactivated via MMC 
treatment and used for ES cell culturing whenever needed. 
MEFs that were isolated for immunohistochemical stainings were obtained from E13.5 
embryos, too.  A wt female of clean C57BL/6N background was bred with a PLS3V5tg/wt 
animal. At E13.5, the mother animal was sacrificed and again heart and liver were removed 
from the embryos while the head was used for genotyping. Individual embryos were 
homogenized by pressing the tissue through a cell sieve using the plunger of a 10 ml 
syringe. The sieve containing the cells was then rinsed with 10 ml of MEF media and the 
flow-through collected in a 50 ml tube. The cell suspension was centrifuged at 1,200 for 5 
min rpm, the resulting pellet was resuspended in an adequate volume of MEF media and the 
cells plated on 6 cm Petri dishes. MEFs could then be expanded as described above and 
used for immunohistochemical stainings. 
4.13.2.2 Mitomycin C treatment of EF cells 
For usage in ES cell culture, it is important to mitotically inactivate EF cells by MMC 
treatment. Before MMC treatment, EF cells were rinsed once in PBS. After the washing step, 
15 ml of sterile-filtered MMC/MEF media of 10 µg/ml concentration were added per one 15 
cm Petri dish of EF cells. This way, EF cells were incubated for 2-4 h at 37°C in a sterile 
incubator. Next, MMC solution was removed from the cells followed by two washing steps in 
PBS. Finally, normal EF media was added to the cells. Before EF cells were used for ES cell 
culture, 2 h of incubation were given allowing the EF cells to release intracellular MMC that 
might inhibit ES cell proliferation. MMC treated EF cells were always prepared on gelatinized 
Petri dishes. Preceding gelatinization of Petri dishes was performed by incubation of the Petri 
dishes with 0.1 % gelatin/PBS for 5 min at 37°C. After gelatin-excess was removed EF cells 
were plated. 
4.13.3 Murine embryonic stem cells 
Murine embryonic stem cells (ES cells) are derived from the inner cell mass of the 
blastocysts of an early stage embryo at around 3dpc. ES cells are pluripotent cells, meaning 
that they have the capacity to differentiate into all derivates of every of the three germ layers, 
namely endo-, ecto- and mesoderm. They replicate indefinitely and can be cultured on a 
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monolayer of mitotically inactivated feeder cells. Feeder cells serve as an ideal substrate to 
allow proper proliferation of ES cells (Evans and Kaufman, 1981, Martin, 1981). Furthermore, 
feeder cells secrete leukemia inhibitory factor (LIF), a protein inhibiting the differentiating 
process of ES cells. Therefore, they are of highest importance to preserve pluripotency of ES 
cells while culturing. Additionally, the ES cell media is usually supplied with recombinant LIF 
to preserve an undifferentiated state of the ES cells.  
It is possible to genetically manipulate ES cells in vitro and to inject these cells 
afterwards into host-blastocysts. Thereupon, the ES cells can incorporate into the early stage 
embryo to differentiate into all the various tissues and cellular subtypes, including sperm- or 
oocytes of the germ line (Bradley et al., 1984, Gossler et al., 1986, Robertson et al., 1986). 
The resulting animal consists of cells of the host embryo and of donor ES cells and is thus 
chimeric, whereby the degree of chimerism depends on the proliferative ability and the 
degree of pluripotency of the injected ES cells. If the germ-line in the Chimera has formed of 
transgenic ES cells, the respective ES cell genotype can be inherited and a stable founder 
generation of genetically modified animals be established.  
4.13.3.1 Cultivation of murine embryonic ES cells 
ES cells were grown on mitotically inactivated fibroblasts under standard culturing 
conditions of 37°C, 5 % CO2 and 95 % air humidity. ES cell media was changed daily. When 
ES cell colonies reached app. 80 % confluence, cells were passaged, usually in a ratio of 
1:3.  
4.13.3.2 Transfection of ES cells  
Transfection of DNA into eucaryotic cells can be accomplished via different methods. Next 
to methods using lipophilic carrier substrates to deliver DNA into the cell, the transfection via 
electric pulses has turned out to be a highly efficient technique (Neumann et al., 1982). The 
so called electroporation-method was used in this work for the targeted transgenesis of ES 
cells. 
 For one round of electroporation, a total of 60 µg of Rosa26 targeting vector was 
linearized by restriction digestion using Asis I. The linearized vector was afterwards 
phenol/chloroform extracted and could be stored in 70 % ethanol at -20°C until the 
transfection time point. For transfection, the linearized vector was centrifuged at 13,200 rpm 
for 10 min, excess 70 % Ethanol was removed from the tube and the pellet was air dried at 
RT under the sterile hood for 15-20 min. Finally, the targeting construct was resuspended in 
400 µl RPMI medium (w/o phenol-red) and was then ready to use. In one round of 
electroporation, the ES cells (Type V6.5, (Eggan et al., 2002)) of one 10 cm dish (~1x107 
cells) were first trypsinized, centrifuged at 1,200 rpm for 5 min and also resuspended in 400 
µl of RPMI-media. ES cell- and DNA suspension were mixed together and the whole 
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approach (800 µl) was pipetted into the electroporation cuvette. Electroporation was then 
conducted applying 500 µF at a current of 240 mV. Immediately after the transfection, 0.7 ml 
of ES-media was pipetted into the cuvette, the cells were incubated for 10 min and finally 
resuspended in 40 ml of ES-media. 10 ml of the ES cell suspension were pipetted on one of 
four 10 cm Petri dishes that had previously been prepared with mitotically inactivated EF3 
cells. 
4.13.3.3  Selection of recombinant ES cell clones 
After the transfection of the targeting construct, the ES cells were positively selected using 
the Neomycin analogon G418. Since the targeting vector carries the Neomycin resistance 
gene Neor, only ES cells that have stably inserted the construct into their genome should 
survive the selection. Two days after the transfection, positive selection was started by 
adding G418 to a final concentration of 250 µg/ml to the ES cell media.  
Next to the positive selection, it was also possible to negatively select the ES cells against 
random insertion of the construct into the genome. For that purpose, the thymidin-kinase 
gene was cloned downstream of the 3´-homology arm of the Rosa26 targeting construct. 
Thymidin-kinase can convert the selection substrate Ganciclovir (nucleoside-analogon) into 
Ganciclovir-monophosphate. Cellular kinases then phosphorylate the monophosphate into 
Ganciclovir-triphosphate. This molecule can be incorporated into DNA during the process of 
replication which is toxic to the cell and finally leads to cell death. Since the Thymidin-kinase-
gene was cloned downstream of the 3´-homology arm it should be lost in case of 
homologous recombination but not if the construct was inserted randomly. As a 
consequence, only cells in which the construct had inserted via homologous recombination 
should survive negative selection with Ganciclovir. Negative selection was started at day 5 
after transfection. For it Ganciclovir was added to the media to a final concentration of 2 µM 
while positive selection was further continued, too. Between 8-10 days after transfection, 
surviving ES cell colonies were picked into 96 well plates that had been covered with 
mitotically inactive EF3 cells. 
4.13.3.4 Isolation of ES cell clones 
Between days 8-10 after transfection, the positive and negatively-selected ES cells had 
formed nicely oval-shaped colonies with rounded borders. For ES cell colony harvesting, the 
10 cm dishes harboring the colonies were rinsed once with cold PBS and then kept in PBS. 
Using a pipette-tip, single colonies were carefully detached and then sucked up in a total 
volume of 40 µl of PBS. The colonies were then transferred into a single u-shaped slot of a 
96 well plate. To avoid contamination, this work was performed under a sterile hood using a 
stereo-microscope. The slots of the 96 well plate had each been provided with 25 µl of 1 x 
trypsin solution. Since trypsin can harm the cells, the isolation of a total of 96 clones was 
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completed in a maximum time of 30 min. After sampling, the 96 well plates were incubated 
for 5 min at 37°C in a sterile incubator and the reaction was stopped by adding 100 µl of ES 
cell media. After properly pipetting up- and down, the suspension of each slot (total volume 
165 µl) was split (each 50µl) to 3 further 96 well plates with flat bottoms to produce triplicates 
of each clone. These 96 well plates had been covered with MMC treated EF3 cells before. 
When these plates were almost confluent two of the three plates were frozen on two 
consecutive days. For that purpose, plates were first washed 2 x with 100 µl of PBS and then 
treated with 50 µl of 1 x trypsin solution for 3 min at 37°C in a sterile incubator. The reaction 
was stopped adding 100 µl ES cell media and 100 µl 2 x freezing media. Plates were 
accurately sealed using parafilm, properly labeled and frozen in a box at -80°C. The last of 
the three plates was again split to 3 new gelatinized 96 well plates. When the clones of these 
plates had grown confluently, the plates were washed twice with 100 µl of 1 x PBS. The PBS 
was removed and two of the three plates were sealed and then frozen without media for later 
DNA isolation and subsequent southern blot analysis at -20°C. The third plate was 
immediately used for DNA isolation (chapter 4.13.3.6) 
4.13.3.5 Freezing and passaging of isolated ES cell clones on 96 well plates 
After culturing the 96 well plates harboring the individual clones for 2-3 days, 2 of the 3 
plates were frozen on following days. For that purpose, cells were rinsed once with 200 µl of 
1 x PBS and then treated with 50 µl of trypsin for 5 min at 37°C in a sterile incubator. To stop 
the reaction, 50 µl of 2 x freezing media were added to the cells (80 % FK, 20 % DMSO). To 
properly suspend the cells, the solution was pipetted up- and down several times. The plates 
were sealed with parafilm and frozen at -80°C.  
To obtain DNA for Southern blotting the remaining 96 well plate was split on 3 more 96 
well plates. Since the cells served only for DNA-isolation, the plates were not prepared with 
MMC treated EF3 cells but only gelatinized instead.  
4.13.3.6 Identification of positive ES cell clones from 96 well plates 
Positive ES cell clones were identified via Southern blotting (chapter 4.11.1.11) from 96 
well plates. Both, the isolation of DNA and the enzymatic restriction with EcoR I were 
performed directly on the 96 well plate. To isolate DNA, 50 µl of lysis buffer/Proteinase K 
were pipetted into each slot and the well was sealed with parafilm. To avoid drying-out, the 
wells were additionally wrapped in wet paper and placed in a wet chamber for o.n. incubation 
at 55°C in a water bath. After cooling to RT, 100 µl of EtOH were added to each of the slots 
and the DNA was allowed to precipitate for 1 h. By carefully inverting the plates over tissue 
paper, the supernatant EtOH was removed. The remaining DNA pellet was 3 x washed in 70 
% EtOH and then air dried for 30 min at 37°C in an incubator. In a next step, DNA was 
enzymatically restricted by adding 35 µl of restriction solution to each of the slots and 
Materials and methods 
 
76 
incubating o.n. again in a wet chamber (chapter 4.11.1.9). The following day, the restricted 
DNA was subjected to Southern blot analysis. 
4.13.3.7 Thawing and expansion of positive ES cell clones from 96 well plates 
After identification of positive ES cell clones, clones from triplica-96 well plates were 
thawed to expand the cells for blastocyst injection. For that purpose, 100 µl RT ES cell media 
was given to each positive clone and the cell suspension was carefully pipetted up and 
down. Positive clones were first dispersed in 24 wells that had been covered with MMC 
treated EF3 cells. To avoid mixing up of positive clones, the neighboring clones were 
isolated, too. Additionally, these clones served as negative controls in later Southern blot 
analyses. When subconfluent, clones were further split on 6 cm wells covered with EF3 cells 
for further expansion. When grown nicely, the clones of one 6 well were finally split on two 10 
cm Petri dishes covered with EF3 cells. When subconfluent, the ES cells of one 10 cm dish 
were frozen as ¼ as described in chapter 4.13.1.2. A small amount of every clone was 
additionally given on a gelatinized 24 well for later DNA isolation and reconfirmation via 
Southern blotting.  
4.13.3.8 In vitro Cre mediated deletion of the stop-cassette 
ES cells were subjected to in vitro Cre-mediated deletion of the stop cassette to analyse 
functionality of the system and proof proper transgene expression. For in vitro deletion of the 
stop cassette, a modified version of Cre recombinase (HTN-Cre) is used that carries a 
hydrophobic N-terminal tag including a nuclear localization signal (NLS). This modification of 
the protein allows HTN-Cre to pass the membrane of cells and to even enter the nucleus 
(Peitz et al., 2002). In the nucleus, Cre catalyzes site-specific recombination (deletion of the 
stop cassette) between the two loxP sites. In vitro Cre-deleted positive ES cell clones were 
analyzed visually under a microscope and via fluorescent activated cell sorting (FACS) 
analysis for Green fluorescent protein (GFP) expression (chapter 4.13.3.9). Furthermore, the 
expression of the PLS3V5 transgene was demonstrated via Western blotting and 
immunological detection of the transgene with a V5-antibody.  
For in vitro HTN-Cre deletion, 2 x 105 cells of positive clones (served as negative controls) 
were plated on a 6 well and incubated for 5 h. After the incubation phase, the cells were 
washed once in 1 x PBS and sterile filtered HTN-Cre solutions of molarities ranging from 0.5-
8 µM/DMEM were added to the cells as a total volume of 600 µl. As negative control, one 
well of each positive clone was treated with DMEM only. After 20 h of incubation with HTN-
Cre, the media was taken off, the cells were washed once in 1 x PBS and  fresh ES cell 
media was added. To allow GFP and PLS3V5 expression, cells were incubated in another 3 
days.  
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4.13.3.9 Fluorescent activated cell sorting of positive ES cell clones (FACS) 
FACS is a specialized type of flow cytometry that allows sorting of a mixture of cells based 
on the fluorescent characteristics of the cells.  
For FACS analysis, HTN-Cre deleted cells (chapter 4.13.3.8) were first trypsinized and 
then sedimented at 1,200 rpm for 5 min. The pellet was reconstituted in 500 µl PBS and 
pipetted up and down several times to perfectly suspend the cells. Cells were kept on ice 
until FACS analysis using the BD FACS Vantage SE and CellQuest analysis software. 
Excess of cells was further used for Western blot analysis. 
4.13.3.10 Preparation of ES cells for injection into blastocysts 
To prepare positively tested ES cells for injection, one vial of expanded ES cells (4.13.3.7) 
was thawed on a EF3 cells-covered 10 cm Petri dish and grown to subconfluently for 2-3 d. 
The cells were then split at different densities on 3 new 10 cm Petri dishes provided with EF3 
cells (e.g. 1:3, 1:5, 1:8). At the day of injection, the clones with the optimum density grade 
and morphology were chosen for the final preparation steps. Cells were first trypsinized as 
described previously, sedimented at 1,200 rpm and resuspended in 10 ml of ES cell media. 
The cell suspension was given to a fresh 10 cm dish and cells allowed to settle for 30-40 
min. EF-3 cells settle faster than ES cells and therefore ES cells can be enriched in the 
supernatant media this way. Supernatant ES cells were centrifuged at 1,200 rpm for 5 min 
and the pellet was resuspended in 500 µl of prechilled injection media. Cells were kept on ice 
until injection into blastocysts.   
4.13.3.11 Injection of positive ES cells into blastocysts 
The injection of prepared ES cells (chapter 4.13.3.10) was performed as a service of the 
centre for mouse genetics of the University of Cologne. In brief: ES cells were sucked into 
the injection needle fixed to a micro manipulator (Leica) and injected into blastocysts derived 
from CB20 females (white coated). The chimeric blastocysts were then surgically 
transplanted into the uteri of pseudopregnant females that had been produced by breeding 
with vasectomized males. In the best case, chimeric animals were born 21 d later. After 
another 4 weeks, chimeras could be bred with C57BL/6N male and the offspring be analyzed 
for germline transmission.  
4.14  Working with mice 
4.14.1 Mouse inbred strains 
To exclude the influence of the genetic background on a given phenotype it is essential to 
use mouse inbred strains of high homozygosity (Silver, 1995). In this work, all experiments 
were performed using mice on a genetically pure C57 black 6 N (C57BL/6N) background. If 
not on a C57BL/6N background, mouse mutant- or transgenic lines were backcrossed for at 
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least 7 generations to 100 % pure C57BL/6N wt animals. Mice were housed in micro-
isolation chambers in the mouse facility of the Institute of Genetics, Cologne. All experiments 
conducted had previously been described in the animal experimental form as such was 
confirmed by the local animal protection committee under reference number 
93.2.10.31.07.186. All mice were humanely euthanized according to protocols set forth by 
the Landesamt für Natur, Umwelt und Verbraucherschutz NRW. In the following, mutant- and 
transgenic mouse strains used in this study are explained.  
4.14.1.1 SMA-mice 
The FVB.Cg-Tg(hSMN2)2Hung Smn1tm1Hung/J were purchased from The Jackson 
Laboratory (Bar Harbor, Maine (USA), Stock number: 005058) and served as SMA mouse 
model in this study. In these mice, Smn exon 7 is replaced by a targeted insertion of the 
hypoxanthine phosphoribosyl transferase (HPRT) cassette. Since the homozygous knockout 
of Smn (Smn-/-) results in early embryonic lethality, transgenic mice with a 115-kb genomic 
DNA fragment encompassing the human SMN2 region from a human BAC library were 
generated (Hsieh-Li et al., 2000). Importantly, these mice carry 2 hSMN2 copies per 
integrate (Riessland et al., 2010). In a next step, the hSMN2 transgene was crossed into the 
existing SMA background. This way, normal living and fertile Smn-/-;hSMN2tg/tg animals could 
be generated. It is then possible to breed Smn-/-;hSMN2tg/tg mice with Smn-/+ animals to 
produce 50 % SMA-offspring of the disease genotype Smn-/-;hSMN2tg/wt and 50 % of 
heterozygous control animals of the genotype Smn+/-;hSMN2tg/wt. In the course of this work 
this SMA mouse line is termed “Hung SMA” mouse line or the “Taiwanese mouse model” 
referring to the fact that it was generated by a Taiwanese group (Hsieh-Li et al., 2000). 
Originally, SMA-Hung mice were obtained on pure FVB genetic background by the Jackson 
Laboratory. In contrast to that, all used Cre-lines and PLS3V5-transgenic mice were bred 
onto a pure C57BL/6N background. To investigate possible disease modifying effects of 
PLS3V5 expression on the SMA background, SMA-Hung mice had to be backcrossed 
against C57BL/6N wt animals for 7 generations to reach 99 % genetic purity.  
4.14.1.2 PLS3V5-transgenic mice 
4.14.1.2.1  PLS3V5-floxed mice  
In the scope of this work PLS3V5 transgenic mice were generated. An N-terminally V5-
tagged version of human PLS3 (PLS3V5) was first cloned into a murine Rosa26 locus 
targeting construct (Kindly provided by Dr. Thomas Wunderlich, Cologne). Targeted 
transgenesis was performed using the Hybrid ES cell line V6.5 (Eggan et al., 2002). Since 
this cell line represents a mixture of 129/Sv and C57BL/6 genetic background the resulting 
PLS3V5-floxed line had to be backcrossed against C57BL/6N wt animals for 7 generations to 
reach 99 % genetic purity. In the targeting construct, the PLS3V5 coding sequence (cds) is 
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located downstream of the CMV enhancer/chicken β-actin (CAG) fusion promoter. However, 
a loxP sites flanked stop-cassette is present between promoter and PLS3V5 transgene 
preventing uncontrolled PLS3V5 expression. By breeding with tissue-specific Cre-strains 
conditional overexpression of the PLS3V5 transgene can be achieved. For a detailed 
description of the generation and nomenclature of the PLS3V5-floxed line see chapters 5.3.1 
and 5.3.2. 
4.14.1.2.2 PLS3V5-ubi mice 
By intercrossing the PLS3V5-floxed line with the Cre-deleter line cytomegalovirus minimal 
promoter (CMV)-Cre (Schwenk et al., 1995), permanent deletion of the stop-cassette 
between promoter and PLS3V5-cds was achieved. In the resulting and from now on termed 
PLS3V5-ubi mice deletion of the stop-cassette resulted in ubiquitous expression of the 
transgene in nearly all tissues investigated (chapter 5.4.1.1). Neither animals heterozygous 
nor homozygous for PLS3V5 displayed any obvious outer phenotypes. PLS3V5-ubi animals 
are fully fertile and show a normal life expectancy. Since CMV-Cre mediated deletion 
includes germ cells, the deletion of the stop-cassette is inherited to further generations also 
in the absence of the CMV-Cre allele. For a detailed description of the generation and 
nomenclature of the PLS3V5-floxed line see chapters 5.3.1 and 5.3.3.  
4.14.1.3 Cre-lines 
4.14.1.3.1 CMV-Cre-deleter mice 
The CMV-Cre deleter line expresses Cre-Recombinase under the control of the human 
cytomegalovirus minimal promoter (CMV) (Schwenk et al., 1995). Using this mouse line, 
deletion of loxP flanked genes or stop-cassettes occurs in all tissues, including germ cells. 
For this reason and because it was available in the mouse facility of the Institute of Genetics 
(Cologne) the CMV-Cre line was chosen to permanently remove the stop-cassette between 
promoter and PLS3V5-cDNA in the PLS3V5-floxed line. In this context, it is important to 
mention that the CMV-Cre transgene is located on the X-chromosome (Schwenk et al., 
1995). Due to gene silencing effects via X-chromosomal inactivation only CMV-Cre 
homozygous females (CMV-CreX_tg/X_tg) were used to efficiently delete the stop-cassette in F1 
male mice of the genotype PLS3V5fl_st/wt;CMV-CreX_tg/y (For a detailed explanation see 
chapter 5.3.3). 
4.14.1.3.2 Hb9-Cre mice 
In the Hb9-Cre mouse line the Cre gene is expressed under the intrinsic motor neuron-
specific promoter of the Hb9 gene. Since homozygous loss of Hb9 results in perinatal 
lethality and because the Cre insertion disrupts Hb9 function (Arber et al., 1999, Yang et al., 
2001) it is only possible to keep the Hb9-Cre transgene in a heterozygous state. By breeding 
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the PLS3V5-floxed line with Hb9-Cre mice, it was possible to delete the stop-cassette 
specifically in the motor neurons. This technique allows to investigate possible cell 
autonomous effects of PLS3V5 overexpression on motor neurons, nerve terminals as well as 
AChR clustering. The Hb9-Cre line was on pure C57BL/6N background. 
4.14.2 Preparation of mouse tissues and organs 
For the preparation of mouse organs, the animals were euthanized, placed on their dorsal 
side and arms and legs were fixed using needles.  A longitudinal section was cut through the 
abdominal wall and the rib cage to open the animal. The rib cage and abdominal skin were 
stretched sideways and also fixed with needles. Organs were isolated into 1.5 ml tubes using 
ligature scissors and dissecting forceps and could directly be used for isolation of RNA or 
proteins. Alternatively, organs were snap frozen in liquid nitrogen and placed at -80°C for 
longer storage. 
4.14.2.1 Isolation of the spinal cord 
To isolate the spinal cord as a whole, the fur and skin on the dorsal side of the euthanized 
animal had to be removed. Next, it was cut in posterior to anterior direction along the spine. 
Head and tail were cut off and the spine was removed by carefully detaching it from ventral 
connective tissue. Using a scalpel, the tail region of the spinal cord was removed up to where 
the lumbar region begins. In a next step, PBS was loaded into a 20 ml syringe and the blunt 
grinded 20G needle inserted into the lumbar end of the spinal cord. Under constant pressure, 
the spinal cord was flushed out of the spine into a glass containing 1 x PBS. For subsequent 
staining procedures, the spinal cord was fixed for 2 d in 4 % PFA at 4°C and then embedded 
into paraffin. When used for RNA or protein isolation, the halves of the spinal cord were 
separated longitudinally. One half was used for RNA while the other half was used for protein 
isolation. 
4.14.2.2 Preparation of muscle tissue 
4.14.2.2.1  Transversus abdominis muscle 
The isolation of the proximal Transversus abdominis (TVA) muscle is laborious and 
requires working under a stereomicroscope. To open the skin, first a little cut was made 
above the genitals of the euthanized animal. Next, a careful section once around the belly 
and immediately under the skin was performed. Using forceps, the animal was skinned over 
the head so that the underlying abdominal wall was exposed. Before the next steps, the 
connective- and muscle tissue of the neck and the throat had to be removed. Then, the 
abdominal wall was opened carefully just above the bladder of the animal. In a next step, it 
was cut on both sides laterally towards the spine and on the dorsal side of the animal along 
the spine towards the neck through the dorsal part of the ribcage. To remove the ribcage 
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from the abdominal cavity, it was sectioned through the diaphragm from both sides. The 
whole ribcage was then placed on Sylgard-filled Petri dishes, the abdominal wall was stretch-
fixed using fine minutien-pins and covered in 1 x PBS. To expose TA muscle, small windows 
were cut through the first three muscle layers (Rectus abdominis, external oblique muscle 
and internal oblique muscle) using micro scissors. After fixing the whole rib cage for 20 min 
in 4 % PFA the windows were excised and stored in 1 x PBS at 4°C for subsequent staining 
procedures. 
4.14.2.2.2  Isolation of Gastrocnemius and Vastus lateralis muscle 
To isolate Gastrocnemius and Vastus lateralis muscle, the legs were cut off from the 
euthanized animal just above the pelvises. Using forceps, remaining skin and hair were 
removed.  
For preparation of Gastrocnemius muscle, attaching tendons of the femoral bone and 
Achilles tendon were intersected so that the muscle could easily be isolated. For Vastus 
lateralis isolation, the lower leg was cut off after Gastrocnemius preparation. The upper leg 
was fixed and embedded as whole prior sectioning. 
For fixation, muscles were incubated for 10 min in 4 % PFA. Gastrocnemius was most of 
the times immediately used in subsequent neuromuscular junction (NMJ) staining 
procedures. Alternatively, it was stored for up to one week in 1 x PBS at 4°C. For isolation of 
protein, Gastrocnemius was snap frozen and proteins were isolated whenever needed. 
Vastus lateralis was exclusively used for muscle fiber size determination and therefore 
dehydrated and subsequently embedded for sectioning.  
4.14.2.3 Motoric ability testing and weight measurement 
To analyze the motoric ability of animals, the tube test and the righting reflex test were 
recruited (El-Khodor et al., 2008).  
Via the tube test, the proximal hind limb muscle strength, weakness and fatigue in mouse 
Neonates can be assessed. The test is performed in two consecutive trials, whereby the 
animal is placed head down into a 50 ml Falcon tube hanging by its hind limbs. In the 
following, the so called hind limb score (HLS) was evaluated based on the positioning of the 
hind limbs towards each other (Figure 5).  
The righting reflex test is another method to examine muscle strength. For this test, 
animals were placed on their back on a flat surface. The time to reposition themselves was 
measured over a 30 sec period. The righting times were related to a score in the following 
manner: >1 sec = 0, 1-2 sec = 1, 3-4 sec = 2, 5-6 sec = 3, 7-8 sec = 4, 9-10 sec = 5, <10 sec 
= 6. 
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Figure 5:  Tube test (El-Khodor et al., 2008): Hind limb scores (HLS) and respective leg positions 
for motoric ability assessment  
4.14.3 The Cre/loxP system for conditional gene-deletion or activation  
The Cre/loxP system is a genetic recombination tool which was developed in the 1980s 
and patented by DuPont. The system allows the deletion of any kind of DNA sequences 
located between two loxP sequences, which are target sites for the recombinase Cre 
(Cyclyzation recombination).  
For gene deletion, the loxP sites are targeted into the endogenous gene locus flanking the 
whole gene or only certain parts, e.g., an exon important for proper function of the protein. 
The targeted mouse line with the so called floxed allele is then crossed with another mouse 
line expressing Cre recombinase under a tissue specific promoter. In the offspring carrying 
both the floxed allele as well as the Cre recombinase the target gene (or exon) will be 
deleted only in the tissue where Cre is active (Figure 6, A). 
For conditional transgene expression, as used in the present work, a floxed stop cassette 
is cloned between a ubiquitously active promoter (e.g. CAG promoter) and the transgene 
(chapter 5.1.1). When the LoxP line is then crossed with another line expressing Cre under a 
tissue specific promoter, the stop cassette is conditionally deleted resulting in tissue specific 
transcription of the transgene (Figure 6, B). In this work, motor neuron specific activation of 
PLS3V5 was established using a Cre-line carrying Cre under the motor neuron specific Hb9-
promoter . 
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Figure 6 Cre/loxP system. A: Cre is expressed under a tissue specific promoter and therefore 
tissue specifically deletes the floxed target gene. B: Cre/loxP system in conditional 
transgene expression. Cre is expressed under a tissue specific promoter and 
accomplishes deletion of the floxed stop cassette present between promoter and 
transgene. This results in tissue specific transgene expression. 
4.15 Statistical methods 
To test significance of measurements the directional student`s t-test was recruited. Three 
levels of statistical significance were distinguished: p<0.05 = *, p<0.01 = **, and p<0.001 = 
***. Furthermore, a Wilcoxon-rank-sum test was performed in order to determine the 
significance of the survival differences (the shift of the Kaplan-Meier curves) between SMA 
and PLS3V5 + SMA mice and SMA mice on different genetic backgrounds. 
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5 Results 
5.1 Generation of the Rosa26 targeting construct 
5.1.1 Rosa26 targeting and structure of the targeting construct 
Currently, the two most common methods for the generation of transgenic animals are (i) 
pronuclear injection or (ii) gene targeting into a certain locus of the mouse genome. For 
pronuclear injection, a solution of DNA is directly injected into fertilized oocytes with a micro 
syringe under a microscope (Costantini and Lacy, 1981, Gordon and Ruddle, 1981). In a 
next step, the blastocysts are then transplanted into pseudopregnant recipient females. 
Transgenic founder can be obtained after 3 weeks and be bred with wt animals another 7 
weeks later to identify germline transmission. This method of transgenesis offers the 
advantage of being relatively fast and cost effective. Since the insertion of the transgene into 
the genome is random, however, the chance exists that it integrates into another gene or its 
promoter region, thereby disrupting the function of the gene. Insertional mutagenesis can 
therefore contribute to any observed phenotype and complicate analysis. Furthermore, 
transgenes are often silenced due to multiple transgene copy number insertions (up to 1000+ 
tandem copies of the transgene) (Garrick et al., 1998).  
To circumvent these problems, targeted transgenesis into the Rosa26 locus was used in 
this work. For targeted transgenesis, ES cells were stably transfected with the targeting 
vector carrying the transgene. After selection of clones that had correctly inserted the 
targeting construct in the Rosa26 locus, cells of such clones were injected into blastocysts 
and these transplanted into pseudopregnant females. After 3 weeks chimeric mice were 
born, raised to adulthood and bred with wt mice to scan the F1 offspring for transgenic 
founder animals.  
The Rosa26 locus is frequently used for transgenesis of mice since integration into this 
site occurs highly efficient, it supports strong and ubiquitous expression of inserted 
sequences and is not subjected to gene silencing effects (Zambrowicz et al., 1997). 
Importantly, the murine Rosa26 locus is located on chromosome 6. Since Smn, hSMN2 and 
Hb9-Cre all map to other chromosomes, it was possible to cross the PLS3V5 transgene onto 
the SMA background (Figure 7) or to motor neuron specifically express the transgene. E.g., 
to study the effect of PLS3V5 overexpression on the SMA phenotype, PLS3V5tg/wt;Smn-/-
;hSMN2tg/wt mice were generated. In case, however, that PLS3V5 and the Smn knockout 
mapped to the same chromosome, it would not be possible to express PLS3V5 on an Smn-/- 
background since the allele carrying PLS3V5 carries a wt version of Smn. 
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Figure 7: Illustration of the chromosomal location of transgene and knockout alleles important in 
this work. Rosa26 maps to chromosome 6 and thus PLS3V5, Smn is located on 
chromosome 13, the hSMN2 transgene is on chromosome 4. Hb9-Cre maps to 
chromosome 5 and has been inserted under the Hb9-promoter. 
In the Rosa26 targeting construct (Kindly provided by Dr. Thomas Wunderlich, University 
of Cologne (Belgardt et al., 2008)) the gene of interest, in this work PLS3V5, is cloned via an 
Asc I restriction site and driven by the CMV enhancer/chicken β-actin (CAG) promoter 
(Figure 8). The Neomycin resistance gene (Neor) and the transcription stop cassette are 
flanked by loxP sites on both sides and are located between promoter and transgene to allow 
conditional activation of the transgene (Cre/loxP system, chapter 4.14.3). 3´ of the gene of 
interest, green fluorescent protein (GFP) is cloned behind an internal ribosomal entry site 
(IRES) allowing indirect detection of the transgene in vivo. The size of the DNA homology 
arms was 1.080 and 4.247bp for the short and long arm, respectively. The sequences were 
cloned 5´ and 3´ flanking the internal elements to allow targeted homologous recombination. 
Additionally, Diphteria toxin A was cloned 3´ of the long homology arm and served as 
negative selection marker in case of non homologous random insertion of the construct. The 
sequence including both homology arms and internal elements has a size of 16.054 bp. The 
nucleotide sequence of the targeting construct is included in the appendix of this work.  
 
Figure 8: The Rosa26 targeting construct. (Abbreviations: CAG = CMV enhancer/chicken β-
actin promoter, Neo
r
 = Neomycin, IRES = internal ribosomal entry side, GFP = green 
fluorescent protein; DTA = Diphteria toxin A).  
5.1.2 3 Step (A-C) strategy for cloning PLS3V5 into the Rosa26 targeting vector – 
Overview 
Before PLS3 was inserted into the Rosa26 targeting vector, a V5-tag was cloned in frame 
with the PLS3 coding sequence (cds) so that the transgene could be discriminated from 
murine Pls3. For that purpose, PLS3 cds was inserted into the pcDNA3.1V5/His Topo vector 
(Figure 9, Step A). After confirmation of the sequence, Asc I restriction overhangs were 
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added to the 5´ and 3´ ends of PLS3V5 via HiFi Taq PCR and the product was subcloned 
into Zero blunt Topo (Step B). The sequence was again confirmed and using enzymatic 
restriction with Asc I, PLS3V5 was cut out of the vector and finally ligated into the Rosa26 
targeting vector (Step C). The GVO numbers of the sequence-confirmed clones are depicted 
in Figure 9.   
 
Figure 9: Steps of PLS3V5 cloning into the targeting vector. A: Amplification of PLS3 and 
subcloning into pcDNA3.1V5/HIS Topo vector to add the V5-tag. B: Amplification of 
PLS3V5 using Asc I restriction overhang primers and subcloning into Zero blunt Topo. 
Note that Asc I-PLS3V5-Asc I was reversely cloned as indicated by the 5´ and 3´ 
orientation of the vector. C: Enzymatic restriction with Asc I and ligation into the Rosa26 
targeting vector. (Abbreviations: GVO # = Gentechnisch veränderter Organismus) 
5.1.2.1 Step A: Subcloning of PLS3 into the pcDNA3.1V5His Topo vector 
At the beginning of this work, PLS3 cds (1893bp) was present in the pcDNA3.1V5/His 
Topo vector, however it was inversely oriented. To correctly add the V5-tag 3´ of the PLS3 
cds, PLS3 was first amplified using Hifi Taq, purified via a 1 % agarose gel and again 
subcloned into the pcDNA3.1V5/His vector (Figure 9). Clones with correct orientation of the 
PLS3 insert were identified via colony-PCR, amplified, plasmids isolated and subjected to 
test restriction using Xmn 1 and Hind III restriction enzymes (Figure 10).  
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Figure 10: A: Colony PCR of PLS3V5 in pcDNA3.1V5/His (Primer:  #1840 + 2457, expected size 
= 714 bp) B: Test restriction of clone 1 of PLS3V5 in pcDNA3.1V5/His and respective 
expected sizes. (Abbreviations: C = clone; u.c. = uncut vector) 
Clones showing the expected restriction band pattern were analyzed via sequencing to 
assure that no mutations were present after the PCR-amplification step and that the V5-tag 
was in frame with PLS3 cds. Clones were backup-frozen in liquid nitrogen under GVO 
reference number 500. 
5.1.2.2 Step B: Addition of Asc I restriction overhangs to PLS3V5 and subcloning 
into Zero blunt Topo 
For inserting PLS3V5 into the Rosa26 targeting vector, Asc I restriction sites had to be 
cloned 5´ and 3´ of PLSV5. For this purpose, PLS3V5 was Hifi Taq-amplified from GVO # 
500 (Figure 9) with Asc I restriction-overhang primers, gel purified and subcloned into Zero 
blunt Topo. Since the orientation of PLS3V5 in this vector was of no relevance, a colony PCR 
using primers binding in the internal region of PLS3 was performed. Through test restriction 
clone one (C 1) was identified as reversely inserted into Zero blunt and afterwards confirmed 
to be correct by complete sequencing of the insert (Figure 11). Bacteria of this clone were 
backup-frozen in liquid nitrogen under GVO reference number 502. 
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Figure 11: A: Colony PCR of PLS3V5 with Asc I restriction sites in Zero blunt Topo (Primer: 
#2463 + 2456, expected size = 1.1kb). B: Test restriction of C 1 using EcoR I and 
Hind III revealed a reversed insertion of Asc I-PLS3V5-Asc I into Zero blunt Topo. 
(Abbreviations: C = Clone; u.c. = uncut) 
5.1.2.3 Step C: Insertion of PLS3V5 into the Rosa26 targeting vector 
To insert PLS3V5 into the Rosa26 targeting vector, GVO clone # 502 and the empty 
targeting vector were enzymatically restricted using Asc I (Figure 12, A). After restriction was 
completed, the PLS3V5 band (~2 kb) and the linearized Rosa26 targeting vector (~16 kb) 
were cut out of the gel and purified using QIAquick Gel Extraction Kit. To avoid religation, the 
linearized targeting vector was alkaline phosphatase treated and subsequently 
phenol/chloroform extracted. Since transformation of large constructs into bacterial cells can 
be problematic, XL1-Blue bacteria were used in this approach. Bacteria were selected 
against Ampicilin, clones picked the next morning and subjected to colony PCR (Figure 12, 
B). Positive clones were amplified and a test restriction was performed using EcoR V, XhO I 
and Asc I (Figure 12, C) After observation of the correct band pattern, clone 1 (GVO # 503) 
was analyzed by sequencing and found to be 100 % correct (Figure 12, D). Since large 
amounts of Rosa26 targeting vector were needed for the transfection of ES cells, new media 
was inoculated with GVO clone # 503 and Maxi preparation of the plasmid was performed 
using the EndoFree Plasmid Maxi Kit (Qiagen). The transfection of ES cells, ES cell 
selection, clone picking and DNA preparation for subsequent Southern blot analysis were 
performed as described in the Material and Methods part of this work (chapter 4.13.3). 
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Figure 12: A: Enzymatic restriction digestion of the Rosa26 targeting vector and PLS3V5 in Zero 
blunt Topo with Asc I. B: Colony PCR with clones obtained after ligation of PLS3V5 
into the Rosa26 targeting vector (Primer: #2533 + 2459, expected size = 817bp). C: 
Test restriction of the targeting vector containing PLS3V5 demonstrated the correct 
insertion of PLS3V5 into the Rosa26 targeting vector. Note that restriction with Asc I 
results in appearance of the 2 kb PLS3V5 band. D: Snapshot of Seqman sequencing 
analysis software showing 100 % correct sequence for the ready cloned targeting 
construct (Abbreviations: C = clone, u.c. = uncut). 
5.2 Transgenesis of ES cells  
5.2.1 Stable integration of the targeting construct into the genome of ES cells  
The transfection of ES cells, ES cell selection, picking of recombinant clones and DNA 
restriction using EcoR I for subsequent Southern blot analysis were performed as described 
in the Material and Methods part of this work (chapter 4.13.3). In the following chapters, the 
identification of correctly targeted ES cells via Southern blotting and the evaluation of such 
clones via in vitro Cre-deletion will be described. 
5.2.1.1 Southern blotting strategy 
The correct insertion of a targeting construct into its destined region is typically 
investigated and confirmed via Southern blotting. For this purpose, genomic DNA of 
recombinant clones was enzymatically restricted with EcoR I and then transferred on a 
Hybond XL membrane. To identify recombinant clones with a correctly inserted targeting 
construct, also termed positive clones, two different radioactively labeled probes were used: 
(i) An external probe, termed Rosa probe, that binds in the genomic region 5´ of the short 
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homology arm of the construct. After restriction of genomic DNA with EcoR I, a 6.8 kb 
recombinant fragment is observed in the case of correct insertion of the targeting vector 
(Figure 13, A). Since homologous recombination is a rare event, the targeting construct 
typically inserts on one chromosome only, while the other chromosome remains wt. On the 
wt chromosome, restriction with EcoR I then leads to a fragment of 16 kb size (Figure 13, B). 
(ii) An internal probe, termed Neo probe, which is complementary to parts of the Neor gene 
and detects the same 6.8 kb fragment as the Rosa probe in case of correct homologous 
recombination into the target site and digestion of DNA with EcoR I enzyme (Figure 13, C). 
However, random integration of the insert can only be detected by the Neo probe: In case of 
non homologous recombination a fragment of undefined size is observed ranging from the 
internal EcoR I restriction site in the stop-cassette to the next genomic upstream EcoR I 
restriction site in the region 5´ of the short homology arm (Figure 13, D). 
 
Figure 13: Southern blotting strategy to identify recombinant ES cell clones with correct insertion into 
the Rosa26 locus. A: In case of homologous recombination of the targeting vector into 
the Rosa26 locus, the Rosa probe detects a 6.8 kb DNA fragment. B: On a wt 
chromosome, the Rosa probe recognizes a 16 kb fragment. C: The Neo probe binds in 
the Neo
r
 gene and identifies the same 6.8 kb fragment as the Rosa probe in case of 
homologous recombination. D: In case of random integration of the targeting construct, 
the Neo probe will detect a fragment of undefined size 
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5.2.1.2 Identification of positive clones via Southern blotting 
The Southern blot strategy for the identification of positive recombinant ES cell clones with 
a correctly inserted targeting construct using an external (Rosa) as well as internal (Neo) 
probe was described in detail (chapter 5.2.1.1). To identify positive clones, genomic DNA 
was isolated from 96 well backup plates and enzymatically restricted by EcoR I digestion. 
The genomic DNA of each clone was separated by gel electrophoresis and the DNA blotted 
on a nylon membrane. In a next step, the membrane was incubated with the radioactively 
labeled external Rosa probe and analyzed using a phosphorimager (Figure 14, A). Of 196 
spotted clones, 8 clones were identified as recombinant for the Rosa26 targeting construct 
resulting in a recombination efficiency of 4.1 %. 
 
Figure 14: A: Snapshot of a membrane of clones from one 96 well plate hybridized with the Rosa 
probe. Clones were loaded next to each other in two vertical rows (E.g., A5-A13, B11-
B19). Next to the 16 kb wt band, clones A6 and A11 (underlined) showed the 6.8 kb 
recombinant band (red arrows) and were identified as positive clones. B: Exclusion of 
random integration of the Rosa26 targeting construct into the genome in positive 
clones A6 and A11 
All 8 positive clones were thawed from 96 well plates, expanded to 10 cm dishes and 
finally frozen as ¼ aliquots of one 10 cm dish. However, only clones A6 and A11 showed a 
high proliferation rate and were further analyzed via in vitro Cre deletion of the stop cassette 
(chapter 5.2.1.3). Since the Rosa probe does not identify random genomic integration of the 
targeting construct and to exclude this possibility, clones A6 and A11 were additionally 
investigated using the Neo probe. As expected and considering that homologous 
recombination is a rare event both clones A6 and A11 showed exclusively the predicted band 
at a size of 6.8 kb (Figure 14, B). 
 Therefore, it was concluded that the Rosa26 targeting vector had correctly integrated 
into the Rosa26 genomic locus in clones A6 and A11. 
5.2.1.3 In vitro Cre deletion and analysis of positive ES cell clones 
In vitro Cre deletion is a powerful tool to delete loxP flanked sequences in cell culture 
experiments. The technique makes use of a modified version of Cre recombinase (HTN-Cre) 
that carries a hydrophobic N-terminal tag including a nuclear localization signal (NLS) (Peitz 
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et al., 2002). If added to the cell media, HTN-Cre can permeate the membrane, be 
transported into the nucleus and catalyze recombination of loxP- flanked sequences. Here, 
this method was recruited to evaluate the potential of positive ES cell clones to express 
PLS3V5 before they were injected into blastocysts. Moreover, any cell toxicity effects caused 
by the overexpression of the transgene would become obvious. In line with that, such 
observations would make it necessary to reassess the chances of success in establishing a 
transgenic PLS3V5 overexpressing mouse line.  
To analyze HTN-Cre-mediated activation of PLS3V5, positive ES cell clones A6 and A11 
(chapter 5.2.1.2) were thawed from ¼ aliquots of one 10 cm petri dish. After expansion of the 
clones to 80 % confluence, in vitro Cre treatment was conducted (chapter 4.13.3.8). Since in 
vitro HTN-Cre treatment is a rather harsh method that can lead to cell death, ES cells were 
given 4 days to recover prior analysis.  
In vitro Cre-deleted ES cells were first analyzed under a fluorescence microscope. Given 
that GFP is located downstream of the PLS3V5 cds in the targeting vector (Figure 8), the 
deletion of the stop-cassette should result in a green fluorescent signal. As anticipated, both 
recombinant clones (A6 and A11) that were treated with HTN-Cre showed a green 
fluorescent signal while no signal was detected under UV light for untreated cells (Figure 15, 
compare A+B with E+F and I+J with M+N). To further support these observations, clones A6 
and A11 were trypsinized and subjected to FACS analysis. When gating the ES cell 
population, a clear peak-shift towards GFP was detected for both clones and only when cells 
were treated with HTN-Cre (Figure 15, compare D with H and L with P). Additionally, by 
comparing HTN-Cre treated with untreated cells under transmitted light no morphological 
differences could be observed. Stop-cassette-deleted clones exhibited the typical ES cell-like 
shape as untreated controls and appeared to proliferate normally. Taken together, these 
experiments demonstrate that the deletion of the stop-cassette results in GFP expression 
and that, accordingly, the Cre/loxP expression system of the targeting vector is functional. 
Since GFP expression after stop-cassette deletion alone is only a principle proof for the 
functionality of the Cre/loxP expression system, proteins were isolated from the remaining 
cells and examined for PLS3V5 expression via Western blotting. Using a V5 antibody for the 
specific detection of PLS3V5, a sharp and clear signal in the calculated size of ~75 kDa 
could only be observed for HTN-Cre treated cells of both clones, A6 and A11 (Figure 16).  
To summarize, via HTN-Cre mediated deletion of the stop-cassette the expression of 
both, PLS3V5 and GFP could be induced. These findings demonstrate the functionality of 
Cre-inducible conditional activation of the vector-expression system. Additionally, the 
absence of any GFP or PLS3V5 signals in untreated cells, either via FACS as well as in 
Western blot analysis, proves that the stop-cassette successfully prevents uncontrolled 
transcription of the transgenes. Based on these findings and in combination with the proof of 
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correct insertion of the targeting vector into the Rosa26 locus (chapter 5.2.1.2), clones A6 
and A11 were used for the injection into blastocysts (chapter 5.3.2). 
 
Figure 15: GFP expression after HTN-Cre mediated deletion of the stop-cassette. A-H: 
Microscopical- and FACS detection of GFP fluorescence after stop-cassette deletion 
in clone A6. I-P: Microscopical- and FACS detection of GFP fluorescence after stop-
cassette deletion in clone A11. For FACS analysis, the ES cell population was gated 
and analyzed for GFP expression. 
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Figure 16: Western blot analysis of ES cell clones A6 and A11 with or without HTN-Cre 
treatment. Using an antibody directed against the V5-tag of the PLS3V5, only cells 
treated with HTN-Cre and deleted for the stop-cassette express PLS3V5 and show a 
sharp signal at the correct size of ~75 kDa 
5.3 Generation of PLS3V5 transgenic mice 
5.3.1 Nomenclature of the PLS3V5 transgenic mouse lines generated in this thesis - 
Overview 
In the course of this work, first a stable cohort of PLS3V5 transgenic mice was generated 
that still carried the stop-cassette between promoter and the PLS3V5 cds (chapter 5.3.2). 
This line is from now on termed the PLS3V5-floxed line. To indicate that the stop-cassette is 
still present between promoter and the PLS3V5 cds in these mice, e.g. heterozygous 
individuals of this line are from now on defined as PLS3V5fl_st/wt (fl = floxed, st = stop) mice. 
Due to the presence of the stop-cassette in PLS3V5fl_st/wt mice, PLS3V5 is not yet being 
expressed in such individuals. By breeding PLS3V5fl_st/wt mice with Cre-lines expressing Cre 
under tissue specific promoters, conditional activation of PLS3V5 can be achieved. In this 
thesis, PLS3V5fl_st/wt animals were e.g. bred with the motor neuron specific Cre line Hb9-Cre 
(Arber et al., 1999, Yang et al., 2001) to exclusively activate transcription of the PLS3V5 
transgene in motor neurons.  
To activate PLS3V5 expression ubiquitously, the stop-cassette in PLS3V5fl_st/wt animals 
was deleted by breeding animals of the PLS3V5-floxed line with the ubiquitously Cre-
expressing line CMV-Cre (Schwenk et al., 1995). As a result, a stable cohort of PLS3V5 
ubiquitously expressing animals was generated (chapter 5.3.3). This line is from now on 
termed the PLS3V5-ubi line. E.g., heterozygous individuals of this line are by now defined as 
PLS3V5tg/wt mice. Once the stop-cassette was genomically deleted via Cre in the germline 
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and this was inherited to the next generation, the Cre allele was no longer necessary to 
ubiquitously activate PLS3V5 expression.  
In Table 13, an overview about the two different PLS3V5 transgenic lines and their 
respective nomenclature is given.  
Table 13: Nomenclature of transgenic PLS3V5 lines generated in this thesis 
PLS3V5 transgenic 
line 
E.g. heterozygous 
individual 
(exemplary) 
E.g. homozygous 
individual 
(exemplary) 
Description 
PLS3V5-floxed PLS3V5fl_st/wt PLS3V5fl_st/fl_st 
Stop cassette 
present, conditional 
activation of PLS3V5 
via breeding with 
Cre-lines. 
PLS3V5-ubi PLS3V5tg/wt PLS3V5tg/tg 
Permanent and 
inherited deletion of 
stop cassette. 
Ubiquitous PLS3V5 
expression.  
 
5.3.2 Generation of chimeras and identification of transgenic PLS3-floxed mice 
For the generation of chimeric animals in which the germline carries the PLS3V5 
transgene, cells of both positive clones, A6 and A11, were prepared (4.13.3.10) and injected 
into blastocysts derived from CB20-background females (Table  14). Using ES cells of clone 
A6, an additional pilot-injection-series using morulae (2-3 dpf) was performed. At morula 
stage, cells are completely undifferentiated while around blastula stage, first gastrulation 
events take place and along with that the determination of cell fate precedes. For that reason 
and because morulae consist of fewer cells, it is assumed that injected ES cells are better 
integrated and can stronger contribute to the developing embryo. 
Table  14: ES cell injection and chimera production  
Injected 
clone 
(V6.5) 
Date 
Injected 
Blastulae / 
Morulae 
Foster / 
pregnant 
Pups / DOB Chimeras (gender, % chimerism) 
A6 
11.12.08 29 Blastulae 3 / 3 13 / 28.12.08 
7 (6 ♂, 10, 15, 25, 25, 45, 75 
(#94); 1 ♀ 20) 
18.12.08 29 Blastulae 3 / 1 3 / 04.01.09 1 (1 ♂, 70 (#97)) 
18.12.08 9 Morulae 1 / 1 1 / 05.01.09 1 (1 ♂, 75 (#98)) 
A11 12.12.08 26 Blastulae 3 / 0 - - 
 
Even though ES cells of both clones were injected, chimeric animals were only obtained 
following injection with clone A6 (Table  14). From injections into blastocysts and morulae, all 
together 9 chimeric mice were produced of which 3 male mice were of higher chimerism 
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(estimated by the percentage of dark hair contributing to the coat color), namely one 70 % (# 
97) and two 75 % (# 94, 98) chimeric animals (Table  14, highlighted in red). Only the 3 
higher chimeric animals were used for breeding with wt animals and the offspring screened 
for the presence of the insertional allele via PCR. (Figure 17).  
 
Figure 17: Chimera breedings with wt mice (F0) to obtain transgenic offspring in the F1 
generation. A: Example of a 90 % chimeric mouse (picture kindly provided by Dr. Ylva 
Mende). B: Numbers of litters, offspring and transgenics obtained. Only a single 
transgenic female was obtained by chimera # 94. 
Of the three chimeric mice used for F0 breedings with wt mice, animal # 97 was infertile 
and did not produce any offspring. However, chimeras # 94 and 98 were normally fertile and 
generated potentially transgenic F1 offspring that was screened via PCR for the presence of 
the targeting construct. Of a total of 92 F1 offspring screened via PCR (Primer see chapter 
4.8), only one female mouse showed the recombinant band (Figure 18, A).  
 Since PCR is in fact a fast but also sensitive method, another PCR was conducted using 
a forward primer within PLS3V5 and a reversed primer located in the 3´-V5-tag. Thereupon, 
a signal of correct size was only observed using DNA of the assumed PLS3V5fl_st/wt 
(explanation of nomenclature see chapter 5.3.1) animal, but not in control wt DNA (Figure 18, 
B).  
To further confirm the transgenic state of the animal, DNA of the tail tip was subjected to 
Southern blotting using Rosa- and Neo probes. When compared to wt control DNA, using the 
Rosa probe the recombinant band was only detected in the DNA of the PLS3V5fl_st/wt mouse 
(Figure 18, C). With the Neo probe, a single band could be observed at the correct size in the 
PLS3V5fl_st/wt animal. 
A picture of the first PLS3V5fl_st/wt female is depicted in Figure 18, D. 
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Figure 18: Confirmation of the first PLS3V5
fl_st/wt
 female A: Screening (genotyping) PCR (primers 
# 3648, # 3649 and # 3650), B: PCR targeting PLS3V5 (primer # 3911 and # 3913), 
C: Southern blot using the Rosa probe. D: Picture of the first PLS3V5
fl_st/wt
 female   
To conclude, ES cells of clones A6 and A11 were injected into blastocysts and morulae 
and 3 higher percentage chimeras could successfully be produced from clone A6. Of the 
three chimeras, two males were fertile and one of them, chimera # 94, produced one single 
transgenic PLS3V5fl_st/wt female. The presence and correct insertion of the targeting construct 
into the Rosa26 locus of the female was confirmed via PCR and Southern blotting. By 
breeding with a C57BL/6N wt male mouse a stable founder generation of the PLS3V5-floxed 
line was established. Given that the first transgenic female was of 129/Sv and C57BL/6 
mixed genetic background, the PLS3V5-floxed line was backcrossed for 7 generations to a 
clean C57BL/6 background. 
5.3.3 Generation of the PLS3V5-ubi line by permanent deletion of the stop cassette 
in PLS3V5-floxed mice 
PLS3 has been shown to be expressed in a broad variety of tissues in rat, including liver, 
lung and heart as well as brain and muscle (Lin et al., 1994). Also in SMA patients, PLS3 is 
highly expressed in brain, spinal cord and muscle tissue, with its highest expression in the 
spinal cord (Oprea et al., 2008). In blood, however, PLS3 was shown to be present in 5 % of 
the control population only, confirming that PLS3 expression in blood is rare. In order to 
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optimally mimic the situation in unaffected patients, ubiquitous expression of the PLS3V5 
transgene was established.  
Since PLS3V5 expression is inhibited in the PLS3V5-floxed line by the presence of the 
stop-cassette, the ubiquitously Cre-expressing line CMV-Cre (Cre is located on the X-
chromosome in these mice, see also 4.14.1.3.1) was used to permanently delete the stop-
cassette in the PLS3V5-floxed line. For that purpose, male mice of the genotype 
PLS3V5fl_st/wt were bred with homozygous CMV-CreX_tg/X_tg female mice (Figure 19, A). In 
resulting female offspring, one X chromosome originates from the father while the Cre- 
transgenic X chromosomes is derived from the mother. Due to X inactivation, however, one 
X chromosome is randomly silenced. Accordingly, the female offspring is mosaic for the Cre 
expression and the stop cassette is not deleted in all cells. Yet in the resulting male offspring 
the Cre-carrying X chromosome can only result from the CMV-CreX_tg/X_tg mother. Because 
the only X chromosome in PLS3V5fl_st/wt;CMV-CreX_tg/Y male mice is never silenced, Cre is 
active in all cells of the body and consequently, the stop-cassette should be deleted in all 
cells as well. By breeding a PLS3V5fl_st/wt male with a CMV-CreX_tg/X_tg female mice, males 
with the genotype PLS3V5fl_st/wt;CMV-CreX_tg/Y were obtained (Figure 19, A, B). 
 
Figure 19: Ubiquitous deletion of the stop cassette. A: Breeding scheme for PLS3V5
fl_st/wt
 X 
CMV-Cre crossings. B: Genotyping PCR (Primer: PLS3V5: # 3648, # 3649 and # 
3650; CMV-Cre: # 3104 and # 3105 ): E.g., male # 5702 showed the recombinant 
PLS3V5 band in combination with the CMV-Cre allele. (wt = 576 bp; rec = 380 bp; 
Cre-tg = 600 bp) 
To investigate the real deletion efficiency of CMV-Cre in PLS3V5fl_st/wt;CMV-CreX_tg/Y male 
mice, a multiplex PCR was designed allowing the simultaneous detection of the stop-
cassette-containing allele, here termed “stop-in” allele (band size = 505 bp), and the stop-
cassette-deleted allele, termed “stop-out” allele (band size = 412 bp). Multiplex PCR was 
then performed on genomic tail tip DNA of PLS3V5fl_st/wt;CMV-CreX_tg/Y male mice. Despite 
carrying the same genotype, big discrepancies could be observed regarding the deletion 
efficiency between individuals: Beside the complete deletion of the stop-cassette, also 
mosaic deletion or no deletion at all was observed (Figure 20, A). An analysis of a total of 15 
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male mice of the genotype PLS3V5fl_st/wt;CMV-CreX_tg/Y revealed that indeed 52 % of animals 
showed no stop-out signal albeit the presence of Cre (Figure 20, A). 
To address whether the variable deletion-efficiencies observed among PLS3V5fl_st/wt;CMV-
CreX_tg/Y individuals directly correlated with PLS3V5 expression, proteins from one animal 
completely lacking the stop cassette (Figure 20, A, # 5745) and another animal showing the 
stop-in signal only (Figure 20, A, # 5732) were compared by Western blot analysis. Using a 
V5 antibody, PLS3V5 protein could be detected in all tissues of the stop-out-only animal # 
5745 (Figure 20, B). By contrast, PLS3V5 expression was entirely absent in animal # 5732, 
where only the stop-in signal had been detected by PCR. Thus, the data obtained in Western 
blot analysis were in line with the results from multiplex PCR and multiplex PCR is a powerful 
tool to predict whether any PLS3V5fl_st/wt;CMV-CreX_tg/Y mouse would indeed express 
PLS3V5.  
 
Figure 20: Stop-cassette deletion efficiencies in PLS3V5
fl_st/wt
;CMV-Cre
X_tg/Y
 male mice. A: 
Deletion efficiencies could be classified into three groups: (i) Complete deletion of the 
stop-cassette (1
st 
lane, stop-out only), (ii) mosaic deletion of the stop cassette (2
nd 
lane, stop-in + stop-out) and (iii) no deletion of stop-cassette despite presence of the 
Cre-allele (3
rd
 lane, stop-in only). 52 % of a total of 15 PLS3V5
fl_st/wt
;CMV-Cre
X_tg/Y
 
males showed no deletion of the stop cassette despite presence of the CMV-Cre 
allele. B: Western blot analysis of one stop-out only animal (# 5745) and one stop-in 
only animal (# 5732). Using α-V5 antibody, PLS3V5 expression could be detected in 
all tissues investigated of animal # 5745. In animal # 5732, PLS3V5 expression was 
completely absent despite the presence of the CMV-Cre allele. (wt = 576 bp; rec = 380 
bp; Cre-tg = 600 bp; stop-in = 505 bp; stop-out = 412 bp. Abbreviations: S.c. = Spinal 
cord, POS = positive control (ES cell clone # A6)) 
The knowledge about the deletion efficiency in a certain PLS3V5fl_st/wt;CMV-CreX_tg/Y male 
was also important from a different perspective: For the generation of mice in which 
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effectively all cells are deleted for the stop-cassette and that are ubiquitously PLS3V5 
expressing, PLS3V5fl_st/wt;CMV-CreX_tg/Y males were further bred with wt females. If the stop-
cassette was also deleted in the germ cells of PLS3V5fl_st/wt;CMV-CreX_tg/Y males and since 
PLS3V5 and CMV-Cre are located on different chromosomes, the deletion should be 
inherited to some of the offspring independently of the CMV-Cre allele. Since the deletion 
efficiency in a certain PLS3V5fl_st/wt;CMV-CreX_tg/Y male could be estimated via stop-cassette 
multiplex PCR, only males solely showing the stop-out signal were used in such breedings. 
In fact, when mating PLS3V5fl_st/wt;CMV-CreX_tg/Y-stop-out-only males with wt females, 
PLS3V5 transgenic offspring was identified that did not carry the CMV-Cre allele but at the 
same time showed the stop-out signal only (Figure 21, B). 
 
Figure 21: Generation of PLS3V5-ubi mice (PLS3V5
tg/wt
). A: Breeding scheme for the production 
of PLS3V5
tg/wt
 animals. B: In PLSV5
tg/wt
 animals, the stop-cassette is ubiquitously 
deleted in the absence of the CMV-Cre allele. Animal # 5828 showed the recombinant 
PLS3V5 band and only the stop-out signal coincidental with the absence of CMV-Cre. 
(wt = 576 bp; rec = 380 bp; Cre-tg = 600 bp; stop-in = 505 bp; stop-out = 412 bp. 
Abbreviations: POS = positive controls. # 5733 = PLS3V5
fl_st/wt
;CMV-Cre
X_tg/Y
 (stop-
in+stop-out); # 5745 = PLS3V5
fl_st/wt
;CMV-Cre
X_tg/Y
 (stop-out only); # 5791 = 
PLS3V5
fl_st/wt
 (stop-in only); 5701 = CMV-Cre
tg/wt
 (no stop signal)). 
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In these mice, the stop cassette is heritably deleted in effectively all body cells resulting in 
ubiquitous expression of PLS3V5. Accordingly, the line was termed PLS3V5-ubi and mice 
e.g. heterozygous for the transgene were defined as PLS3V5tg/wt animals. 
In summary, PLSV5 ubiquitously expressing mice (PLS3V5-ubi line, genotypic definition 
PLS3V5tg/wt) were successfully generated crossing the PLS3-floxed line with the CMV-Cre 
line. In the context of these experiments, the functionality of Cre-mediated activation of the 
PLS3V5 transgene was for the first time demonstrated in a Western blot experiment using a 
V5 antibody to specifically detect PLS3V5 in vivo (Figure 20, B). Since a detailed analysis of 
ubiquitous PLS3V5 expression in PLS3V5tg/wt mice is presented in chapter 5.4.1 and 
following, it should at this point only be mentioned that Cre-mediated PLS3V5 
overexpression was activated in the mainly through SMA affected tissues, namely brain, 
spinal cord and muscle. Before PLS3V5tg/wt animals were used in PLS3V5 overexpression 
experiments on an SMA background (chapter 5.4), the line was bred congenic by 
backcrossing to wt C57BL/6N animals for 7 generations. 
5.4 Ubiquitous expression of PLS3V5 in an SMA mouse model 
When PLS3V5-floxed mice were crossed with the Hb9-Cre line, PLS3V5 expression was 
conditionally activated in the resulting offspring. A detailed analysis of the effects of motor 
neuron specific overexpression of PLS3V5 in wt background is given in chapter 5.5 and 
following.  
In the PLS3V5-ubi line, the stop-cassette is permanently deleted resulting in ubiquitous 
expression of the PLS3V5 transgene. Since PLS3 is expressed in all SMA-affected tissues in 
human (Oprea et al., 2008), ubiquitous overexpression of PLS3V5 in a murine SMA 
background would resemble the situation in human best possible. To study the effects of 
PLS3V5 expression on the SMA phenotype, the PLS3V5-ubi line was therefore crossed into 
the Hung SMA background (chapter 5.4.2.1).  
5.4.1 Quantitative and qualitative assessment of PLS3V5 ubiquitous expression on 
wt background 
Prior to studying the effects of PLS3V5 expression on the murine SMA phenotype, 
quantitative expression analysis using qRT-PCR and Western blotting was performed in the 
PLS3V5-ubi line. Furthermore, to prove functionality of the PLS3V5 protein, murine 
embryonic fibroblast cells (MEFs) were isolated from PLS3V5tg/wt animals to investigate the 
cellular localization of PLS3V5 compared to wt murine Pls3 (mPls3) via 
immunohistochemical detection. 
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5.4.1.1 Total plastin 3 mRNA (PLS3V5 + mPls3 mRNA) levels are significantly 
increased in various tissues of PLSV5-ubi mice  
To assess the fold overexpression of plastin 3 mRNA in PLS3V5-ubi animals, mRNA from 
various tissues of wt and PLS3V5tg/wt mice (n=3 each) was isolated and quantitative real time 
PCR (qRT-PCR) performed. The amount of total plastin 3 mRNA was quantified as the sum 
of transgenic PLS3V5 plus murine Pls3 (mPls3) mRNA by using primers detecting both 
genes and standardizing to endogenous Hprt1 expression. Due to drastic discrepancies in 
housekeeper expression between different tissue types, only the fold upregulation for a 
certain tissue could be determined. For this purpose, wt mPls3 mRNA level was set to 100 % 
and excess plastin 3 amount in PLS3V5tg/wt mice assumed to be caused by additional 
transgene expression. For all of the tissues investigated, total plastin 3 mRNA levels were 
significantly increased in PLS3V5tg/wt animals compared to wt basal expression (Figure 22, 
A). While in brain and spinal cord only moderate changes of 3.6 and 3.4 fold were detected, 
the level of plastin 3 expression was remarkably elevated to 206 fold over endogenous level 
in blood. In this context, it is important to mention that mPls3 is naturally almost absent in 
blood. Since total plastin 3 levels in PLS3V5tg/wt mice resemble PLS3V5 + mPls3 expression 
relative to endogenous mPls3 levels in wt this might explain the immense increase observed 
in blood tissue.  
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Figure 22: Assessment of fold overexpression of T-plastin mRNA in PLS3V5
tg/wt
 versus wt 
animals. A Logarithmic scale: Using primers detecting both, PLS3V5 and mPls3, a 
significant increase of T-plastin expression was observed in PLS3V5
tg/wt
 animals 
compared to wt. B: murine Pls3 mRNA levels (mPls3) were not changed in 
PLS3V5
tg/wt
 compared to wt animals, suggesting that the measured excess of total T- 
plastin (PLS3V5 + mPls3) in Figure 22 A reflects the true PLS3V5 overexpression. 
(Animal numbers of both experiments: PLS3V5
tg/wt
 = 3 and Wt = 3; * = p < 0.05; ** = p 
< 0.01; *** = p < 0.001; Abbreviations: S.c. = Spinal cord) 
As mentioned, by setting the wt mPls3 expression to 100 % all measured excess in 
PLS3V5tg/wt animals should be attributed to the additional expression of the PLS3V5 
transgene. This idea holds true except in the presence of regulatory feedback mechanisms 
of PLS3V5 on mPls3 expression. To exclude this possibility, mPls3 mRNA levels were 
analyzed in PLS3V5tg/wt and wt animals using primers solely detecting endogenous mPls3. 
Strikingly, no significant differences were noticed, except for heart tissue where only a very 
slight increase of up to 1.4 fold in PLS3V5tg/wt animals could be observed. These findings 
showed that PLS3V5 has no feedback on endogenous mPls3 expression, legitimizing the 
methodology as well as confirming the measurements of total T-plastin mRNA levels.  
Taken together, total plastin 3 mRNA levels are significantly increased in all tissue types 
investigated in PLS3V5tg/wt animals, including brain, spinal cord and muscle (Figure 22, A). 
Since PLS3V5 expression does not influence endogenous mPls3 levels (Figure 22, B), it can 
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be concluded that the excess of measured total plastin 3 in PLS3V5tg/wt animals is indeed 
attributable to PLS3V5 overexpression. 
5.4.1.2 PLS3V5 protein is detected in nearly all tissues of PLS3V5tg/wt mice using a 
V5 antibody, but quantification of total T-plastin expression on protein level 
is not in line with mRNA measurements  
In the targeting construct, PLS3V5 is located downstream of the CMV enhancer/chicken 
β-actin (CAG) fusion promoter (Figure 8). This promoter is frequently used for driving strong 
and ubiquitous expression of transgenes in the mouse (Niwa et al., 1991, Xu et al., 2001). To 
qualitatively and quantitatively analyze PLS3V5 protein expression in the PLS3V5-ubi line, 
proteins of various tissues from PLS3V5tg/wt mice were isolated and the lysates investigated 
by Western blot analysis using V5 antibody to specifically detect PLS3V5 protein. In order to 
compare PLS3V5 expression levels between individual tissues, standardization of PLS3V5 
protein to a subset of housekeeper proteins was carried out (e.g. actin, rpl13a1, tubulin). 
However, this attempt failed due to immense discrepancies of housekeeper expression in the 
different tissues. Therefore, simply the total protein amount of 15 µg of each of the tissues 
was loaded on an SDS-Gel, Western blotting was performed and PLS3V5 detected with the 
V5 antibody. To confirm loading of equal protein amounts for PLS3V5tg/wt and wt control 
animals, Ponceau staining was conducted prior immunological detection using the V5 
antibody (Figure 23, A). As expected, apart from kidney all other tissues investigated showed 
a clear V5 signal at the expected size of ~75kDa in PLS3V5tg/wt but not in wt animals. This 
way, strongest expression of PLS3V5 was detected in liver while in brain, spinal cord and 
muscle moderate expression levels were observed (Figure 23, B). To exemplarily 
demonstrate the heterogeneous housekeeper expression found in the different tissues, the 
membrane was costained with an antibody directed against β-tubulin. While in brain, spinal 
cord and lung strong to moderate β-tubulin levels were detected, respectively, the β-tubulin 
signal was completely absent in the rest of the tissues for the chosen exposure time. Even if 
rather imprecise, loading equal protein amounts to compare PLS3V5 expression was 
therefore the only appropriate method to estimate expression intensities between the 
different tissues. 
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Figure 23: Analysis of PLS3V5 expression in various tissues of PLS3V5
tg/wt 
and wt animals. A: To 
demonstrate loading of equal protein amounts for PLS3V5
tg/wt 
and wt animals, 
Ponceau staining was performed prior to immunological detection of PLS3V5. Note 
that for all tissues loaded PLS3V5
tg/wt 
and wt animals show approximately the same 
band intensities. B: Using V5 antibody PLS3V5 protein was detected in almost all 
tissues of PLS3V5
tg/wt
 animals, but not in wt.  
Similar to the analysis performed on mRNA level (chapter 5.4.1.1), it was tried to 
determine the fold upregulation of plastin 3 (PLS3V5 + mPls3) expression relative to 
endogenous mPls3 level in brain and spinal cord tissue of PLS3V5tg/wt animals. Protein 
lysates of PLS3V5tg/wt and wt animals (n=3 each) were blotted and subsequently incubated 
with PLS3 antibody that recognizes an N-terminal region in the coding sequence of both, 
mPls3 and PLS3V5. Since the molecular mass of PLS3V5 (~75kDa) is slightly increased due 
to the V5-tag compared to mPls3 (~70kDa), transgenic and murine plastin 3 were expected 
to run as two adjacent bands. Using the PLS3 antibody, however, apart from the signal for 
endogenous mPls3 (~70kDa), no additional PLS3V5 band could be detected in PLS3V5tg/wt 
mice for both brain and spinal cord (Figure 24, A and B, lane II.). Only when the PLS3 
antibody was used in combination with V5 antibody, two separate bands appeared for mPls3 
and PLS3V5 exclusively in PLS3V5tg/wt mice (Figure 24, A and B, lane I.). These findings 
together with an only moderate plastin 3 increase in spinal cord and brain of PLS3V5tg/wt mice 
on mRNA level (Figure 22, A) led to the assumption that PLS3V5 protein concentration in 
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these tissues might be too low for immunological detection. Since for liver a bigger increase 
in plastin expression was detected in PLS3V5tg/wt mice on mRNA (Figure 22, A) and protein 
level (Figure 23, B) as compared to brain and spinal cord, liver protein of PLS3V5tg/wt mice 
was analyzed with the PLS3 antibody. Indeed, for liver both mPls3 and PLS3V5 were 
detected using the PLS3 antibody solely (Figure 24, C´, lane I.). While for liver an almost 8 
fold increase of total plastin 3 (mPls3 + PLS3V5) was observed in PLS3V5tg/wt animals on 
mRNA level (Figure 22), quantification of total plastin 3 protein revealed an only 2 fold 
increase over endogenous mPls3 level (Figure 24, C´, lane I.). Therefore, it is to consider 
that also in brain and spinal cord of PLS3V5tg/wt mice the plastin 3 upregulation on protein 
level is rather below the observed increase on RNA level (Figure 22) and that PLS3V5 was 
therefore not detected in Western blot analysis using the PLS3 antibody.  
Another explanation for the absence of the PLS3V5 band in brain and spinal cord of 
PLS3V5tg/wt mice (Figure 24, A and B, lane II.) could be a different binding affinity of the PLS3 
antibody to mPls3 and PLS3V5. It has previously been shown that the homologue L-plastin 
can be phosphorylated at Serin 7 in the N-terminus of the protein, regulating the actin 
bundling activity of L-plastin (Lin et al., 1998). Serin 7 is highly conserved and also present in 
the epitope region of plastin 3 recognized by the PLS3 antibody (H2N-
MATTQISKDELDELKC-CONH2). However, at least in fibroblasts and leukocytes no 
equivalent phosphorylation of the Serin 7 residue could be observed for plastin 3 (Lin et al., 
1998). Nevertheless, an effect of the recombinant V5 tag on the phosphorylation properties 
of PLS3V5 could not entirely be excluded. Therefore, proteins of spinal cord and brain were 
investigated using another PLS3 antibody (Santa Cruz), accordingly termed PLS3-sc 
antibody, that was raised against a different epitope located between amino acids 482 and 
516 in the C-terminal region of PLS3. Due to strong and unspecific background obtained 
when using the PLS3-sc antibody, however, this question could not further be studied (data 
not shown).  
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Figure 24: Assessment of total plastin 3 (Pls3V5
tg/wt
 + mPls3) protein levels in brain, spinal cord 
and liver of PLS3V5
tg/wt
 and wt animals. A + B: Analysis of total plastin 3 in brain and 
spinal cord using the α-PLS3 antibody resulted in the detection of the mPls3 band only 
(lane II. in A and B). In combination with the α-V5 antibody signals for both, mPls3 
(~70 kDa) and PLS3V5 (~75kDa) were obtained (lane I. in A and B). Quantifying 
mPls3 expression levels (lane II.) and standardizing to Actin, no changes in 
endogenous mPls3 levels were detected between Pls3V5
tg/wt
 and wt animals in brain 
and spinal cord. C: In liver both mPls3 and PLS3V5 were recognized by the PLS3 
antibody leading to two bands of 70 and 75 kDa size, respectively. Quantification of 
only endogenous mPls3 (indicated by the red square in lane I.) revealed no significant 
changes between PLS3V5
tg/wt 
and wt animals as it was also observed in brain and 
liver. C´: Quantification of total plastin 3 protein amount (indicated by the red square in 
lane I.) revealed a significant 2 fold upregulation in PLS3V5
tg/wt
 compared to wt 
animals. (All quantifications were standardized to actin expression; * = p < 0.05; ** = p 
< 0.01; ***) 
Furthermore, endogenous mPls3 protein levels were quantitatively assessed in brain, 
spinal cord and liver of PLS3V5tg/wt and wt mice (Figure 24, A, B and C). As was the case on 
mRNA level (Figure 22, B), no significant changes in mPls3 protein amount were measured 
between PLS3V5tg/wt and wt animals. 
To summarize, using V5 antibody PLS3V5 expression was proven in almost all tissues 
investigated, that is brain, spinal cord, muscle, heart, liver, lung and blood while only in 
kidney PLS3V5 was absent for the given exposure time (Figure 23). Since the PLS3V5 
transgenic band (~75 kDa) was not recognized by the PLS3 antibody in brain and spinal cord 
(Figure 24, A and B), it was not possible to determine the fold upregulation of total plastin 3 
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protein levels in these tissues of PLS3V5tg/wt mice. Using liver proteins showing a stronger 
upregulation of PLS3V5 on mRNA (Figure 22) and protein level (Figure 23) it was possible to 
detect PLS3V5 by PLS3 antibody and to estimate the fold upregulation of plastin 3 protein to 
~2 fold in this tissue (Figure 24, C´). Since the total plastin 3 upregulation was only ~2 fold on 
protein as compared to ~8 fold on mRNA level in liver, it is to assume that also in brain and 
spinal cord PLS3V5 protein upregulation is comparatively low considering the only moderate 
upregulation of 3.6 and 3.4 fold on mRNA level in these tissues, respectively (Figure 22).  
5.4.1.3 Transgenic PLS3V5 colocalizes with actin filaments, shows wt localization 
and results in extensive filopodial outgrowth in murine embryonic 
fibroblasts (MEFs)  
To confirm the functionality of transgenic PLS3V5 protein, murine embryonic fibroblasts 
(MEFs) were isolated from PLS3V5tg/wt and wt control embryos and immunohistochemistry 
was performed.  
To study the capability of PLS3V5 to colocalize with and bundle actin filaments, the V5 
antibody was used together with phalloidin stainings on MEFs of PLS3V5tg/wt animals. This 
way, a strong colocalization of PLS3V5 (green) with actin filaments (red) could be observed 
predominantly in the area of filopodial growth (Figure 25, A + A´). In this regard, 
PLS3V5/actin colocalization did not occur along the entire actin filament but was rather 
restricted to regions of filament consolidation, the region-specific localization pointing out the 
functionality of the PLS3V5 protein (Figure 25, white arrow in C, C´and C´´). To ascertain the 
specificity of the antibody, wt MEFs were incubated with α-V5 antibody using the same 
concentration, incubation condition as well as exposure time in microscopic analysis as for 
PLS3V5tg/wt MEFs. As expected, no green signals were observed using the V5 antibody in wt 
MEFs proving specificity of all signals observed in PLS3V5tg/wt MEFs (Figure 25, B and B´). 
Furthermore, a diffuse PLS3V5 staining was detected all over the cell body with slightly 
increased intensities around the cell nucleus. However, the increase around the nucleus 
might only be a secondary effect caused by an intensity overlay due to a thicker three 
dimensional cell structure in this area.  
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Figure 25: PLS3V5 transgene expression in murine embryonic fibroblasts (MEFs). A + A´: Different 
magnifications (20x and 50x) of PLS3V5 staining using V5 antibody in MEFs of 
PLS3V5
tg/wt
 animals. PLS3V5 colocalizes with actin filaments predominantly in regions of 
filiopodial growth (white arrows in A´). B + B´: No green signal was obtained when wt 
MEFs were stained with the α-V5 antibody, proving specificity of the signals in A and A´. 
C, C´+ C´´: Detailed view of an actin filament branch point. PLS3V5 accumulates where 
actin filaments overlap (white arrow in C, C´and C´´) but is not present on isolated actin 
filaments. (Green = PLS3V5, red = F-actin (Phalloidin), blue = DAPI) 
After PLS3V5 turned out to be functional as based on its very specific localization in regions 
of actin filament consolidation, costainings of PLS3V5 and wt  mPls3 in MEFs of PLS3V5tg/wt 
animals were performed to investigate whether the V5 tagged transgene and the wt protein 
share overlapping expression domains (Figure 26, A – A´´´). The PLS3 antibody was used to 
detect both mPls3 and PLS3V5 (Figure 26, A´). Additionally, the V5 antibody was recruited to 
detect exclusively PLS3V5 (Figure 26, A´´). Since the individual stainings overlapped 
completely and no extra staining domains were observed for mPls3 when the PLS3 antibody 
was used, it is to conclude that transgenic PLS3V5 shows a totally wt localization in MEF 
cells.  
It has previously been reported that plastin 3 colocalizes with vinculin in integrin mediated 
focal adhesions of fibroblast like cells (Arpin et al., 1994). To further support the finding of wt 
localization of transgenic PLS3V5, mPls3 and PLS3V5 were costained with vinculin in wt and 
PLS3V5tg/wt MEFs, respectively. In line with previously published data, mPls3 was observed 
to colocalize with vinculin also in wt MEFs (Figure 26, white arrows in B, B´ and B´´). 
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Importantly, also transgenic PLS3V5 showed a strong overlay with vinculin in focal 
adhesions of PLS3V5tg/wt MEFs (Figure 26, white arrows in C, C´and C´´´). These 
observations further underline that PLS3V5 localizes wildtypic and that the C-terminal V5-tag 
does not interfere with normal PLS3 function.    
 
Figure 26:  PLS3V5 localization analysis. A-A´´´: PLS3V5
tg/wt 
MEFs were stained with either PLS3 
antibody detecting both, mPls3 and PLS3V5
tg/wt
 (A´, blue) or V5 antibody to stain PLS3V5 
protein only (A´´, green). Because no additional expression domains for mPls3 were 
observed in A´ compared to PLS3V5 in A´´, transgenic PLS3V5 displays fully normal and 
wt localization. B-B´´´: Colocalization of vinculin and mPls3 is demonstrated in wt MEFs 
by using vinculin (B, green) and PLS3 antibodies (blue). Arrows in B-B´´´ indicate 
vinculin/mPls3 overlapping regions. C-C´´´: Also for PLS3V5 colocalization with vinculin 
was proven by combined stainings using vinculin (B, green) and V5 antibodies (blue).  
 Moreover, it has been shown that plastin 3 overexpression leads to changes in cell 
morphology of polarized epithelial cells (LLC-PK1) (Arpin et al., 1994). When overexpressed, 
plastin 3 resulted in the formation of thicker microvilli on the surface of LLC-PK1 cells, 
resembling a phenotype similar to that observed after overexpression of Villin, another actin 
bundling protein (Friederich et al., 1989). Besides that, PLS3V5 overexpression led to 
extensive axonal outgrowth in in vitro experiments with PC12 cells and murine primary motor 
neurons (Oprea et al., 2008). Therefore, MEFs derived from wt and PLS3V5tg/wt animals were 
morphologically compared using immunohistochemistry and focusing on filopodial 
protrusions. Such membrane protrusions are continuously initiated at the leading edge of 
migrating fibroblasts in a process that is highly dependent on actin dynamics (Mitchison and 
Cramer, 1996). Typically, filopodia contain a thick stretch of actin that is held together by 
actin bundling proteins such as PLS3. Based on that, it was speculated that PLS3V5 might 
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have a stabilizing effect on filopodia of MEFs from PLS3V5tg/wt mice. When analyzing MEF 
cell structure microscopically, filopodial outgrowth was markedly enhanced in MEFs derived 
from PLS3V5tg/wt animals (Figure 27, compare A and A´ as well as B and B´). Additionally, 
while wt MEFs appeared completely normal, the biggest proportion of PLS3V5tg/wt MEFs 
exhibited an elongated, polarized shape as it is typically observed for migrating fibroblasts. 
According to its function in cytoskeletal regulation, it can therefore be stated that PLS3V5 
overexpression has a severe impact on the cell structure also in MEF cells.  
 
Figure 27: PLS3V5 overexpression leads to structural changes in MEFs derived from PLS3V5
tg/wt
 
animals. A + A´: actin (Phalloidin, red) and PLS3 (green) costainings reveal a drastic 
increase in filopodial growth in PLS3V5
tg/wt
 MEFs (white arrows in A´). B + B´: 
Enhanced filopodial outgrowth was also confirmed in actin (red) and vinculin (green) 
costainings (note white arrows in B´). 
To summarize, by using immunofluorescence it was demonstrated that PLS3V5 
specifically accumulates at distal ends of lamellipodia and filopodia at actin filament branch 
points, proving that PLS3V5 is functional (Figure 25). By costaining with its endogenous 
orthologue mPls3 and vinculin, PLS3V5 was confirmed to entirely colocalize with 
endogenous Pls3 in MEFs (Figure 26). Moreover, PLS3V5 overexpression results in 
excessive filopodial growth in MEFs derived from PLS3V5tg/wt animals (Figure 27). These 
results are in line with previously published data after which PLS3 is important in microvilli 
formation as well as axonal outgrowth in PC12 cells as well as motor neurons (Arpin et al., 
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1994, Oprea et al., 2008). The here presented results anticipate a role of PLS3 in the 
regulation of axon growth in the context of NMJ maturation (chapter 5.4.3 and following).  
5.4.2 Generation of an SMA mouse model for the overexpression analysis of 
PLS3V5 
To ubiquitously express PLS3V5 on an SMA background and to investigate possible 
rescuing effects it was important to select an appropriate SMA mouse model. The Taiwanese 
SMA mouse model (chapter 4.14.1.1), also termed Hung SMA mouse model here, appeared 
to be the most suitable model for three reasons:  
(i) The distribution of the alleles on different chromosomes allows uncomplicated 
breedings (Smn = chromosome 13, human SMN2 transgene (hSMN2) = chromosome 4, 
PLS3V5 = chromosome 6, Hb9-Cre transgene = chromosome 5).  E.g., the homozygous 
expression of PLS3V5 on the Hung SMA background (chapter 5.2) resulting in the genotype 
Smn-/-;hSMN2tg/wt;PLS3V5tg/tg would not be possible if PLS3V5 mapped to the same 
chromosome as either the Smn knockout or the hSMN2 transgene.  
(ii) Hung SMA mice display a life expectancy that is long enough to study effects of 
PLS3V5 expression in postnatal stages. As will be outlined in the following chapters, Hung 
SMA mice on a pure C57BL/6N background live ~15d, allowing e.g. motoric ability testing or 
analysis of possible NMJ phenotypes.  
(iii) As will be described in chapter 5.4.2.1, breedings of the Hung mouse model result in 
50 % of affected SMA animals and 50 % control animals. Since the limitations in time and 
space during daily laboratory routine often interfere with fast analysis progression, the Hung 
SMA line displays an excellent model to overcome these issues.  
Since at the beginning of this work the Hung SMA model was only available on an FVB 
genetic background it had to be backcrossed with C57BL/6N animals to reach 100 % genetic 
purity. It is commonly accepted, that the genetic background of mouse strains can have an 
enormous modifying impact on the severity of a given phenotype. This has also been 
reported for the Hung SMA model: When on pure FVB background, Hung SMA animals 
show a mean survival of ~10d (Riessland et al., 2010). However, on a clean C57BL/6J 
background Hung SMA animals were reported to survive ~13 months, showing first signs of 
spinal motor neuron degeneration from 6 months of age (Tsai et al., 2008). Knowing that 
Hung SMA animals on the closely related C57BL/6J background survive for more than 1 
year, it appeared questionable if Hung SMA mice on C57BL/6N background would show 
earlier signs of SMA symptoms and with a survival time similar to that of FVB-SMA animals. 
Backcrossing is very time consuming. Assuming 7 generations of backcrossing and 
considering the 10 weeks generation time of mice, it was calculated that backcrossing of 
Hung SMA mice to a clean C57BL/6N background would take at least 17.5 months. 
However, a possibly strong ameliorative impact of the C57BL/6N background on the SMA 
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phenotype, e.g. an extremely extended life expectancy, was expected to become apparent 
already after some rounds of backcrossing. Therefore, Hung SMA animals with a statistic 
proportion of 87.5 % C57BL/6N / 12.5 % FVB mixed background, short “mixed background”, 
were phenotypically analyzed and compared to Hung SMA mice on a pure FVB background. 
This way, the Hung SMA phenotype on a relatively high C57BL/6N background was 
analyzed while backcrossings were still ongoing, giving an early first impression whether 
Hung SMA mice on pure C57BL/6N background would be appropriate for subsequent 
analysis at all.  
As will be outlined in the next chapters, the comparison of the phenotype of Hung SMA 
mice on either FVB or mixed background suggests that the SMA phenotype is severely 
influenced by the genetic background, underlining the importance of genetic purity for 
accurate phenotypic analysis.  
5.4.2.1 Nomenclature of Hung SMA mice and breeding scheme for the production 
of SMA mice 
As was mentioned, the Hung SMA mouse model was selected to serve for the analysis of 
PLS3V5 overexpression on an SMA background. In this mouse line, hSMN2 is 
homozygously present on Smn null background. These animals, here defined as Smn-/-
;hSMN2tg/tg, carry 2 SMN2 copies per integrate, thus homozygous transgenic mice have 4 
SMN2 copies. They do not develop an SMA phenotype, are fully fertile and live for > 1 year 
but develop a shortened and thick tail as well as necrotic ears (Riessland et al., 2010). By 
breeding Smn-/-;hSMN2tg/tg mice with animals heterozygous for the Smn knockout (Smn+/-), in 
each litter 50 % of SMA mice (Smn-/-;hSMN2tg/wt) and 50 % of control carriers (Smn+/-;hSMN 
tg/wt) were produced. In the following, for reasons of simplicity SMA mice of the genotype 
Smn-/-;hSMN2tg/wt are abbreviated with “SMA animals” and control carriers of the genotype 
Smn+/-;SMN tg/wt are termed “HET animals” (derived from heterozygously for the Smn 
knockout). An overview about the breeding scheme to produce SMA offspring and the 
nomenclature used for SMA animals as well as control carriers is given in Figure 28.  
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Figure 28: Breeding scheme and nomenclature of Hung SMA mice. Breeding of Smn
-/-
;hSMN2
tg/tg 
with Smn
+/-
 mice produces 50 % of SMA offspring of the genotype Smn
-/-
;hSMN2
tg/wt
 and 
50 % of control carriers of the genotype Smn
+/-
;hSMN2
tg/wt
. SMA and control carriers are 
abbreviated as “SMA” and “HET” animals, respectively 
5.4.2.2 Survival, weight and motoric ability of Hung SMA mice are strongly 
dependent on the genetic background 
In order to get an impression of the influence of the C57BL/6N genetic background on the 
SMA phenotype, SMA animals (Smn-/-;hSMN2tg/wt) of the mixed background (87.5 % 
C57BL/6N / 12.5 % FVB) were analyzed and compared with SMA mice from a clean FVB 
background. First survival, weight gain and motoric ability of SMA animals were compared, 
before also morphological differences were analyzed (Endplate occupancy, endplate area, 
muscle fiber size, chapter 5.4.2.3). Since at the end of this work data for survival, weight and 
motoric ability were available for pure C57BL/6N SMA animals and HET controls, these were 
included into the respective diagrams. Regarding morphological analyses, only data of FVB 
and mixed background animals were available and could thus be compared with each other.  
SMA animals on the different backgrounds showed highly significant differences in 
survival, as revealed by Student`s t-test. While FVB SMA mice show a mean survival of 9.9 
d, mixed background SMA animals survive only ~ 9 d longer, namely ~19.2 d, despite the 
relative high proportion of 87 % C57BL/6N background (Figure 29, A). It was therefore 
assumed that also further backcrossing to C57BL/6N background would not increase the 
survival of mixed background SMA animals to such extent as it was observed when the Hung 
SMA model was backcrossed onto clean C57BL/6J background  (Mean survival ~13 mo) 
(Tsai et al., 2008).  
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Figure 29: Survival and weight analysis of Hung SMA mice (Smn
-/-;
;hSMN2
tg/wt
) on different 
genetic backgrounds (100 % FVB, mixed (87 % C57BL/6N + 13 % FVB) and 100 % 
C57BL/6N). A: SMA mice on pure FVB background show a mean survival of 9.9 d, 
mixed background SMA animals have a mean life expectancy of 19.2 days and SMA 
animals on clean C57BL/6N background survive for 15.5 days. B: Example of P13 
SMA animals on the three different backgrounds: FVB, mixed and C57BL/6N. Note the 
size differences. C: Weight diagram of HET controls (Smn
+/-;
;hSMN2
tg/wt
) of all three 
genetic backgrounds. D: Weight progression in SMA animals of all three genetic 
backgrounds. C57BL/6N animals weigh less than pure FVB or mixed background 
mice. (Animal numbers for weight and survival measurements: HET animals: nFVB=29, 
nmixed=51, nC57BL/6N=23; SMA animals: nFVB=33, nmixed=44, nC57BL/6N=22) 
Based on this assumption, backcrossing to C57BL/6N background was continued in order 
to produce an appropriate SMA model for PLS3V5 overexpression studies. It was found, that 
SMA mice of clean C57BL/6N background had an again reduced mean life expectancy of 
15.5 d as compared to mixed SMA animals (Figure 29, A). The fact that Hung SMA mice 
show reduced survival on both pure FVB and C57BL/6N background if compared to mixed 
SMA animals suggests an ameliorative effect through heterogeneity on the disease 
phenotype. Furthermore, the increase in survival observed for C57BL/6N SMA mice (15.5 d) 
when compared to FVB SMA animals (9.9 d) may indicate the presence of background 
specific modifiers in the C57BL/6N background.  
The general picture of SMA mice on different backgrounds did not forcedly correlate with 
the observed survival. Around P13, mixed SMA mice, that lived longest, showed a significant 
increase in weight when compared to FVB or C57BL/6N SMA animals (Figure 29, D). 
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Additionally, they were visibly larger and seemed more robust than FVB or C57BL/6N SMA 
mice of the same age (Figure 29, B). In contrast to that, between FVB and C57BL/6N SMA 
mice the disease picture did not correlate with the survival data: Even though C57BL/6N 
SMA live ~5 d longer than FVB SMA animals, C57BL/6N SMA mice weighed significantly 
less at P13 and are by far smaller compared to FVB SMA mice of the same age (Figure 29, 
B and D). One possible explanation for this contradictive observation could be that even 
when smaller and lighter, C57BL/6N mice possess an increased muscle/fat tissue ratio 
compared to FVB SMA animals. Noteworthy, HET animals (Smn+/-;HSMN2tg/wt) of all genetic 
backgrounds showed no significant weight differences at P13 (Figure 29, C).  
To investigate the motoric ability of SMA animals on the different backgrounds, mice were 
subjected to the tube test. In this test, SMA animals of mixed background showed the best 
motoric ability from P0 until P15 again pointing at an ameliorative effect of heterogeneity on 
the SMA phenotype (Figure 30, B). Between P15 and P30, the motoric ability of mixed 
background SMA animals improved to almost the level of HET animals (Figure 30, A). In this 
context it is important to mention that only a few mixed SMA animals survived P25 (n=3). 
Therefore, it is to keep in mind that these animals displayed exceptional motoric abilities but 
were not representative for the gross of mixed SMA mice. In the time period between P5 and 
P11 and similar to the weight results, FVB SMA mice displayed a tendency towards better 
motoric performance compared to C57BL/6N SMA animals (Figure 30, B), even though they 
live significantly shorter than C57BL/6N mice (Figure 29, A). At around P10, however, the 
curve steeply decreases for FVB SMA animals, reflecting the progression of SMA pathology. 
 
Figure 30: Motoric evaluation of HET (Smn
+/-;
;hSMN2
tg/wt
) and SMA mice (Smn
-/-;
;hSMN2
tg/wt
) 
using the tube test. A: Motoric ability of HET mice over a time period of 35 days. B: 
Motoric ability curve of SMA animals over a time period of 35 days. (Used animal 
numbers: HET animals: nFVB=29, nmixed=51, nC57BL/6N=23; SMA animals: nFVB=33, 
nmixed=44, nC57BL/6N=22) 
HET animals of mixed and FVB background behaved similar reaching the maximum tube 
score of 4 at around P9. Interestingly, however, HET mice on clean C57BL/6N background 
displayed significantly weaker performance between P2 and P12 (p=0.0003). This finding 
might indicate that C57BL/6N animals do principally exhibit reduced motoric abilities in early 
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stages. On the other hand, the weight of HET C57BL/6N mice did not significantly differ from 
FVB and mixed background animals in this time period. Additionally, the overall size and 
appearance of HET animals on C57BL/6N was by all means comparable to that of FVB and 
mixed background mice.  
Taken together, SMA mice show significantly different survival times, weight gain and 
motoric abilities depending on the genetic background. In this regard heterogeneity seems to 
have a positive influence on the SMA phenotype since mixed background SMA mice were 
the longest living and motorically fitter compared to clean FVB or C57BL/6N SMA mice. 
5.4.2.3 Hung SMA mice on pure FVB and mixed genetic background show highly 
significant differences regarding endplate area size and occupancy as well 
as muscle fiber size   
The vertebrate neuromuscular junction (NMJ) consists of the terminal part of the motor 
neuron, the so called presynapse, and the muscular accumulation of acetyl 
cholinetransferase receptors (AChR), called endplate. It has previously been demonstrated 
that the maturation of the NMJ is seriously impaired in SMA-like mice, including poor 
arborization of presynaptic motor neuron terminals as well as reduction of the endplate area 
size in SMA mice compared to control littermates (Kariya et al., 2008).  
Taking these characteristics of SMA pathology as criteria, NMJs of Gastrocnemius muscle 
of SMA mice on FVB and mixed genetic background were compared with each other. For 
this purpose, muscle sections were prepared and nerve terminals stained using an antibody 
against neurofilament-M (green) and endplates using rhodamine labeled bungarotoxin (red).  
The arborization degree of incoming motor neuron terminals was assessed in P5 SMA 
and HET mice by allocating the observed phenotypic appearance of NMJs to one of 4 
different branching types (Figure 31, A). For each respective genotype (SMA or HET) and 
background (FVB or mixed) 100 NMJs of a total of 3 animals were analyzed. When 
comparing HET animals on FVB and mixed background, no significant differences regarding 
the distribution of branching types could be observed (Figure 31, B), as was confirmed by 
Student`s t-test. In contrast to that when comparing SMA animals on FVB and mixed genetic 
background, mixed SMA animals showed a significantly reduced number of type I (p=0.039) 
and a significantly increased number of type III NMJs (p=0.02). These results suggest that 
endplates of SMA mice on a mixed genetic background display a stronger occupation by 
nerve terminals compared to FVB mice.  
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Figure 31: Analysis of NMJ occupancy in Gastrocnemius muscle of P5 SMA and HET mice on 
pure FVB and mixed genetic background. A: Categorization scheme depicting the 4 
different branching types: Type I like endplates display one, Type II two, Type III three 
and Type 4 four or more nerve branchings per endplate. B: Assessment of the 
percentages of the different occupancy types (A) in HET and SMA mice of FVB and 
mixed background. While HET mice exhibited no significant changes among the 
different genetic backgrounds, mixed SMA mice displayed a significantly lower 
proportion of type I but instead increased number of type III occupied endplates. (Used 
animal numbers : HET animals: nFVB=3, nmixed=3; SMA animals: nFVB=3, nmixed=3; 
Stainings: Red = bungarotoxin (Btx); Green = α-neurofilament (NF); 100 NMJs were 
classified per animal) 
Next the endplate area size of SMA and HET animals was determined in a time course 
experiment for both genetic backgrounds, FVB and mixed. For this purpose, endplates were 
visualized using rhodamine labeled Bungarotoxin and the sizes of AChR clusters were 
measured with help of Axio Vision computer software (Zeiss) under a fluorescent 
microscope. 
Including P1, P5 and P10 time points it was found that HET animals on FVB or mixed 
genetic background exhibited no significant differences in their endplate sizes (Figure 32, B). 
However, when SMA animals of FVB and mixed background were compared a significant 
increase in endplate size was observed for SMA mice of mixed background starting at P5 
(SMAFVB = 100,29 ± 36,53 µm
2, SMAmixed = 129,37
 ± 33,93 µm2; p=0.00193) and becoming 
even more evident at P10 (SMAFVB = 120,30 ± 38,45 µm
2, SMAmixed = 169,28 ± 84,16 µm
2; 
p=0.00066). To visualize the measurements, the difference in endplate size of FVB and 
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mixed SMA animals is additionally depicted in Figure 32, A. These findings are in line with 
the observed increase in endplate occupancy in mixed SMA animals. In the past, numerous 
studies have identified a broad spectrum of diffusible and non diffusible factors provided by 
the presynapse that are important for AChR clustering, one of the most important effectors in 
AChR clustering being the secreted MuSK receptor ligand Agrin (Wu et al., 2010). Assuming 
that a higher degree of arborization of nerve terminals in mixed SMA animals results in 
elevated secretory vesicle release it seems plausible that motor endplate size of mixed SMA 
animals increases simultaneously.  
Together with the data from the occupancy studies, the increase of endplate size in mixed 
SMA animals points at an improved NMJ maturation process compared to FVB SMA 
animals.  
 
Figure 32: Analysis of endplate size in Gastrocnemius muscle of SMA and HET mice on FVB and 
mixed genetic background. A: Representative picture of NMJ sizes in P10 SMA and 
HET animals on FVB and mixed genetic background. The endplate size of mixed SMA 
animals is markedly increased compared with SMA mice on FVB background. B: Time 
course experiment (P1, P5 and P10) depicting NMJ sizes of SMA and HET mice on 
FVB and mixed genetic background. While FVB and mixed HET mice show nearly the 
same endplate size at the various time points, the endplates of mixed SMA animals 
are clearly enlarged compared to FVB SMA mice starting at P5 (p=0.00193) and 
becoming even more evident at P10 (p=0.00066). (Used animal numbers: HET 
animals: nFVB=3, nmixed=3; SMA animals: nFVB=3, nmixed=3; Stainings: Red = 
bungarotoxin (Btx); Green = α-NF; 100 endplates were measured per animal) 
To investigate whether the improved NMJ maturation process observed for mixed SMA 
mice resulted in increased muscle fiber size compared to FVB SMA animals, cross sections 
of Vastus lateralis muscle from mouse upper legs were produced and H&E stainings 
performed. As could be observed HET animals of both, FVB and mixed background 
displayed no significant differences in muscle fiber size at the various time points, as 
evaluated by the Student`s t-test. However, muscle fiber size of mixed SMA mice was highly 
significantly increased at P1 (SMAmixed = 111.00 ± 49.00 µm
2, SMAFVB = 87.38 ± 30.02 µm
2; 
p=2.2 x 10-12), P5 (SMAmixed = 129.37 
± 33.93 µm2, SMAFVB = 100.29 ± 36,53 µm2; p=2.3 x 10
-
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23) and P10 (SMAmixed = 169.28 ± 84.16 µm
2, SMAFVB = 120.30 ± 38.45 µm
2; p=8.5 x 10-15) 
time points when compared to SMA mice of FVB genetic background animals. These results 
are highly consistent with the previous findings of improved motoric ability (chapter 5.4.2.2) 
as well as NMJ maturation in mixed background SMA animals.  
 
 
Figure 33: H&E staingins to determine Vastus lateralis muscle fiber size in SMA and HET 
controls on FVB and mixed genetic background. A: Cross section through Vastus 
lateralis muscle of P10 SMA and HET mice of FVB and mixed background to illustrate 
muscle fiber size differences. B: Time course experiment (P1, P5 and P10) depicting 
Muscle fiber sizes of SMA and HET mice on FVB and mixed genetic background. 
While HET mice on FVB and mixed background display identical muscle fiber sizes at 
the various time points, mixed SMA mice show an increase of muscle fiber size at P1 
(p=2.2 x 10
-12
), P5 (p=2.3 x 10
-23
) and P10 (p=8.5 x 10
-15
) when compared with FVB 
SMA mice. (Used animal numbers: HET animals: nFVB=3, nmixed=3; SMA animals: 
nFVB=3, nmixed=3, 100 muscle fibers were measured per animal) 
To summarize, mixed SMA were found to exhibit longer survival and improved motoric 
abilities compared to SMA animals on pure FVB or C57BL/6N background. The assumption 
that heterogeneity causes an amelioration of the SMA phenotype was further confirmed by 
morphological analyzes of mixed and FVB SMA animals: In this context, mixed SMA mice 
when compared with FVB SMA animals showed clear improvement of the NMJ maturation 
process, as demonstrated by occupancy as well as endplate size measurements. 
Furthermore, improved NMJ maturation in mixed SMA mice was accompanied by an 
increase in muscle fiber size strengthening the view of an ameliorative effect of heterogeneity 
on the SMA phenotype. 
Finally, SMA animals on pure C57BL/6N background showed a ~5 days prolonged mean 
survival compared to SMA mice on pure FVB background. Since heterogeneity can be 
excluded, this suggests the presence of background specific SMA ameliorative modifiers in 
C57BL/6N SMA mice. 
5.4.3 Functional analysis of PLS3V5 expression on the SMA phenotype 
To study a possible rescuing effect of PLS3V5 expression on the SMA phenotype, the 
ubiquitously PLS3V5 expressing PLS3V5-ubi line (chapter 5.3.1) was crossed onto the Hung 
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SMA background. Since the genetic background had been demonstrated to markedly 
influence the severity of the SMA phenotype (chapters 5.4.2.2 and 5.4.2.3) both, the 
PLS3V5-ubi as well as the SMA line were first backcrossed on pure C57BL/6N background. 
Functional analysis of PLS3V5 overexpression effects comprised survival, weight and 
motoric ability assessment of PLS3V5 expressing SMA mice and controls (chapter 5.4.3.2). 
Furthermore, morphological studies were performed with particular focus on the development 
and integrity of the NMJ. In a previous study, transient PLS3V5 expression has been shown 
to rescue axonal outgrowth defects observed in primary motor neurons from SMA mice and 
in zebrafish, in which Smn was knocked down by morpholino injection (Oprea et al., 2008). 
Moreover, in chapter 5.4.1.3 of this work PLS3V5 overexpression was shown to result in the 
stabilization of filopodial protrusions in MEF cells (chapter 5.4.1.3). Therefore, it was 
assumed that PLS3V5 overexpression might also in the mouse play an important role for 
axonal integrity at the level of NMJ formation in vivo.   
5.4.3.1 Crossing PLS3V5 onto the SMA background and nomenclature of animals  
To facilitate PLS3V5 expression on the SMA background, heterozygous Smn knockout 
mice were crossed with PLS3V5tg/wt mice in a first step to obtain Smn+/-;PLS3V5tg/wt offspring 
(Figure 34). Smn+/-;PLS3V5tg/wt mice were then bred with Smn-/-;hSMN2tg/tg animals. The 
resulting offspring was made up of 4 different genotypes, each occurring with a statistically 
equal incidence of 25 %:  
 
 Smn-/-;hSMN2tg/wt :  SMA mice 
 Smn-/-;hSMN2tg/wt;PLS3V5tg/wt :  SMA mice expressing PLS3V5 
 Smn+/-;hSMN2tg/wt : HET mice 
 Smn+/-;hSMN2tg/wt;PLS3V5tg/wt :   HET mice expressing PLS3V5 
 
Since all resulting offspring could be used for further examinations, the 100 % outcome of 
this breeding scheme accelerated the process of analysis.  
For reasons of simplicity, in the next chapters all genotypes of SMA and PLS3V5 
expressing SMA animals as well as the HET and PLS3V5 expressing HET mice are 
abbreviated as is defined in Figure 34.  
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Figure 34: Breeding scheme for the production of PLS3V5 overexpressing Hung SMA mice 
5.4.3.2 PLS3V5 expression does not improve survival, weight or motoric ability of 
Hung SMA mice 
Since SMN1-deleted unaffected siblings of discordant SMA families, who are highly 
expressing PLS3, are fully asymptomatic (Oprea et al., 2008), it was nearby to first 
investigate the survival of SMA animals compared to SMA mice expressing PLS3V5 (SMA + 
PLS3V5 mice). A total of 20 animals were analyzed for each genotype, whereby the group 
consisted always of 10 males and 10 females to exclude any gender specific effects. 
Unexpectedly, SMA + PLS3V5 mice displayed no different life expectancy compared to SMA 
animals (Figure 35, A): While SMA animals showed a mean survival of 15.5 ± 2.9 d, SMA + 
PLS3V5 animals have a mean life expectancy of 14.6 ± 3.4 d. However, the slight 
divergence of 0.9 d between the two genotypes was not significant (p=0.529). Since only 
female patients were observed to be protected by high levels of PLS3 (Oprea et al., 2008), it 
was plausible to ask if also in mice a possible rescuing effect was restricted to female mice 
only. To answer this question, the mean survival of female SMA and SMA + PLS3V5 mice 
was separately compared. While female SMA mice exhibited a mean survival of 15.9 ± 3.1 d, 
the mean life expectancy of SMA + PLS3V5 females was reduced to 13.7 ± 3.1 d. However, 
when applying Student`s t-test, this difference turned out to not be significant (p=0.148). Also 
male SMA and SMA + PLS3V5 mice did not display obvious changes in their survival times: 
While male SMA animals have a mean survival of 15.1 ± 2.6  d, male SMA + PLS3V5 mice 
live for an average of 15.5 ± 4.0 d, the observed differences again not being significant 
(p=0.777). Since no changes regarding survival time were observed in the groupwise 
comparison of females and males this indicates that there is no gender specific ameliorative 
effect on the SMA phenotype in mice.   
The absence of survival differences between SMA + PLS3V5 and SMA animals was also 
reflected in the general phenotypical picture of these mice. During the developmental 
 
123 Results 
process from birth until death, SMA and SMA + PLS3V5 mice were not at all distinguishable 
(Figure 35, B). Also HET + PLS3V5 animals did not phenotypically differ from HET mice by 
any means. Additionally, also the analysis of weight revealed no differences between SMA 
and SMA + PLS3V5 animals as well as HET and HET + PLS3V5 mice (Figure 35, C).  
 
Figure 35: Survival, gross appearance and weight analysis of PLS3V5 expressing SMA animals and 
HET controls. A: Kaplan Meier curve of SMA and SMA + PLS3V5 animals, demonstrating 
no beneficial effect of PLS3V5 expression on survival (Mean survival times: SMA = 15.5 
d, SMA + PLS3V5 = 14.6 d (p=0.529)). HET and HET + PLS3V5 animals are not 
depicted since they showed normal survival B: Gross appearance of SMA and SMA + 
PLS3V5 mice as well as HET and HET PLS3V5 control mice. C: Weight progression of 
SMA and SMA + PLS3V5 as well as HET and HET + PLS3V5 mice. (Animal numbers: In 
survival as well as weight progression analysis 20 animals (10 males and 10 females) 
were analyzed for each genotype) 
Next, a possible effect of PLS3V5 overexpression on the motor function of SMA animals 
was investigated by applying the tube test and the righting reflex test. As has been described 
by others, SMA mice showed in the tube test a highly significant decrease in motor function 
compared to HET mice starting around P10 (p=0.0009) (Figure 36, A). However, no 
improvement of motoric ability was detected in SMA + PLS3V5 animals compared to SMA 
mice and also HET + PLS3V5 mice did not display any functional changes when compared 
with HET animals.  
These results were further confirmed by the righting reflex test. While SMA animals 
displayed a highly significant weakening in motor function compared with HET mice starting 
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at P10 (p= 3.7 x 10-5), the presence of PLS3V5 once again had no positive impact on motor 
function in SMA mice: As confirmed by Student`s t-test, no significant changes in their ability 
to right could be measured between SMA + PLS3V5 and SMA animals over the whole life 
span (Figure 36, B).  
 
Figure 36: Evaluation of motoric ability in SMA and SMA + PLS3V5 as well as HET and HET + 
PLS3V5 controls by tube and righting reflex test. A: The tube test did not reveal any 
changes in motoric ability between SMA and SMA + PLS3V5 animals. B: Also in the 
righting reflex test, SMA and SMA + PLS3V5 animals performed similar and did not 
display any significant differences. (Animal numbers: In both tube- and righting reflex test, 
20 animals (10 males and 10 females) were analyzed for each genotype) 
Taken together, no ameliorative effects of PLS3V5 overexpression were observed on 
neither survival, nor on weight or the general clinical picture of SMA mice. Furthermore, SMA 
+ PLS3V5 mice did not show any improvement in their motoric ability as assessed by tube 
and righting reflex test. These data are not in line with the previous findings in human, where 
high PLS3V5 levels had a fully rescuing effect on the SMA phenotype. In this context, it is 
important to mention that unaffected human siblings in most cases carried 3 hSMN2 copies, 
reflecting Type III SMA while Hung SMA mice display a very severe form of SMA. Therefore, 
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one might speculate that a high PLS3 level exerts its ameliorative effect only in the presence 
of certain amounts of SMN/Smn protein. 
5.4.3.3 NMJ endplate area but not muscle fiber size is increased in the distal 
Gastrocnemius muscle of ubiquitously PLS3V5 expressing P10 SMA mice 
Unexpectedly, PLS3V5 overexpression had no influence on the survival or motoric 
abilities of SMA mice (chapter 5.4.3.2). Nevertheless, it was observed before that PLS3V5 
overexpression results in extensive filopodial protrusions in MEF cells derived from 
PLS3V5tg/wt animals (chapter 5.4.1.3). Additionally, a positive effect of PLS3V5 on the 
outgrowth of axons from Smn depleted PC12 cells as well as murine primary motor neurons 
has been reported before (Oprea et al., 2008). Therefore, the focus of further analysis lay on 
studying a potential effect of PLS3V5 expression on the integrity of the neuromuscular 
junctions (NMJ).  
To investigate on that, NMJs of Gastrocnemius muscle sections from 6 animals (3 males 
and 3 females) of SMA, SMA + PLS3V5, HET and HET + PLS3V5 mice were analyzed using 
an antibody directed against neurofilament and bungarotoxin. Next, AxioVision Rel.4.7 
software was employed to measure the surface area size of muscular acetylcholine receptor 
(AChR) clusters (also termed “endplates”). As depicted in Figure 37 (A and B), SMA + 
PLS3V5 animals demonstrated markedly increased endplates when compared with SMA 
mice (SMA = 121.28 ± 8.31 µm2; SMA + PLS3V5 = 141.75 ± 2.76 µm2; p = 2.8 x 10-38). 
However, the endplate size in SMA + PLS3V5 mice was not restored to that of HET mice 
(HET = 162.15 ± 2.99 µm2), highlighting the importance of Smn protein in the process of 
proper NMJ formation. Moreover, this effect of PLS3V5 overexpression became also 
apparent in healthy HET + PLS3V5 mice when compared with HET mice (HET + PLS3V5 = 
190.48 ± 7.22 µm2; p = 1.9 x 10-50).  
Noticeably, endplate measurements of male and female mice of each genotype did not 
reveal any gender specific differences. For that reason and in combination with the finding 
that no survival differences were detectable between sexes (chapter 5.4.3.2) the gender was 
no longer considered in further analyzes. 
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Figure 37: Endplate measurements in Gastrocnemius muscle of SMA, SMA + PLS3V5, HET and 
HET + PLS3V5 controls. A: Endplate size differences as visualized by confocal 
microscopy. B: Quantification of endplate sizes found in the different genotypes. SMA 
+ PLS3V5 possess enlarged endplates than SMA mice. Also in HET animals, the 
endplate size increased highly significant upon PLS3V5 expression. (Animal numbers: 
For endplate measurements, 6 animals (3 males and 3 females) were analyzed for 
each genotype; Stainings: Red = Bungarotoxin (Btx); Green = α-Neurofilament (NF); * 
= p < 0.05; ** = p < 0.01; *** = p < 0.001; 100 endplates were measured per animal) 
In view of the fact that these results pointed towards improved NMJ integrity, next cross 
sections of Vastus lateralis, a proximal muscle, were prepared and the muscle fiber size of 
the same animals was determined. Different from what was expected, SMA + PLS3V5 and 
HET + PLS3V5 animals showed no increase in muscle fiber size compared to SMA or HET 
mice, respectively (Figure 38, B; SMA = 142.66 ± 51.54 µm2; SMA + PLS3V5 = 147.02 ± 
66.1 µm2; HET = 179.10 ± 55.91; HET + PLS3V5 = 181.71 ± 54.53). At the same time, 
however, these results are in line with the observation that SMA + PLS3V5 animals were not 
displaying any signs of improved motoric function compared to SMA mice (Figure 36).   
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Figure 38: H&E stainings to determine Vastus lateralis muscle fiber size in SMA, SMA + PLS3V5, 
HET and HET + PLS3V5 mice. A: Cross section through Vastus lateralis muscle of P10 
animals of the 4 different genotypes. No obvious size differences were observable B: 
Quantification of muscle fiber size found in the different genotypes. SMA + PLS3V5 and 
SMA mice as well as HET and HET + PLS3V5 display no significant differences 
regarding muscle fiber size. (Animal numbers: 3 animals were analyzed for each 
genotype; Abbreviations: n.s.= not significant; 100 muscle fibers were measured per 
animal) 
In summary, PLS3V5 led to an increase of endplate size in SMA or HET animals 
compared to the respective controls, independent of the gender. Since these results pointed 
towards improved NMJ integrity in PLS3V5 expressing mice, it was assumed that this might 
result in increased muscle fiber size in the same animals. However, muscle fiber size was 
unchanged between SMA + PLS3V5 and SMA mice as well as HET + PLS3V5 and HET 
control animals at P10 time point.  
5.4.3.4 Ubiquitous PLS3V5 expression leads to improved axonal connectivity in 
the proximal Transversus abdominis (TVA) muscle of SMA animals  
PLS3V5 expression resulted in an increased postsynaptic endplate size in P10 SMA 
animals. Since factors secreted by presynaptic terminals regulate AChR clustering, e.g. Agrin 
(Nitkin et al., 1987), an improved axonal integrity might explain this observation. The actin 
cytoskeleton plays an important role in axon growth, branching and retraction, but also in 
synapse formation and stability (Luo, 2002). Particularly in motor neurons, Smn has a 
function in promoting presynaptic differentiation by contributing to the translocation of β-actin 
mRNA to the presynaptic compartment (Rossoll et al., 2003). In another work, the lack of 
presynaptic β-actin protein has been linked to defective clustering of voltage-gated Ca2+ 
channels in motor neurons isolated from SMA animals (Jablonka et al., 2007). The authors 
speculate that this, in turn, could impair transmitter release from the axon terminals (Zhong 
and Zucker, 2004), finally leading to NMJ degeneration. Furthermore, PLS3V5 transient 
overexpression has been demonstrated to rescue axon outgrowth defects caused by Smn 
depletion in PC12 cells and primary motor neurons derived from SMA animals (Oprea et al., 
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2008). Moreover, as was reported before (Arpin et al., 1994) and was additionally shown in 
this work for MEF cells, PLS3V5 expression led to extensive filopodial outgrowth (chapter 
5.4.1.3), reflecting its function in actin bundling and cytoskeletal stabilization.  
Together, these findings highlight the importance of cytoskeleton integrity in presynaptic 
development. Therefore, a possible effect of PLS3V5 expression on the stability of terminal 
motor axons in vivo was assumed. To investigate on that, the process of axonal pruning was 
studied in a time course experiment at P1, P4 and P8 time points. The process of vertebrate 
nervous system development results in an overabundance of axonal connections. In this 
context, axonal pruning is a strategy to selectively remove exuberant neuronal branches and 
connections in the immature nervous system to ensure the proper formation of functional 
circuitry (Low and Cheng, 2006). The vertebrate NMJ has been a perfect model to study 
NMJ disassembly for a long time. During early postnatal stages, each muscle fiber is 
innervated by multiple axons or terminal arbors (Sanes and Lichtman, 1999). In a process of 
fine tuning, axon collaterals and axon arbors are removed or remodeled over time. Then, 
with ongoing maturation, postsynaptic endplates finally become innervated by only one 
terminal arbor from a single motor neuron (Low and Cheng, 2006). To find out whether 
PLS3V5 has any “stabilizing” effect on axons in the process of axonal pruning, the number of 
axons innervating individual endplates was determined in SMA, SMA + PLS3V5, HET and 
HET + PLS3V5 animals via fluorescent microscopy at P1, P4 and P8 time points. For this 
purpose, proximal Transversus abdominis (TVA) muscle was prepared from 3 animals for 
each of the described genotypes and time points and co-stained with neurofilament + 
Synaptic vesicle 2 (SV2) antibodies and bungarotoxin to outline incoming axon terminals of 
the NMJ. The number of axons was then counted for 100 endplates as is exemplarily 
depicted in Figure 39, A.  
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Figure 39: PLS3V5 delays axon withdrawal in the process of axonal pruning in Transversus 
abdominis muscle (P1 – P8). A: Exemplary pictures for axon counting. The number of 
axonal inputs of 100 endplates in 3 mice of each genotype (SMA, SMA + PLS3V5, 
HET and HET + PLS3V5) were determined and classified as I = 1 axon, II = 2 axons, 
III (+) = 3 or more axons. B: Calculation of the mean axon input number of all four 
genotypes revealed that PLS3V5 expressing SMA and HET animals show an 
increased mean number of axonal inputs per endplate at all given time points 
compared with SMA and HET mice. B´: Endplate size of all four different genotypes. 
First significant differences in endplate size get obvious around P4 and manifest at P8, 
whereby PLS3V5 expressing SMA and HET mice show an increase in endplate size 
compared with SMA or HET mice, respectively. C: Different representation of the data 
given in B, depicting the distribution of either I, II or III(+) axonal inputs / endplate (in 
percent) for each genotype at the respective time points P1, P4 and P8. (Animal 
numbers: 3 animals were analyzed for each genotype and time point; Stainings: Red = 
bungarotoxin; Green: neurofilament + SV2; * = p < 0.05; ** = p < 0.01; *** = p < 0.001; 
100 NMJs were classified per animal) 
  
As is shown in Figure 39 B and C, the mean number of axons innervating one single 
endplate decreased constantly from P1 until P8 in all genotypes investigated. Importantly, 
during the whole developmental phase of 8 days, HET animals showed a significantly higher 
mean number of axons per endplate compared to SMA mice, indicating poorer 
neuromuscular connectivity in TVA muscle of SMA animals. Interestingly, this result is 
contrary to findings by others, who were not able to observe a significant disturbance of the 
axonal pruning process in SMA mice (Kariya et al., 2008). However, a possible explanation 
for this could be that Kariya et al. investigated the distal and thus less affected 
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Gastrocnemius muscle, whereby in this thesis the proximal Transversus abdominis muscle 
was analyzed.  
Furthermore, and most strikingly, SMA + PLS3V5 mice displayed a highly increased mean 
number of axons per endplate compared to SMA animals at all given time points (Figure 39, 
B and C). These findings strongly suggest that PLS3V5 expression causes a delay in the 
axonal pruning process and exerts a “stabilizing” effect on axons, as it was similarly 
observed for filopodial protrusions in MEF cells before (chapter 5.4.1.3). Moreover, the 
observation of increased axon number was not only restricted to SMA + PLS3V5 mice but 
could also be seen in HET + PLS3V5 animals. Compared to HET mice, HET + PLS3V5 mice 
displayed significantly more axons reaching the endplates at all time points. Importantly, the 
number of incoming axons was almost identical between SMA + PLS3V5 and HET + 
PLS3V5 mice over the whole time course, indicating that the axon “stabilizing” effect of 
PLS3V5 is likely independent of Smn.  
Measurement of the endplate size in PLS3V5 expressing SMA and HET animals 
previously revealed that PLS3V5 has a positive effect on the endplate size at P10 (chapter 
5.4.3.3). Also in the time course experiment, PLS3V5 expression in SMA and HET animals 
resulted in highly significantly increased endplates when compared to SMA or HET animals, 
respectively (Figure 39, B´). This observation was first detectable around P4 and manifested 
at P8, whereas at P1 almost no significant differences in endplate size were observable in 
the different genotypes. At P1, however, the mean axon number per endplate was already 
highly significantly increased in PLS3V5 expressing SMA and HET mice. This observation 
indicates that the increase in endplate size timely follows improved axonal connectivity 
observed in PLS3V5 expressing animals and implicates that enhanced AChR clustering 
might be a consequence of stronger innervation. Even though the mean axon number per 
endplate in SMA + PLS3V5 mice significantly exceeded the level of HET controls at P1 and 
P4, this was not sufficient to restore endplate size in SMA + PLS3V5 mice to the level of HET 
mice (Compare B and B´ in Figure 39).  
This result highlights the importance of Smn in correct NMJ formation and suggests that 
PLS3V5 alone, at least at heterozygous expression levels, is not sufficient to compensate 
endplate defects observed in SMA animals. As shown in unaffected siblings of discordant 
families, who in most cases possess three or four hSMN2 copies, a certain amount of SMN 
protein seems to be required for full rescue. 
It has been demonstrated in the past that actin filament assembly in the muscle is a 
necessary pre-requisite for Agrin induced AChR clustering (Dai et al., 2000). Since PLS3V5 
was ubiquitously expressed in the here described experiments, including muscle tissue, an 
influence of PLS3V5 on the endplate size by stabilizing actin filaments in the muscle must be 
considered. In order to dissect the impact of presynaptic PLS3V5 expression on the endplate 
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size, experiments in which PLS3V5 was motor neuron specifically activated will be presented 
in the course of this work (chapter 5.5.). 
Taken together, it was shown that the presence of PLS3V5 results in a “stabilization” of 
incoming motor axons in SMA and HET animals during the process of axonal pruning. Since 
the extend of axon “stabilization” mediated by PLS3V5 was similar between SMA and HET 
animals, this indicates an Smn independent mechanism. The increase in axonal input 
number was accompanied by enhanced AChR clustering, whereby SMA + PLS3V5 mice 
displayed a highly significant increase in endplate size when compared to SMA animals. At 
least when heterozygously expressed, PLS3V5 was not able to fully restore endplate size in 
Gastrocnemius muscle of SMA animals to the level of HET controls, pointing at the 
indispensability of Smn protein in the process of proper NMJ maturation.  
5.4.3.5 Ubiquitous PLS3V5 expression results in highly occupied endplates and 
extensive presynaptic branching at the NMJ 
It was studied next, whether PLS3V5 had a direct influence on the occupancy level of 
postsynaptic endplates. For this purpose, the degree of nerve occupation at the NMJ was 
estimated for 100 NMJs of 3 P4 animals of each of the genotypes SMA, SMA + PLS3V5, 
HET and HET + PLS3V5 regarding to the reference given in Figure 40, A. As has been 
reported before (Cifuentes-Diaz et al., 2002), the comparison between HET and SMA mice 
revealed less occupied endplates in SMA animals, with 68 % of all investigated NMJs 
reflecting Type I (poorly occupied) AChR cluster (Figure 40, A). In contrast to that, PLS3V5 
expressing SMA as well as HET animals displayed hyperinnervated endplates with the main 
proportion of NMJs reflecting Type III (fully occupied) AChR clusters (63  and 67 %, 
respectively) when compared to SMA or HET animals, respectively. No significant 
differences were found regarding occupancy level between PLS3V5 expressing SMA and 
HET animals, further supporting the view that PLS3V5 mediated “stabilization” of presynaptic 
structures occurs Smn independently. Moreover, careful microscopical analysis of PLS3V5 
expressing SMA and HET mice revealed generally stronger arborized and branched 
presynaptic nerve terminals, reflecting the positive impact of PLS3V5 on axon outgrowth as 
was observed in PC12 as well as isolated murine motor neurons (Oprea et al., 2008) (Figure 
40, B). 
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Figure 40 Increased NMJ occupancy and nerve terminal sprouting in Transversus abdominis 
muscle of PLS3V5 expressing SMA and HET mice. A: Classification of occupancy 
level into poorly occupied (Type I), medium occupied (Type II) and fully occupied 
(Type III) endplates. SMA + PLS3V5 and HET + PLS3V5 mice displayed a higher 
degree of fully occupied endplates compared to SMA and HET animals, respectively. 
B: Presynaptic nerve terminals are strongly arborized and branched in SMA + 
PLS3V5 and HET + PLS3V5 mice compared to SMA and HET animals, respectively. 
Four representative examples (1-4) are given per genotype. (Animal numbers: 3 P4 
animals were analyzed for each genotype ;Stainings: Red = Bungarotoxin; Green = α-
Neurofilament + SV2; 100 NMJs were classified per animal). 
In summary, PLS3V5 expressing SMA and HET animals show highly increased endplate 
occupancy as well as presynaptic branching when compared to non expressing animals. 
These findings are in line with the observed axon stabilization phenotype during the process 
of axonal pruning (chapter 5.4.3.4) and implicate that an increased endplate size in the 
presence of PLS3V5 might be caused by enhanced presynaptic release, e.g. Agrin.  
5.4.3.6 PLS3V5 protein has no stabilizing effect on Smn protein and vice versa 
Via 2-dimensional gel electrophoresis Pls3 and Smn were shown to exist in a 200- and in 
a 500 kDa complex in murine spinal cord (Oprea et al., 2008). Furthermore, via Co-
immunoprecipitation experiments it was found that Pls3 and Smn indirectly interact with each 
other. These observations led to the assumption that Pls3 and Smn might have a stabilizing 
effect on each other. In line with this idea, it was previously reported that Pls3 levels were 
significantly reduced in brain and spinal cord of SMA mice, as shown by quantitative Western 
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blotting and immunohistochemistry (Bowerman et al., 2009). Similar results were obtained 
when Smn was knocked down via morpholino (MO) injection in zebrafish: Also here, pls3 
protein levels were significantly reduced when smn was depleted, whereas restoration of 
smn resulted in a simultaneous normalization of pls3 levels (Oral presentation Dr. Christine 
Beattie at the 15th FSMA meeting, San Francisco, USA).  
To investigate whether the loss of Smn protein affects Pls3 levels also in the here used 
SMA mouse model, proteins were isolated from brain and spinal cord tissue of 3 animals of 
HET controls and SMA mice and subjected to semi-quantitative Western blotting detecting 
Pls3. As was found for both brain and spinal cord Pls3 protein levels were not significantly 
changed between SMA and HET mice (Figure 41, A). In the inverse experiment, Smn levels 
were measured in PLS3V5tg/wt mice of the PLS3V5-ubi line and compared with wt animals. It 
was speculated that in case of PLS3V5/Smn interaction PLS3V5 might have a stabilizing 
effect on Smn protein, however, no increase in Smn protein could be detected in PLS3V5tg/wt 
animals (Figure 41, B). Together, these data do not confirm the observations made by others 
((Bowerman et al., 2009) and Dr. Christine Beattie) who reported a correlation of Pls3/pls3 
and Smn/smn protein amounts in mouse and zebrafish.  
 
Figure 41 Pls3 expression analysis in the SMA background and Smn protein expression analysis 
in PLS3V5
tg/wt 
mice of the PLS3V5-ubi line. A: Pls3 protein amount was not changed 
between HET and SMA mice. B: Smn protein amount did not change in the presence 
of PLS3V5.  
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5.5 Motor neuron specific expression of PLS3V5 on a wt background 
In the last few years, diverse publications have proven a direct involvement of actin 
polymerization in the process of AChR clustering (Dai et al., 2000, Campagna and Fallon, 
2006, Stetzkowski-Marden et al., 2006, Willmann et al., 2006, Zhu et al., 2006, Pato et al., 
2008, Lee et al., 2009). To address the question whether the observed positive effect of 
ubiquitous PLS3V5 expression on endplate size (chapters 5.4.3.3 and 5.4.3.4) is driven by 
PLS3V5 present in the muscle or whether motor neuron specific expression is sufficient, 
PLS3V5 was overexpressed specifically in motor neurons on a wt background. For this 
purpose, PLS3V5fl_st/wt mice of the PLS3V5-floxed line were crossed with the motor neuron 
specific Cre expressing line Hb9-Cre (Arber et al., 1999) (Figure 42). Resulting offspring was 
then analyzed via immunohistological methods for the effect of motor neuron specific 
PLS3V5 expression on motor neuron-, endplate- and muscle fiber size.  
 
Figure 42  Breeding scheme for the production of motor neuron specific PLS3V5 expressing 
mice: In PLS3V5
tg/wt 
; Hb9-Cre
tg/wt
 animals, Cre is motor neuron specifically expressed 
and leads to the deletion of the Stop-cassette between promoter and PLS3V5 
transgene. In WT, PLS3V5
tg/wt
 and Hb9-Cre
tg/wt
 control animals, PLS3V5 is not 
expressed. 
5.5.1 Effects of motor neuron specific expression of PLS3V5  
5.5.1.1 PLS3V5 is motor neuron specifically expressed in PLS3V5fl_st/wt;Hb9-Cretg/wt 
mice and leads to an increase of motor neuron cell body size 
To analyze whether Hb9-Cre mediated deletion of the stop-cassette between promoter 
and PLS3V5 transgene was successful and resulted in motor neuron specific PLS3V5 
expression in PLS3V5fl_st/wt;Hb9-Cretg/wt mice, immunohistological stainings were performed. 
For this purpose, spinal cord sections from lumbar regions 4 to 5 of P10 PLS3V5fl_st/wt;Hb9-
Cretg/wt mice were stained using V5 antibody to specifically detect PLS3V5 protein. In this 
approach, WT, PLS3V5fl_st/wt and Hb9-Cretg/wt mice were used as negative controls to exclude 
false positive signals due to unspecific binding of the antibody. Importantly, PLS3V5 protein 
was only detectable in motor neurons of PLS3V5fl_st/wt;Hb9-Cretg/wt mice but not in WT, 
PLS3V5fl_st/wt or Hb9-Cretg/wt controls (Figure 43).  
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Figure 43 PLS3V5 is motor neuron specifically expressed in PLS3V5
fl_st/wt
;Hb9-Cre
tg/wt
 mice, but 
not in PLS3V5
fl_st/wt
 and Hb9-Cre
tg/wt
 controls. For a better orientation, the respective 
ventral horn area is delineated in the above Nissl overview. (Stainings: Red = Chat 
staining; Green = V5) 
Since it is known from MEF cells that PLS3V5 overexpression can lead to morphological 
changes (chapter 5.4.1.3), it was next asked whether PLS3V5 overexpression might have an 
influence on motor neuron cell shape also in vivo. To investigate on that, AxioVision Rel.4.7 
software was used to determine the motor neuron soma size in spinal cord sections of P21 
PLS3V5fl_st/wt;Hb9-Cretg/wt animals as well as PLS3V5fl_st/wt and
 
Hb9-Cretg/wt controls. As 
depicted in Figure 44, PLS3V5fl_st/wt;Hb9-Cretg/wt animals showed a highly significant increase 
in motor neuron size compared to PLS3V5fl_st/wt and
 
Hb9-Cretg/wt controls (p = 3.52 x 10-40 and 
p = 3.62 x 10-34, respectively; PLS3V5fl_st/wt;Hb9-Cretg/wt  =  931.44 ± 24.64 µm2, PLS3V5fl_st/wt 
= 726.70 ± 55.6 µm2, Hb9-Cretg/wt = 754.24 ± 11.75 µm2), whereby motor neuron size 
between PLS3V5fl_st/wt
 
and
 
Hb9-Cretg/wt animals did not significantly differ (p = 0.05263). The 
finding of increased motor neuron size in PLS3V5fl_st/wt;Hb9-Cretg/wt animals is of particular 
interest since reduced proprioceptive reflexes of motor neurons have recently been 
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correlated with decreased number and function of synaptic connections between motor 
neurons and muscle spindle afferents in SMA mice (Mentis et al., 2011). Since an increased 
motor neuron soma might provide extra surface area for afferent synapses this could 
possibly have a positive impact on spinal circuit function. 
 
Figure 44 Measurement of motor neuron size revealed highly significantly increased motor 
neuron soma size in PLS3V5
fl_st/wt
;Hb9-Cre
tg/wt
 compared  to PLS3V5
fl_st/wt
 and
 
Hb9-
Cre
tg/wt 
controls. (Animal numbers: 3 animals were analyzed for each genotype; 
Stainings: Red: Chat; Green: PLS3 or PLS3V5; * = p < 0.05; ** = p < 0.01; *** = p < 
0.001; 100 motor neurons were counted per animal) 
Here it was shown that PLS3V5 is activated specifically and exclusively in motor 
neurons of PLS3V5fl_st/wt;Hb9-Cretg/wt mice. These findings allowed to investigate, whether 
motor neuron specific expression of PLS3V5 is sufficient to increase endplate size or if 
improved AChR clustering is solely regulated by muscular PLS3V5 protein (chapter 5.5.1.2.) 
Furthermore, in P21 PLS3V5fl_st/wt;Hb9-Cretg/wt animals PLS3V5 expression lead to a highly 
significant increase in motor neuron soma size compared to control mice.  
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5.5.1.2 Motor neuron specific expression of PLS3V5 is able to rescue endplate 
defects observed in Hb9-Cretg/wt p10 and p21 animals and leads to a highly 
significant muscle fiber size increase in p21 PLS3V5fl_st/wt;Hb9-Cretg/wt mice.   
As was speculated in chapter 5.5, PLS3V5 in the muscle might account for the observed 
increase in endplate size in P10 PLS3V5 ubiquitously expressing SMA and HET mice 
(chapters 5.4.3.3 and 5.4.3.4.). To assess if also motor neuron specific expression of 
PLS3V5 was sufficient to increase endplate size in Gastrocnemius muscle, PLS3V5 was 
motor neuron specifically activated on a wt background by crossing with the Hb9-Cre line 
(chapter 5.5). In Hb9-Cre mice, Cre recombinase is inserted in the intrinsic Hb9 gene causing 
loss of function. In 1999, Arber et al. reported that the homozygous loss of Hb9 in Hb9-Cretg/tg 
mice resulted in total absence of motor axons and consequentially perinatal lethality. 
Furthermore, severe AChR clustering defects were observed as the process of prepatterning 
and the individual shape of early endplates was disturbed (Arber et al., 1999).  
In line with these observations, P10 Hb9-Cretg/wt mice showed a highly significant 
reduction in endplate size when compared to PLS3V5fl_st/wt and PLS3V5fl_st/wt;Hb9-Cretg/wt 
mice (Figure 45, A; p = 3.09 x 10-39 and 3.46 x 10-44, respectively; P10 Hb9-Cretg/wt = 136.66 ± 
10.09 µm2, PLS3V5fl_st/wt = 160.08 ± 4.14 µm2, PLS3V5fl_st/wt;Hb9-Cretg/wt = 162.96 ± 5.66 µm2) 
. The fact that the endplate size in PLS3V5fl_st/wt;Hb9-Cretg/wt mice was restored to that of 
PLS3V5fl_st/wt animals demonstrated that motor neuron specific overexpression of PLS3V5 
was sufficient to rescue endplate size defects of Hb9-Cretg/wt animals. Nevertheless, an 
involvement of muscular PLS3V5 protein in the process of AChR clustering cannot be 
excluded based on these findings. Furthermore, when comparing muscle fiber diameter of 
Vastus lateralis muscle, PLS3V5fl_st/wt, Hb9-Cretg/wt and PLS3V5fl_st/wt;Hb9-Cretg/wt mice did not 
display any differences at P10 (Figure 45, A´). 
At later time point P21, PLS3V5 expression in PLS3V5fl_st/wt;Hb9-Cretg/wt led to a highly 
significant increase in endplate size relative to PLS3V5fl_st/wt and Hb9-Cretg/wt animals in 
Gastrocnemius muscle (Figure 45, B; p = 5.16 x 10-5 and p = 0.00081, respectively; 
PLS3V5fl_st/wt;Hb9-Cretg/wt = 372.62 ± 15.02 µm2, PLS3V5fl_st/wt = 306,49 ± 6.02 µm2;     Hb9-
Cretg/wt = 319.03 ± 5.17 µm2). In addition and most strikingly, the bigger endplate size in 
PLS3V5fl_st/wt;Hb9-Cretg/wt animals was accompanied by the observation of a highly significant 
increase in muscle fiber size (Vastus lateralis) compared to PLS3V5fl_st/wt and Hb9-Cretg/wt 
controls (Figure 45, B´, p = 3.15 x 10-11 and p = 5.81 x 10-15, respectively; PLS3V5fl_st/wt;Hb9-
Cretg/wt = 539.53 ± 16.85, PLS3V5fl_st/wt  =  408.87 ± 9.36 µm2;  Hb9-Cretg/wt = 382.48 ± 9.94 
µm2 ). These findings strongly suggest that the observed improvement in axonal connectivity 
and NMJ occupation in PLS3V5 expressing mice (chapters 5.4.3.4 and 5.4.3.5) is indeed 
functional. However, since endplate size and muscle fiber size were determined in different 
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muscles, further experiments will include endplate size measurements in Vastus lateralis 
muscle as well as muscle fiber size determination in Gastrocnemius muscle. 
 
Figure 45: Motor neuron specific expression of PLS3V5 at P10 and P21 time points and its 
effects on endplate (Gastrocnemius muscle) as well as muscle fiber size (Vastus 
lateralis muscle). A and A´: PLS3V5 expression in P10 PLS3V5
fl-st/wt
;Hb9-Cre
tg/wt 
mice 
is able to compensate endplate size defects observed in Hb9-Cre
tg/wt
 animals, 
whereby muscle fiber size did not differ between PLS3V5
fl_st/wt
, Hb9-Cre
tg/wt
 and 
PLS3V5
fl-st/wt
;Hb9-Cre
tg/wt
 mice. B and B´: At P21, PLS3V5 expression in PLS3V5
fl-
st/wt
;Hb9-Cre
tg/wt
 resulted in highly increased endplate- and muscle fiber size compared 
to PLS3V5
fl_st/wt
 and Hb9-Cre
tg/wt
 mice. (Animal numbers: 5 animals were analyzed for 
each genotype at P10 and 3 animals for each genotype at P21; * = p < 0.05; ** = p < 
0.01; *** = p < 0.001, 100 endplates and 100 muscle fibers were counted per animal in 
the respective tissue) 
To summarize, conditional expression of PLS3V5 exclusively in motor neurons was 
sufficient to increase endplate size at both time points, P10 and P21. These results support 
the view that enhanced axonal connectivity and endplate occupancy observed in PLS3V5 
expressing SMA and HET animals directly augmented AChR clustering, possibly through 
improved presynaptic release. Importantly, motor neuron specific PLS3V5 expression was 
able to highly significantly increase Vastus lateralis muscle fiber size in PLS3V5fl_st/wt;Hb9-
Cretg/wt mice at P21 time point. This finding demonstrates that improved axonal connectivity 
and endplate occupancy in PLS3V5 expressing animals is functional. The finding of 
increased muscle fiber size at P21 but not at P10 suggests that PLS3V5 effects on muscle 
fiber size become obvious first at later time points. However, sever Hung SMA mice die 
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already around P15. Therefore, SMA mice might just die too early to profit from PLS3V5 
overexpression. 
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6 Discussion 
6.1 Generation of a PLS3V5 expressing mouse 
PLS3 has previously been proven to be a fully protective modifier in unaffected SMN1-
deleted siblings of discordant SMA families (Oprea et al., 2008). Therefore, it was the main 
aim of the present study to investigate, whether PLS3 overexpression is also able to rescue 
the phenotype of an SMA mouse model.  
PLS3-overexpressing mice were produced by targeting a V5-tagged version of the human 
PLS3 gene (PLS3V5) controlled by the CMV enhancer/chicken β-actin (CAG) fusion 
promoter into the Rosa26 locus. Since a LoxP sites flanked stop-cassette was present 
between promoter and transgene (Figure 8), PLS3V5 expression could be driven either 
ubiquitously or tissue specifically. We induced a motor neuron specific expression by 
breeding PLS3V5-floxed mice with the Cre-expressing line Hb9-Cre (Arber et al., 1999). 
For transgenesis, the hybrid ES cell line V6.5 (SV129 and C57BL/6N) was used in this 
study (Eggan et al., 2002). V6.5 ES cells offer the big advantage of being insensitive and 
robust in handling. Furthermore, favorable germline transmission rates have been reported 
for those cells by various laboratories. Altogether, two rounds of ES cell transgenesis 
(chapter 5.2) and injection into blastocysts were performed using V6.5 ES cells before a 
single PLS3V5fl_st/wt transgenic female could be identified by genotyping PCR. Nevertheless, 
to study a possible modifying function of PLS3V5, a clean genetic background was required. 
Therefore, resulting PLS3V5fl_st/wt founder animals had to be backcrossed for more than 7 
generations to reach a statistical genetic purity of 100 % prior to further analysis.  
While constantly backcrossing PLS3V5fl_st/wt mice onto a clean C57BL/6N background, the 
same line was bred with the ubiquitously Cre-expressing line CMV-Cre (Schwenk et al., 
1995) in order to permanently delete the stop cassette between CAG promoter and 
transgene. Importantly, the Cre transgene is located on the X-chromosome in CMV-Cre 
mice. In animals of the genotype PLS3V5fl_st/wt;CMV-CreX_tg/Y the transgene was expected to 
be expressed ubiquitously in every cell type (chapter 5.3.3). However, using a PCR allowing 
to detect the presence or absence of the stop cassette, it was found that the stop cassette 
was present in ~50 % of PLS3V5fl_st/wt;CMV-CreX_tg/Y mice despite the presence of Cre, likely 
due to insufficient penetrance of the Cre enzyme (Figure 20, A). In line with this, the 
presence of the stop cassette in PLS3V5fl_st/wt;CMV-CreX_tg/Y mice was correlated with an 
absence of PLS3V5 expression on protein level (Figure 20, B). Importantly, this finding 
proved that the stop cassette between CAG promoter and PLS3V5 transgene successfully 
prevents uncontrolled transgene expression. This observation was of particular importance 
with respect to motor neuron specific overexpression of the PLS3V5 transgene. 
Cre expression has been shown to act toxic on cells in a dose dependent manner in 
various organisms and should therefore be outcrossed for further analyzes whenever 
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possible (Silver and Livingston, 2001). Moreover, Cre recombinase has been shown to 
induce proliferation disturbances in Drosophila melanogaster, resulting in phenotypic 
aberrations (Heidmann and Lehner, 2001). Finally, mice expressing Cre at high levels in 
spermatids display chromosome scrambling after meiosis II, causing complete male sterility 
(Schmidt et al., 2000). Since Cre was not necessary to activate PLS3V5 expression once the 
stop cassette had been deleted in the germline and to avoid unspecific side effects of Cre, 
PLS3V5 was outcrossed by breeding PLS3V5fl_st/wt;CMV-CreX_tg/Y mice with C57BL/6N wt 
animals (chapter 5.3.3). 
This way, heterozygous PLS3V5tg/wt animals of the so termed PLS3V5-ubi line (Table 13) 
were established, invariably carrying the stop-cassette-deleted allele in every cell and tissue. 
Notably, PLS3V5tg/wt animals displayed completely normal behavior, motoric ability, weight 
gain and fertility and were indistinguishable by their wt littermates. This suggested that 
PLS3V5 overexpression, at least when driven by the CAG promoter, is not per se toxic to 
cells. Additionally, the absence of toxic effects of PLS3V5 transgene expression allowed to 
model the situation in unaffected SMA siblings best possible, namely by ubiquitously 
overexpressing PLS3V5 in the murine SMA background.  
PLS3V5tg/wt animals on C57BL/6N wt background were further analyzed for PLS3V5 
expression on mRNA and protein level. By comparing total plastin 3 mRNA levels (here 
defined as the sum of PLS3V5 + endogenous Pls3) between wt and PLS3V5tg/wt mice, it was 
shown that plastin 3 is significantly overexpressed in all examined tissues affected by SMA, 
including brain, spinal cord and muscle (Figure 22, A). However, total plastin 3 mRNA levels 
were only moderately increased in brain, spinal cord and muscle to 3.6, 3.4 and 21.5 fold of 
endogenous level, respectively. In other tissue types, e.g. heart or blood, plastin 3 levels 
were more significantly increased, with 76.2 and 206 fold overexpression. Notice that the 
fold-expression reflects the difference compared to the endogenous level. Since there is 
usually no Pls3 expression in blood, a 200 fold increase is easy to be achieved. On the other 
hand, endogenous Pls3 is highly expressed in spinal cord or muscle, which means that the 
total plastin 3 level observed in spinal cord or muscle of transgenic mice might still exceed 
the level in blood. To ultimately compare plastin 3 overexpression levels between different 
tissue types, an absolute quantification would be necessary.  
On protein level, PLS3V5 was neither detectable in brain, nor in spinal cord of PLS3V5tg/wt 
mice using a PLS3 antibody recognizing both, endogenous Pls3 as well as PLS3V5 (Figure 
24, A, B). In this regard, it was only possible to obtain the endogenous Pls3 protein band and 
only in combination with V5 antibody, also PLS3V5 was detectable. Together, these findings 
indicated that PLS3V5 is present in brain and spinal cord of PLS3V5tg/wt animals, however, in 
lower concentrations as was indicated on mRNA level. This finding gets further support from 
experiments with liver proteins, where total plastin 3 mRNA amount was 7.8 fold increased 
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compared to endogenous level (Figure 22, A). Concomitantly with an increased PLS3V5 
expression on mRNA level, PLS3V5 protein was indeed detectable by using the PLS3 
antibody (Figure 24, C`). Nevertheless, as assessed by densitometric analysis, the 
expression of total plastin 3 protein in liver of PLS3V5tg/wt mice was only ~2 fold increased 
compared to wt level. Therefore, it is likely that also in brain, spinal cord and muscle the real 
plastin 3 upregulation is far below the levels indicated by mRNA expression analysis. These 
findings suggest that PLS3V5 mRNA is not likewise converted into PLS3V5 protein, 
indicating translational regulation of the transgene or other possible negative feedback 
mechanisms on its own expression. In this context it might be possible that 5` and 3` 
sequence elements of the targeting vector might account for lower translation rates. 
Furthermore, the V5-tag of the human PLS3 transgene might negatively impact on protein 
folding or stability and might thus induce degradation via the ubiquitin-proteasome system. 
Additionally, PLS3V5 was successfully activated specifically in motor neurons by crossing 
PLS3V5fl_st/wt mice with the motor neuron specific Cre line Hb9-Cre. Via qRT-PCR and 
Western blotting it was tried to detect PLS3V5 expression on mRNA and protein level in 
spinal cord of PLS3V5fl_st/wt;Hb9-Cretg/wt mice. Unexpectedly, PLS3V5 expression was 
detectable neither on mRNA, nor on protein level (data not shown). It is known that only a 
small percentage, in the range of 3-5 % of the total cell population, of spinal cord consists of 
motor neurons (Arce et al., 1999, Wiese et al., 2010). Therefore, it must be considered that in 
spinal cord lysate PLS3V5 mRNA and protein also hold only a very small percentage of total 
transcripts and proteins. Since no expression differences were detectable between 
PLS3V5fl_st/wt;Hb9-Cretg/wt animals and PLS3V5fl_st/wt as well as Hb9-Cretg/wt controls, it was 
concluded that qRT-PCR and Western blotting methods are not sensitive enough to detect 
such low levels of PLS3V5 mRNA and protein, respectively. A similar observation has been 
made in the context of motor neuron specific deletion of the splicing factor Sfrs10 in 
Sfrs10fl/fl;Hb9-Cretg/wt mice by our group (Mende et al., 2010). Finally, motor neuron specific 
expression of PLS3V5 was proven via immunohistochemical stainings using a V5 antibody 
on spinal cord sections of PLS3V5fl_st/wt;Hb9-Cretg/wt mice.  
6.2 The genetic background influences the phenotypic severity in Hung SMA 
mice 
The PLS3V5 transgenic lines were backcrossed onto pure C57BL/6N background in this 
thesis while the Hb9-Cre line for motor neuron specific overexpression was already present 
on pure C57BL/6N. It is commonly accepted that genetic purity is absolutely essential for the 
reliability and consistency of precise analysis. For that reason, also Hung SMA mice, at that 
time only present on FVB background, were backcrossed for at least 7 generations to 
C57BL/6N wt animals. Hung SMA mice on FVB background show a mean survival of 9.9 d 
(Riessland et al., 2010), while SMA mice on a C57BL/6N background live for 15.5 d. 
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Interbred SMA mice containing a statistical portion of 87 % C57BL/6N and 13 % FVB (mixed 
background), however, displayed the longest mean survival with 19.2 d. Because mice on 
pure C57BL/6N background live longer compared to SMA mice on FVB background, this 
suggests the presence of genomic modifying factors. Furthermore, the fact that mixed SMA 
mice survive longer than SMA animals on either of the two clean backgrounds indicates that 
genetic heterogeneity mitigates phenotypic severity. In contrast to the short survival time of 
only 15.5 d in Hung SMA mice on pure C57BL/6N background found here, Tsai et al. found 
that Hung SMA mice on pure C57BL/6J background survived for ~13 months (Tsai et al., 
2008).  
How can these huge discrepancies between genetically distinct backgrounds, but in 
particular between the relatively close two C57BL/6 substrains (“N” and “J”), be explained? 
Of the two strains mentioned, C57BL/6J was the “original” strain, whereby subline C57BL/6N 
originated at the National Institute of Health (NIH) and was separated by C57BL/6J in 1951 
(Zurita et al., 2011). Until today, the individual lines were kept over many generations by 
various investigators and vendors. Due to genetic drift, it is supposed that each of these 
sublines is genetically distinct, although externally, they are very similar (Zurita et al., 2011). 
Genetic differences comprise a whole consortium of minor or major genomic alterations, 
among these single nucleotide polymorphisms (SNPs), microsatellites, copy number 
variations but also genomic rearrangements as well as mutations in genes or promoter 
regions of genes. E.g., with regard to the latter, most substrains derived from C57BL/6J mice 
carry a mutation in the nicotinamide nucleotide transhydrogenase (Nnt) gene, resulting in 
inappropriate glucose homeostasis (Freeman et al., 2006, Zurita et al., 2011). Up to now, 
only little information is available on the differences between various substrains. In a screen 
applying an Illumina® Mouse Medium Density (MD) Linkage mapping panel, one study 
comprised alltogether 1.449 SNPs selected from 20 mouse chromosomes and compared 
these between different C57BL/6 substrains (Zurita et al., 2011). In this study, only 12 SNPs 
were found to be polymorphic between the C57BL/6J and C57BL/6N substrains. Although 5 
of the 12 SNPs mapped to boundaries of known genes (Naaladl2, Fgf14, Lims1, Aplp2, 
Snap29), it appears unlikely that the enormous survival differences between Hung SMA mice 
on C57BL/6J and C57BL/6N can be explained by only those variants. Moreover, considering 
a mean coverage of 3 SNPs per 5 Mb interval when using only 1.449 SNPs, it seems even 
more obvious that further genetic differences must be present among the two substrains that 
account for the phenotypical discrepancies.  
Last but not least, it must be mentioned that also environmental factors can have a major 
impact on the severity of SMA-pathology. Besides different animal care and health 
standards, e.g. also nutrition has been demonstrated to significantly influence the course of 
disease in the SMNΔ7 mouse model. In this regard, combining Trichostatin A (TSA, an 
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HDAC inhibitor) treatment with nutritional support extended the median life span of SMA 
mice to about 170 %, compared to only 40 % when TSA was given alone (Narver et al., 
2008).  
6.3 The effects of PLS3V5 overexpression on the morphology of murine 
embryonic fibroblasts 
In the present study, murine embryonic fibroblasts (MEFs) were isolated from PLS3V5tg/wt 
animals and the transgene detected using an antibody against the V5-tag. By comparing the 
localization pattern of wt Pls3 with PLS3V5, it was found that transgenic protein localizes 
completely normal and specifically at sites of actin filament consolidation. Moreover, PLS3V5 
overexpression led to significant changes in MEF cell morphology as was implicated by a 
significantly increased number of filopodial and lamelipodial structures compared to wt cells.  
In the year 1980, PLS3 was first described as a 68 kDa protein colocalizing with actin 
filaments and being present in membrane ruffles, microspikes and microvilli of chicken 
fibroblast cells (Bretscher and Weber, 1980). Based on these observations, further analysis 
revealed that PLS3 is an F-actin bundling protein with main function in cytoskeletal 
organization (Bretscher, 1981, Glenney et al., 1981). By overexpressing PLS3 in fibroblast 
like CV-1 cells and in the polarized epithelial cell line LLC-PK1, it was found that high levels 
of PLS3 exert significant effects on cell morphology (Arpin et al., 1994). In CV-1 cells, PLS3 
overexpression led to the reorganization of F-actin filaments into polygonal networks around 
the cell surface and consequentially to a rounding up of cells, structural properties 
reminiscent of rat embryo cells just before spreading (Lazarides, 1976). Moreover, PLS3 
overexpression was associated with a partial loss of adherence in CV-1 cells as concluded 
by the observation of a diminution of focal contacts. In contrast, PLS3 overexpression 
induced the formation of thickened and elongated microvilli in LLC-PK1 cells. Also, when 
overexpressed in stereocilia of developing auditory hair cells, PLS3 led to an increase in 
length, width, and density of microvilli (Daudet and Lebart, 2002). Together, these results 
suggest an important role for PLS3 in the rearrangement of cytoskeletal structures towards 
membrane outgrowth. Accordingly, in the present study overexpression of PLS3V5 in MEFs 
derived from PLS3V5tg/wt mice led to a significant stabilization of lamelipodial as well as 
filopodial structures when compared to wt cells.  
The observation of stabilized filopodia in PLS3V5 overexpressing MEFs raises the 
question how an actin bundling protein might affect the length of an actin microfilament. In 
the yeast null-mutant of fimbrin (SAC6Δ) cytoplasmic actin filaments are completely absent 
(Belmont and Drubin, 1998). The other way around, in yeast strains expressing the V159N 
mutant form of actin (act1-159), filaments depolymerize approximately three times slower 
than in wt filaments and are more abundant than in wt (Belmont and Drubin, 1998). However, 
in the sac6Δ act1-159 double mutant the number of F-actin cables is restored to almost wt 
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level while filaments seemed mislocalized and displayed an abormal organization. 
Furthermore, by a rhodamine-phalloidin-binding assay as well as G-actin measurement in 
permeabilized yeast sac6Δ mutant cells, F-actin was found to be decreased, G-actin to be 
increased while no change in total actin levels compared with wt was observed (Karpova et 
al., 1995). Also in lymphoblastoid as well as HEK cells, overexpression of PLS3 led to 
increased F-actin levels (Oprea et al., 2008). Together, these findings suggest that PLS3 has 
multiple roles in stabilizing F-actin by inhibiting depolymerization and directing F-actin 
filament orientation. However, in order to find out how PLS3 mechanistically prevents F-actin 
depolymerization further biochemical investigations are required.  
6.4 Effects of PLS3V5 overexpression at NMJ level 
The main goal of this study was to investigate a possible rescuing effect of PLS3V5 
overexpression on the murine SMA phenotype. As outlined previously, PLS3V5 
overexpression did not have a positive impact on survival and motoric ability of the severe 
Hung SMA mouse model (chapter 5.4.3.2). Nevertheless, careful morphological analysis 
revealed a very prominent phenotype at the neuromuscular junction (NMJ) of ubiquitously 
PLS3V5 expressing SMA and HET control mice (Figure 39 and Figure 40). Additionally, to 
further dissect pre- and postsynaptic effects of PLS3V5 expression on AChR clustering, 
PLS3V5 was motor neuron specifically activated on a wt background (chapter 5.5). In the 
next chapters, the effects of PLS3V5 overexpression on NMJ morphology and the 
implications for SMA pathology will be discussed. 
6.4.1 Increased AChR clusters – effect of pre- or postsynaptic PLS3V5 action? 
Since no improvement in survival and motoric ability were detected in PLS3V5 
overexpressing SMA mice, morphological analysis was performed on muscle sections to 
investigate whether PLS3V5 overexpression affects NMJ morphology. Thereupon, it was 
found that the size of postsynaptic AChR clusters was highly significantly increased in the 
Gastrocnemius muscle of P10 SMA + PLS3V5 and HET + PLS3V5 animals when compared 
to SMA and HET mice (Figure 37). At early time points of mouse development and still 
preceding axon arrival, patches of AChR spontaneously assemble along the midline of 
muscles in a process termed AChR-prepatterning (Lin et al., 2001, Yang et al., 2001). Upon 
nerve arrival, synaptogenic factors are released that further trigger and refine AChR 
clustering to sites of nerve innervation. In this context, the most important presynaptic factor 
known to trigger AChR clustering is the proteoglycan and MuSK receptor ligand Agrin (Wu et 
al., 2010). Since in the initial experiments PLS3V5 was ubiquitously expressed in SMA + 
PLS3V5 and HET + PLS3V5 animals, the question was raised whether PLS3V5 at pre- or 
postsynaptic sites accounts for the increase in endplate size of P10 animals.  
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Noteworthy, addressing this question was of particular interest since a presynaptic effect 
of PLS3V5 expression on AChR clustering would point at improved presynaptic signaling in 
transgenic mice. Initial support for the view of a presynaptic contribution of PLS3V5 
overexpression on AChR cluster size came from a time course experiment: Here, it was 
found that the endplate size between SMA, SMA + PLS3V5, HET and HET + PLS3V5 
animals did not significantly differ at the early time point P1 (Figure 39). Importantly, endplate 
size differences between PLS3V5 expressing and control mice were first seen around P4. 
However, the CAG promoter driving PLS3V5 expression is ubiquitously active already very 
early during development, also in the muscle (Sakai and Miyazaki, 1997). Therefore, in case 
of a muscle specific effect of PLS3V5 on AChR cluster size, one would expect an effect of 
PLS3V5 on AChR clustering already during the AChR prepatterning process, just before first 
nerve terminals arrive. In line with that, an increase in endplate size should also be 
detectable at P1. Around P4, significant morphological changes take place in the context of 
mouse NMJ maturation. Principally, these changes comprise synapse elimination (axonal 
pruning) and concomitant conversion of the uniform patch-like shape of AChR cluster into a 
perforated pretzel-like appearance (Kariya et al., 2008, Murray et al., 2008). In this context, 
postnatal endplate maturation is known to be dependent on excitation from motor nerve 
terminals (Misgeld et al., 2002). The fact that endplate size increase in PLS3V5 transgenic 
mice falls together with motor axon rearrangement processes further suggests a presynaptic 
role for PLS3V5 in AChR clustering. At this point it should be remembered that PLS3V5 
overexpression indeed results in significant changes of presynaptic organization, such as 
delayed axonal pruning as well as hyperinnervation of endplates. Therefore, these effects of 
PLS3V5 on presynaptic organization might well account for the observed increase in 
endplate size.  
To further analyze the influence of presynaptic presence of PLS3V5 on endplate size, 
PLS3V5 was motor neuron specifically overexpressed in PLS3V5fl_st/wt;Hb9-Cretg/wt mice. In 
heterozygous Hb9-Cretg/wt mice, Cre is located in the endogenous Hb9 locus, resulting in 
heterozygous knockout of Hb9 (Arber et al., 1999). Moreover, homozygous Hb9-Cretg/tg mice 
are even perinatally lethal and display a complete loss of motor neuron axons (Yang et al., 
2001). Furthermore, AChR prepatterning has been shown to be clearly disturbed in Hb9-
Cretg/tg mice with abnormal scattered distribution of AChR clusters across the diaphragm 
muscle at the early time point E12-E18.5. Although postsynaptic prepatterning defects of 
homozygous Hb9-Cretg/tg are long known, until now no study has ever focused on later time 
points in living heterozygous Hb9-Cretg/wt mice. In the present study, it was found that also 
Hb9-Cretg/wt mice exhibit AChR clustering defects by means of reduced endplate size in 
Gastrocnemius muscle as compared to controls at P10. This finding highlights the essential 
role of Hb9 for normal motor neuron development (Yang et al., 2001). Furthermore, these 
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findings underline the importance of normal motor neuron development and nerve 
innervation for proper AChR clustering. Most strikingly, endplate size was restored to normal 
level in PLS3V5fl_st/wt;Hb9-Cretg/wt mice. As muscular PLS3V5 expression can be excluded in 
PLS3V5fl_st/wt;Hb9-Cretg/wt animals, it seems plausible that presynaptic changes must account 
for the observed increase in endplate size. Since PLS3V5 overexpression led to an 
amelioration of the endplate size defects not only in SMA but also in Hb9-Cre mice, these 
findings together point at a general PLS3V5 neuroprotective effect, which might in turn 
impact on endplate size.  
Nevertheless, despite clear evidence for presynaptic contribution of PLS3V5 
overexpression to enhanced AChR clustering, an additional muscle specific effect of PLS3V5 
from P4 time point on cannot be excluded. Many studies have focused on the relationship 
between the actin cytoskeletal organisation and AChR clustering in the past. In myotubes, F-
actin filament formation clearly precedes Agrin induced AChR clustering (Dai et al., 2000). 
Additionally, it has been shown in the same study, that AChR clusters did not form in the 
presence of Latrunculin, a toxin that sequesters globular (G)-actin and prevents F-actin 
assembly. From these experiments, it can be concluded that F-actin assembly is a 
prerequisite for the formation of Agrin induced AChR clusters. Furthermore, AChR clustering 
involves signaling by positive regulators of actin polymerization and filament growth, e.g.  
Rho-family GTPases (regulate actin polymerization-driven processes) (Weston et al., 2003, 
Hall, 2005), p21-activated kinase 1 (effector of the GTPase Cdc42, which in turn regulates 
actin polymerization) (Luo et al., 2002) or geranylgeranyl transferase (enhances the 
membrane association and activation of GTPases) (Luo et al., 2003). Additionally, cortactin, 
which is an activator of the Arp 2/3 complex, has been shown to be important for AChR 
clustering (Madhavan et al., 2009). Most interestingly, however, many F-actin-associated 
proteins with impact on filament organization have been found to colocalize with AChR 
clusters at the mature or developing NMJ, such as vinculin (links integrins to the actin 
cytoskeleton) or filamin as well as α-actinin (function in F-actin bundling and interconnection) 
(Bloch and Hall, 1983, Cartaud et al., 2011). α-actinin has been shown to inhibit the rate of F-
actin depolymerization, thereby stabilizing F-actin (Cano et al., 1992). This observation is in 
line with findings for PLS3 which, when overexpressed in LB or HEK cells, increases the F-
actin to G-actin ratio (Oprea et al., 2008). Although mechanics of PLS3-mediated F-actin 
stabilization have not yet been sufficiently studied, the findings together indicate that F-actin 
filament stabilization through inhibition of depolymerization might be a feature common to 
actin bundling proteins. Assuming that PLS3 exerts a stabilizing effect on F-actin and on the 
background that F-actin formation is essential for AChR clustering and maintenance, muscle 
specific PLS3 might hence be positively involved in endplate maturation. To examine 
possible muscle specific contribution of PLS3, it would be interesting to compare AChR 
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cluster size between motor neuron specifically and ubiquitously PLS3V5 expressing mice.  
Any increase in endplate size in PLS3V5 ubiquitously expressing animals compared  to 
motor neuron specifically expressing mice would then indicate muscle specific effects.  
6.4.2 Delayed axonal pruning in PLS3V5 overexpressing mice 
Based on the fact that presynaptic PLS3V5 overexpression influences AChR cluster size 
(chapter 6.4.1), it was speculated whether improved nerve connectivity in PLS3V5 
expressing mice might account for the bigger endplates. It has previously been reported that 
smn-depleted zebrafish as well as cultured motor neurons derived from SMA mice exhibit 
severe axon outgrowth defects. Since no defects in initial axon outgrowth have ever been 
observed in mice in vivo, it is assumed that loss of nerve connectivity at the NMJ results 
rather from a dying-back mechanism (McWhorter et al., 2003, Rossoll et al., 2003, McGovern 
et al., 2008, Sleigh et al., 2011). Nevertheless, severe SMA mice have been shown to exhibit 
a significant reduction of axonal inputs per endplate during the axonal pruning process in 
proximal TVA muscle (Murray et al., 2008). In order to analyze the impact of PLS3V5 on 
axonal integrity, the process of axonal pruning was studied in time course experiment (Figure 
39). Including P1, P4 and P8 time points, it was demonstrated that SMA animals showed a 
reduced number of axonal inputs at all given time points compared to HET controls. 
However, in SMA + PLS3V5 animals, the mean number of axonal inputs was highly 
significantly increased compared to SMA controls and exceeded even that of HET animals. 
These findings suggested that PLS3V5 might exert a positive effect on the integrity of 
existing axons. At later time point P11, however, the number of axons per endplate adapted 
between PLS3V5 expressing and non-expressing animals and approached a nearly singular 
innervation pattern (preliminary data and thus not shown). Therefore, rather a retraction-
delaying than a “stabilizing” function of PLS3V5 on axons during the axonal pruning process 
must be assumed.  
Nevertheless, the observations raise the questions about the mechanism of PLS3V5-
mediated delay in axon retraction. The observation of delayed axonal pruning is highly 
reminiscent of the analogous finding from MEF cells, where PLS3V5 overexpression led to 
an increase in filopodial structures. Additionally, it was observed in MEF cells that PLS3V5 
specifically localizes to sites of actin filament consolidation in filopodia as well as 
lamellipodia. Since the localization pattern of PLS3V5 in motor neurons has not yet been 
resolved, it can only be speculated whether PLS3V5 is enriched in axonal filopodia and 
lamellipodia as well and exerts similar function there as well. It is known that actin dynamics 
play an essential role in regulating axon growth, branching ability as well as motility and 
guidance of the growth cone (Luo, 2002, Dent et al., 2003). Ultimately, the term actin 
dynamics comprises a variety of processes including actin polymerization and 
depolymerization, filament branching, bundling and interaction of actin polymers with other 
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components of the cytoskeleton, such as the microtubule network. Particularly, a balanced 
rate of F-actin polymerization and depolymerization is an important prerequisite for axon 
dynamics, including formation and withdrawal of growth cone filopodia. This has e.g. been 
demonstrated by experiments in which the effect of the drug jasplakinolide (jasp), a cell-
permeable macrocyclic peptide that inhibits F-actin turnover, was tested on retinal and dorsal 
root ganglion (DRG) neuron cultures (Gallo et al., 2002). When neurons were treated with 
jasp, growth cone motility, defined as lamellipodial and filopodial extension, stopped, the 
growth cones contracted and the axons began to retract. In their experiments, the authors 
observed that actin depolymerization was absent in the central zone (C domain) of the 
growth cone. Since polymerization of F-actin at the leading edge of the growth cone (P 
domain) requires G actin release by filament turnover in the C domain (Cramer, 1999), a lack 
of G actin supply might explain axon retraction after jasp treatment. In line with this 
observation, inhibiting actin polymerization using drugs like Cytochalasin or Latrunculin also 
interferes with normal axon growth. At high doses, Cytochalasin treatment has been shown 
to result in the disassembly of F-actin and subsequent defects in neurite outgrowth 
(Letourneau et al., 1987). Furthermore, axons in the developing grass hopper nervous 
system have been shown to lose all pathfinding capabilities upon treatment with 
Cytochalasin (Bentley and Toroian-Raymond, 1986). Interestingly, it was reported in another 
study that neurons form multiple axons upon Cytochalasin and Latrunculin treatment in 
moderate concentrations, suggesting that high actin turnover rates support axon outgrowth 
(Bradke and Dotti, 1999). Based on these findings it appears obvious that actin dynamics 
and turnover, rather than overall cytoskeletal rigidity, are essential for axon elongation and 
growth. As it was already mentioned earlier, α-actinin has been shown to inhibit the rate of F-
actin depolymerization, thereby indirectly stabilizing F-actin (Cano et al., 1992). Similarly, 
also PLS3 overexpression has been demonstrated to increase the F-actin to G-actin ration in 
lymphoblastoid (LB) and HEK cells (Oprea et al., 2008). Therefore, it might be possible that 
PLS3 prevents F-actin depolymerization and thus exerts a stabilizing effect on axons and 
growth cones, however, without shifting the equilibrium of actin poly- and depolymerization 
towards a critical end.  
In this context, it would be interesting to further investigate the substructural location of 
PLS3V5 in growth cones. In MEF cells, PLS3V5 is generally more abundant in filopodia and 
lamellipodia. Nevertheless, a rather weak staining was also detected throughout the entire 
cell body. In the axonal growth cone, F-actin is mainly present in filopodia and lamellipodia of 
the P domain, while C and transition (T) domains represent areas of G-actin regeneration. 
Given that PLS3 binds only filamentous actin and has no intrinsic actin polymerizing activity, 
a possible actin filament-stabilizing effect is therefore likely to be restricted to axonal filopodia 
and lamellipodia. Nevertheless, stabilizing effects of PLS3V5 on F-actin filaments migrating 
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into T and C domain, a normal process during axon dynamics, might consequentially reduce 
regeneration of G-actin in the C domain of the growth cone. Similar to the observations under 
jasp treatment, insufficient regeneration of G-actin would be expected to result in axon 
retraction and withdrawal. In the complainant's view, this raises the question how PLS3V5 
overexpression can result in exactly the opposite effect, namely a delay in axon withdrawal 
from the NMJ? In order to investigate the role of PLS3V5 in actin dynamics of the growth 
cone, high resolution confocal microscopy might be an adequate tool. In a vice versa 
experiment, it would also be interesting to precisely analyze the consequences of Pls3 
depletion for growth cone motility in mouse motor neurons.  
6.4.3 Innervation defects in Hung SMA mice and hyperinnervation of endplates in 
PLS3V5 expressing animals 
Besides delayed axonal pruning, hyperinnervated endplates were found at P4 in SMA + 
PLS3V5 and HET + PLS3V5 mice compared to SMA and HET mice (Figure 40, A). 
Furthermore, SMA + PLS3V5 animals displayed highly arborized nerve terminals at the same 
time point, while nerve terminals of age matched SMA littermates exhibited significantly 
reduced terminal sprouting when compared to HET controls (Figure 40, B). Most strikingly, 
the observed effects of PLS3V5 overexpression at NMJ level seem to be functional, since 
mice specifically overexpressing PLS3V5 in the motor neurons showed a highly significant 
increase in muscle fiber size. 
The finding of reduced endplate occupancy in Hung SMA mice is consistent with previous 
findings from other mouse models (Murray et al., 2008, Kong et al., 2009). In 2008, Kariya et 
al. have been the first to extensively investigate NMJ pathology in the SMNΔ7 SMA mouse 
model (Kariya et al., 2008). In their studies, they have been able to show that SMA mice 
display severe structural abnormalities at the NMJ level in Gastrocnemius muscle, including 
massive neurofilament accumulations and a failure of axons to form fine terminal arbors. 
However, Kariya et al. were unable to observe complete endplate denervation in the distal 
Gastrocnemius muscle of postnatal SMNΔ7 SMA mice. In humans, SMA usually affects the 
proximal muscles first. In line with this, others have detected the presence of 51 % 
unoccupied AChR clusters already at E18.5 and 49 % at P2 in the proximal intercostal 
muscles of the SMNΔ7 mouse (McGovern et al., 2008). Similarly, in late symptomatic SMA 
mice of the very severe Monani model (Smn-/-;SMN2(89Ahmb)tg/tg, survival ~ 5 d, (Monani et 
al., 2000)), ~15 % of endplates have been shown to be completely denervated in proximal 
TVA muscle (Murray et al., 2008). Interestingly, the authors have observed denervated 
endplates also in distal muscles of the lumbricals in Monani SMA animals, however, at 
significantly lower percentage. Therefore, as above findings suggest, NMJs display highly 
variable phenotypic severity among diverse muscles in one and the same SMA model, but 
also between different SMA mouse models. Despite a reduction in presynaptic coverage of 
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endplates, completely denervated endplates were more or less absent in proximal TVA 
muscle of Hung SMA mice in the present study (Figure 40). Surprisingly, however, it has 
been published before that in the distal Gastrocnemius muscle of Hung SMA mice around 9 
% of endplates showed a denervation phenotype (Riessland et al., 2010). Together, these 
observations are not in line with the findings from human, where proximal rather than distal 
muscles are severely affected by SMA. One possible explanation for these findings is that 
the Hung SMA mice analyzed here were on pure C57BL/6N background, while Riessland et 
al. have used Hung SMA mice on pure FVB background in their work. As was found in the 
present study, Hung SMA mice on C57BL/6N background show a five days prolonged mean 
life span (15.5 d) compared to Hung SMA mice on pure FVB background (9.9 d). As it was 
discussed before (chapter 6.2), the C57BL/6N background obviously exerts an ameliorative 
effect on disease severity, which might explain the observation of better nerve connectivity in 
proximal TVA (C57BL/6N) compared to distal Gastrocnemius muscle (FVB) in Hung SMA 
mice.  
As mentioned, P4 SMA and HET animals expressing PLS3V5 displayed increased 
endplate occupancy and extensive sprouting of nerve terminals compared to SMA and HET 
littermates, respectively (Figure 40). What implication do these observations have with 
regards to NMJ maturation and better neurotransmission? Since reduced nerve occupancy is 
a hallmark of SMA, stronger nerve coverage of endplates has frequently been taken as 
positive criteria to verify beneficial effects of various drugs, e.g. in studies investigating the 
therapeutic potential of the HDACi VPA, SAHA or TSA (Narver et al., 2008, Tsai et al., 2008, 
Riessland et al., 2010). In the present work, an increase in endplate occupancy and nerve 
terminal arborization was observed at P4, however, PLS3V5 expressing mice at earlier (P1) 
or later (P8, P11) time points showed similar effects at the NMJ. Therefore, observed effects 
at the NMJ might impact on both endplate maturation and signal transduction of established 
NMJs. It is well known that synaptogenic factors, such as Agrin and ACh, direct endplate 
maturation by refining areas of AChR clustering (Wu et al., 2010). While Agrin positively 
triggers the recruitment, assembly and maintenance of AChR at sites of innervation, ACh 
negatively impacts on AChR clustering, suppresses AChR expression and destabilizes 
AChR clusters globally in entire muscle fibers. During endplate maturation, the patch-like 
structure of AChR clusters gets perforated and clusters only remain at sites of presynaptic 
innervation. In the present work, motor neuron specific PLS3V5 expressing animals showed 
an increase in endplate size (Figure 45). Therefore, one possible explanation for the bigger 
endplates could be that the increased nerve occupancy and terminal arborization leads to a 
higher release of pro-AChR-clustering factors such as Agrin. 
In line with this idea, PLS3V5 overexpression and concomitant cytoskeletal 
rearrangements might have an influence on the location and the release of synaptic vesicles 
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and thus on neurotransmission. In two studies using the  SMNΔ7 mouse model, an abnormal 
synaptic vesicle number and location was accompanied with defects in neurotransmission as 
assessed by detailed electrophysiological analyzes (Kariya et al., 2008, Kong et al., 2009). 
Two pools of vesicles exist in motoric presynapses: Readily releasable vesicles (RRVs), 
which are in proximity to or already docked with the presynaptic membrane and vesicles of 
the reserve pool (RPV), which are located farther from the membrane (Dillon and Goda, 
2005). Kong et al. have observed a 36 % reduction of RRVs in TVA muscle of the SMNΔ7 
mouse (Kong et al., 2009). Moreover, the transmitter per single vesicle (quantal content, QC) 
QA) was unchanged between SMA and control mice, while a significantly reduced number of 
synaptic vesicles was released after nerve stimulation in SMA mice (quantal amplitude, QA). 
Therefore, the authors assumed that reduced density of synaptic vesicles may contribute to 
declined QC at SMA NMJs. As mentioned, not only the number of vesicles was found to be 
reduced, but also overall location of vesicles in the presynapse was disturbed. Therefore, the 
authors further speculated whether the commonly observed neurofilament (NF) 
accumulations are indicative for a more generally disturbed neuronal cytoskeleton. A 
disruption of cytoskeletal structures, in turn, might then result in displacement of vesicles, 
and consequentially in impaired neurotransmission. Interestingly, the idea of cytoskeletal 
disorganization as a pathological feature of SMA also matches the observation of 
significantly impaired β-actin mRNA transport into growth cones of SMA motor neurons 
(Rossoll et al., 2002). Additionally, also many other findings highlight the importance of a 
functional actin cytoskeleton for presynaptic function: E.g., it is well accepted that F-actin 
plays important roles in both recycling and transport of synaptic vesicles (Shupliakov et al., 
2002, Bloom et al., 2003). Furthermore, after a current model synaptic vesicles are tethered 
near the membrane by F-actin via phosphorylation-dependent interaction with the vesicular 
molecule synapsin (Dillon and Goda, 2005). Upon depolymerization, Synapsin undergoes a 
conformational change, thereby freeing synaptic vesicles for release (Li et al., 2010). Last not 
least, F-actin regulates the availability of RPV by surrounding the vesicle cluster, thus 
providing a corralling function by forming a physical barrier to impede vesicle dispersion 
(Dillon and Goda, 2005). Taken together, these observations underline the importance of F-
actin in synaptic vesicle organization and release. Therefore, by influencing F-actin dynamics 
PLS3V5 might act as a regulator of synaptic release, compensating for presynaptic 
dysfunction in SMA nerve terminals.  
6.5 Why does PLS3V5 overexpression not ameliorate the survival of SMA 
mice? SMN and PLS3V5 protein amounts as limiting factors  
In 6 discordant families PLS3 has been demonstrated to act as a fully protective modifier 
of SMA in SMN1-deleted unaffected siblings (Oprea et al., 2008). In the present study, the 
goal was to investigate a possible rescuing effect of PLS3 overexpression on the murine 
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SMA phenotype. To analyze the effect of ubiquitous PLS3V5 overexpression on the SMA 
phenotype, PLS3V5 was heterozygously overexpressed in the severe Hung SMA 
background (chapter 5.4 and following). However, differently from the situation in SMA 
patients, where high PLS3 levels had previously been reported to result in a full rescue of 
SMA symptoms, PLS3V5 overexpression did not affect survival in the murine system: While 
SMA mice showed a mean survival of 15.5 d, SMA + PLS3V5 animals lived for 14.6 d (p = 
0.529). Interestingly, despite the absence of any positive effects of PLS3V5 overexpression 
on survival of SMA mice, the observed pre- as well as postsynaptic morphological changes 
in PLS3V5 overexpressing animals seem to be functional. This assumption is based on the 
fact that motor neuron specific activation of the transgene on wt background led to an 
increase in muscle fiber size at the late time point P21. However, at P10 time point, PLS3V5 
overexpression had no significant effect on muscle fiber size, suggesting that PLS3V5 effects 
on muscle fiber size get obvious only at later time points. 
In recent times, it became more and more clear that the severe form of SMA is not simply a 
motor neuron disease, but that also other neuronal (e.g. proprioceptive neurons, 
hippocampus) and non 
neuronal tissues (e.g. heart, 
bone, blood vessels, liver) 
are affected (Finsterer and 
Stollberger, 1999, Kelly et 
al., 1999, Hsieh-Li et al., 
2000, Felderhoff-Mueser et 
al., 2002, Arai et al., 2005, 
Hachiya et al., 2005, Bach, 
2007, Shanmugarajan et 
al., 2007, Khatri et al., 2008, 
Rudnik-Schoneborn et al., 
2008, Araujo Ade et al., 
2009, Meyer et al., 2009, 
Shanmugarajan et al., 2009, 
Bevan et al., 2010, Gogliotti et 
al., 2010, Heier et al., 2010, Hua et al., 2010, Michaud et al., 2010, Riessland et al., 2010, 
Shababi et al., 2010). The observation of pathological features in cell types other than motor 
neurons has led to the development of the so called threshold theory. This hypothesis 
proposes that there is a differential susceptibility of cells to SMN depletion: While motor 
neurons are affected at already relatively weakly reduced SMN levels, other cells and tissues 
such as the heart, bone and finally all tissue types get affected as SMN levels further 
Figure 46: Differential susceptibility of cell and tissue 
types to SMN reduction (Sleigh et al., 2011)  
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decrease or are even completely absent (Sleigh et al., 2011). Consequentially, in the severe 
Hung SMA model any positive effects of PLS3V5 on survival through improved axonal 
connectivity, NMJ maturation and muscle fiber size might be limited by defects in other 
tissues, which finally result in early death of SMA mice. In other words: An amelioration of the 
survival phenotype by PLS3V5 overexpression might require relatively high SMN levels.  
Importantly, there are two observations strongly supporting this idea. The first hint comes 
from discordant families themselves: It has been found here, that all SMN1-deleted 
unaffected siblings of the 6 discordant families harbored 3 or 4 SMN2 copies, accordingly 
leading to type III SMA in their affected siblings.  
Further support for this idea comes from a study investigating the effects of the Rho-
kinase (ROCK) inhibitor Fasudil on the murine SMA phenotype. Rho/ROCK signaling is a 
major regulatory pathway of actin dynamics and has been demonstrated to be upregulated in 
Smn-depleted PC12 cells and SMA mice (Bowerman et al., 2007, Bowerman et al., 2010). 
Accordingly, Rho/ROCK activation has been implicated in dendritic simplification, reduced 
spine length and density (Nakayama et al., 2000, Govek et al., 2004). In their studies, 
Bowerman et al. have shown that treatment of severe SMNΔ7 SMA mice with Fasudil results 
in increased AChR cluster and TA myofiber size. Most interestingly and very similar to our 
results, despite the positive effect of Fasudil treatment on endplate and muscle fiber size no 
improvements of survival could be detected in severe SMNΔ7 animals. In further 
experiments, the authors treated the intermediate Smn2B/- mouse SMA model (Bowerman et 
al., 2009) with Fasudil and subsequently investigated the effects on survival. Most strikingly, 
Fasudil treatment of Smn2B/- mice led to a significant increase in survival. These findings 
suggest that the improvements at NMJ and muscle level upon Fasudil treatment have an 
ameliorative effect solely in the presence of higher Smn threshold levels.  
Similar to the results obtained upon Fasudil treatment, it might be possible that high PLS3 
levels only improve the SMA survival phenotype in the presence of relatively higher Smn 
levels, too. Since Smn2B/- mice represent an intermediate SMA model with a mean survival of 
~4 weeks (Bowerman et al., 2009), these animals might be appropriate to study possible 
effects of PLS3V5 overexpression on survival as well. However, Smn2B/- mice are currently 
maintained on C57BL/6×CD1 mixed background resulting in a broad distribution in survival 
time of individuals from the same litter. Therefore, to analyze the impact of PLS3V5 
overexpression on the SMA survival phenotype, backcrossing Smn2B/- mice to a clean 
C57BL/6N background would be required first. Additionally, considering that the genetic 
background has a major impact on survival of SMA mice (chapter 6.2), purification of Smn2B/- 
mice to clean C57BL/6N background might result in a significant alteration of mean survival 
in these animals. Finally, it must be considered that Smn2B/- mice are not available at the 
Institute of Genetics, Cologne, and would need to be imported via embryo transfer first, 
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which is time and cost intensive. Another possibility to study the consequences of PLS3 
expression in a milder SMA model would be to cross PLS3V5 onto the homozygous Hung 
Smn-/-;hSMN2tg/tg background. Smn-/-;hSMN2tg/tg mice carry a total of 4 hSMN2 copies (2 per 
integrate) and show only very mild SMA symptoms, e.g. necrosis of ears and tail with 
subcutaneous edema. Moreover, Smn-/-;hSMN2tg/tg mice display normal fertility slightly 
reduced life span of ~1.5 years. Nonetheless, an exact description of the pathological 
features of this model has not been performed yet and therefore bears further analyses (e.g. 
motor neuron count, NMJ pathology, degeneration of muscle). Additionally, due to the 
extremely weakened phenotype of Smn-/-;hSMN2tg/tg mice, subtle improvements upon 
PLS3V5 expression might be hard to detect. To investigate the effect of PLS3V5 
overexpression on a milder SMA background, it would also be possible to make use of the 
fact that a mixed genetic background has an ameliorative effect on survival of Hung SMA 
mice. As it has been demonstrated in the present work, SMA animals of 87 % C57BL/6N / 23 
% FVB mixed background have a prolonged life span of 19.2 d as compared to 15.5 d and 
9.9 d in pure C57BL/6N or FVB background animals, respectively. In this context, Smn-/-
;SMN2tg/tg animals on pure FVB background could be mated with Smn+/-;PLS3V5tg/wt mice on 
pure C57BL/6N background, according to the breeding scheme presented in Figure 28. As 
the resulting offspring represents genetically mixed animals of 50 % C57BL/6N and 50 % 
FVB background, an accompanying increase in life span is expected. Furthermore, Hung 
SMA mice expressing PLS3V5 on pure or mixed background could additionally be treated 
with histone deacetylase inhibitors (HDACi) to increase SMN levels. Due to their ability to 
increase SMN2 expression and in combination with the fact that ~10 % of full length SMN 
protein are being produced by SMN2, a collection of HDACi has been proven to effectively 
counteract SMA pathology in the mouse model, e.g. Sodium butyrate (NaBu), Valproic acid 
(VPA), Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) (Chang et al., 
2001, Avila et al., 2007, Narver et al., 2008, Tsai et al., 2008, Riessland et al., 2010). An 
increase of SMN in Hung SMA mice might also be accomplished by antisense 
oligonucleotides (ASOs) treatment. Via binding to SMN2 pre-mRNA, ASOs have been shown 
to redirect the incorrect splicing of SMN2, resulting in the production of predominantly 
functional SMN (Passini et al., 2011). Moreover, Passini et al. have shown that early 
postnatal delivery of ASOs into the lateral ventricle led to improvements in muscle 
physiology, motor function and survival of SMNΔ7 SMA mice. Therefore, by titrating the 
injected ASO amount in early Hung SMA mice it might be possible to generate an 
intermediate mouse model appropriate for studying PLS3V5 modifying effects in the 
presence of relatively high SMN levels. Both, treatment with HDACi or ASO injection to 
increase SMN levels, however, require high methodological reliability and expertise. 
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It needs to be mentioned that also only moderate PLS3V5 expression levels in transgenic 
animals might explain the absence of ameliorative effects on survival in severe Hung SMA 
animals. It was demonstrated  that PLS3V5 is overexpressed in all tissues affected by SMA 
of transgenic animals, namely brain, spinal cord and muscle (chapter 5.4.1.2). However, 
despite significant, total plastin 3 (endogenous Pls3 + PLS3V5) mRNA levels were only 
moderately increased in PLS3V5 transgenic compared to wt mice with 3.6 fold in brain, 3.4 
fold in spinal cord and 21.5 fold in muscle tissue (chapter 5.4.1.1). Since it was assumed that 
PLS3V5 mRNA is not likewise converted into PLS3V5 protein (previously discussed in 
chapter 6.1), an even lower increase of total plastin 3 in PLS3V5 transgenic mice must be 
expected on protein level. In Epstein Barr virus (EBV) transfected lymphoblastoid (LB) cell 
lines of unaffected siblings from discordant families, PLS3 was shown to be ~40 fold 
upregulated on mRNA level (Oprea et al., 2008). This observation, however, does not reflect 
the situation in the actual target tissue of SMA, namely motor neurons. Since only LB as well 
as fibroblast cell lines of discordant families are available, it is unknown to what extend PLS3 
is upregulated in spinal cord or even motor neurons of unaffected SMN1-deleted  individuals. 
This information, however, might provide important information on the quantitative 
requirement of PLS3 to exert rescuing effects on the survival of SMA patients. As spinal cord 
tissue of unaffected siblings is not available, redifferentiation of fibroblast cells into induced 
pluripotent stem (IPS) cells and subsequent differentiation into motor neurons would be a 
way to address this question. The effort to obtain such cultures is currently being undertaken 
in our laboratory and in cooperation with iPierian (CA, US). While fibroblasts have already 
been successfully redifferentiated into IPS cells, the next steps will include differentiation into 
motor neurons and subsequent confirmation via marker analysis and gene expression 
profiling. Furthermore, motor neuron specific PLS3V5-expressing mice (PLS3V5fl_st/fl;Hb9-
Cretg/wt) might help to investigate the PLS3 amount required for SMA protection. Notice that 
GFP is cloned downstream of PLS3V5 in the targeting construct and is co-activated via an 
internal ribosomal entry site together with PLS3V5 (Figure 8). This might enable to 
specifically isolate motor neurons from PLS3V5fl_st/fl;Hb9-Cretg/wt mice, e.g. via FACS, and to 
compare total plastin 3 expression levels with those from respective controls (e.g. motor 
neuron specifc GFP expressing mice, available at Jacksons laboratories).  
6.6 Does PLS3V5 act together with or independent of Smn? 
It has previously been shown via co-immunoprecipitation (Co-IP) that PLS3 and SMN are 
both present together with Actin in a 500 kDa complex (Oprea et al., 2008). These findings 
were further supported by the fact that Pls3 colocalizes with Smn in growth cones of 
differentiated PC12 cells. Moreover, it has been previously assumed that Smn exerts 
stabilizing function on Pls3. This idea comes from experiments in the Smn2b/- and SMNΔ7 
mouse models, where a low level of Smn was found to be associated with reduced Pls3 
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protein amounts ((Bowerman et al., 2009) and Dr. Christine Beattie, oral presentation at the 
15th FSMA meeting, Orlando, USA). Beattie et al. further showed that also in zebrafish smn 
depletion is correlated with a reduction in pls3 amount. In turn, however, restoration of pls3 
did not result in simultaneous increase in smn protein. Therefore, Beattie et al. suppose that 
smn might positively act on translation of pls3 mRNA.  
In the present study, a possible interaction between Smn and Pls3/PLS3V5 was 
investigated in Hung SMA and PLS3V5 transgenic mice. In a scenario where Smn and Pls3 
interact and based on the above mentioned findings by other groups, Smn and Pls3/PLS3V5 
might exert stabilizing function on each other. In contrast to the results obtained in Smn2b/- 
and SMNΔ7 mice, however, endogenous Pls3 was not downregulated in Hung SMA animals. 
In the vice versa experiment, also Smn levels were not increased in PLS3V5 transgenic mice 
compared to wt (Figure 41). These results suggested, that at least in Hung SMA mice Smn 
and Pls3 do not exert a stabilizing effect on each other. Further support for an Smn-
independent working mechanism of PLS3 comes from the time course experiment, which 
was in this thesis performed to investigate the process of axonal pruning in PLS3V5 
expressing SMA mice (Figure 39). Here, it was found that SMA animals expressing PLS3V5 
display an increased number of axons compared to SMA mice at P1, P4 and P8. Also in HET 
+ PLS3V5 animals, the number of axons was significantly increased compared to HET 
animals at all time points. Importantly, however, the number of incoming axons was almost 
identical between SMA + PLS3V5 and HET + PLS3V5 mice over the whole time course. 
More or less the same was observed regarding nerve occupancy at the endplates. Also in 
this experiment, no difference regarding occupancy status was detected between SMA and 
HET mice expressing PLS3V5. Together, these findings indicate that at least in Hung SMA 
mice Smn and Pls3/PLS3V5 do not act stabilizing on each other. Furthermore, the results 
suggest that the axon retraction-delaying effect of PLS3V5 is likely independent of Smn. 
One explanation for these opposing findings could be that Dr. Bowerman and Dr. Beattie 
used different mouse models (Smn2B/- and SMNΔ7) than was used in this study (Hung SMA). 
Additionally, at least in the case of Smn2B/- mice, animals were kept on C57BL/6×CD1 hybrid 
background, giving rise to the assumption that background depending factors might influence 
the stability of Pls3 in an Smn dependent manner. Similarly, species-specific differences 
might account for the observation of smn/pls3 protein level correlation made by Beattie et al. 
in the zebrafish system.  
6.7 Future prospects and next steps 
In order to investigate the mechanisms underlying PLS3 protection in SMN1-deleted 
unaffected siblings, transgenic PLS3V5 expressing mice were generated in this study. It 
could be shown that PLS3V5 exerts wt function by localizing the transgene in MEF cells of 
transgenic mice. Furthermore, it was demonstrated that PLS3V5 overexpression supports 
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the formation of lamellipodial/filopodial structures in MEF cells and results in increased 
occupancy of endplates and highly arborized nerve terminals at the NMJ in vivo. Moreover, 
by investigating the process of axonal pruning, it was revealed that PLSV5 overexpression is 
able to delay axon withdrawal from NMJs, indicating an important role for PLS3 in the 
maintenance of axonal integrity. Most strikingly, the observed changes at NMJ level seem to 
be functional, as motor neuron specific overexpression of PLS3V5 resulted in a highly 
significant increase in AChR cluster and muscle fiber size. 
Despite first insight into PLS3 working mechanisms, several questions remain open or 
require further investigations. In the following, the next steps to address these questions will 
be outlined briefly: 
I. PLS3V5 overexpression did neither ameliorate survival nor motoric ability of the 
severe Hung SMA mouse model. As previously discussed in chapter 6.5, it might 
be possible that PLS3V5 effects can not compensate the severe and lethal global 
defects of the here used SMA model. Of the different options to investigate 
PLS3V5 effects in a milder SMA background depicted (chapter 6.5), PLS3V5 
overexpression in Hung SMA mice on mixed background is the most time and cost 
effective method and is therefore currently being performed.  
II. Since PLS3V5 was only heterozygously overexpressed in the SMA background, 
also PLS3V5 expression levels might not be sufficiently high to ameliorate the 
survival phenotype. In order to increase PLS3V5 levels, breedings are currently 
ongoing with the goal to homozygously overexpress PLS3V5.  
III. Upon PLS3V5 overexpression, improved axonal connectivity was observed in 
PLS3V5 expressing mice. Additionally, muscle fiber size was significantly 
increased in motor neuron specific PLS3V5-expressing mice. In this context, it is 
important to mention that the observed increase in endplate size in 
PLS3V5fl_st/wt;Hb9-Cretg/wt mice was measured in Gastrocnemius muscle, however, 
muscle fiber size increase was assessed in Vastus lateralis muscle. Since distinct 
muscles are differently affected in SMA mice, a potential muscle fiber size 
increase has to be reassessed in Gastrocnemius muscle of PLS3V5fl_st/wt;Hb9-
Cretg/wt animals. Furthermore, to confirm functionality of the observed 
morphological changes at NMJ level, more precise analyzes, e.g. quantal content 
measurements or Motor Unit Number Estimate (MUNE) are required and will be 
performed in the future. 
IV. Until now, no information is available on the PLS3 amount required for SMA 
protection in motor neurons of unaffected discordant siblings. Therefore, 
approaches to redifferentiate human embryonic fibroblasts into iPS cells and 
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subsequently differentiate these into motor neurons are currently being performed 
in our laboratory and in cooperation with iPierian (CA, US).  
V. Pls3 has been described to be enriched in growth cones of PC12 cells and primary 
motor neurons (Oprea et al., 2008). However, no detailed analysis has been 
performed on the exact subcellular localization of Pls3 within growth cones. In 
order to understand the impact of PLS3 action on neurocytoskeletal organization in 
growth cones, high resolution confocal in combination with electron microscopy will 
be performed.  
VI. Based on the findings of the present study, PLS3V5 might exert an SMN 
independent neuroprotective function. Therefore, it would be interesting to test the 
effects of PLS3V5 overexpression on other motor neuron diseases, e.g. 
amyotrophic lateral sclerosis (ALS). In most familial ALS forms (~20%), mutations 
in the superoxide dismutase 1 (SOD1) gene account for disease development 
(Ticozzi et al., 2011). Since mutated Sod1 resembles the ALS phenotype in mouse 
(Gurney et al., 1994), PLS3V5 transgenic mice might be crossed on a Sod1 
mutant background. 
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7 Summary 
Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by the loss 
of α-motor neurons in the ventral horn of the spinal cord. Depending on the severity, the 
clinical spectrum of SMA ranges from early infant death to normal adult life with only mild 
muscle weakness. To date, no cure is available. SMA is caused by the homozygous loss of 
the survival motor neuron gene 1 (SMN1). Besides SMN1, another nearly identical copy of 
the gene is present in the human genome, thus called SMN2. In the SMN2 gene, a C to T 
transition in exon 7 leads to the disruption of an exonic splicing enhancer, resulting in 
alternative splicing of SMN2 pre-mRNA and skipping of exon 7 in 90 % of total transcript. 
However, about 10 % of full length (FL) transcripts are still being produced by SMN2. 
Through gene duplication events, SMN2 is present in varying copy numbers in the human 
population, ranging from the total absence to a maximum of 4 SMN2 copies per allele. Since 
every copy produces about 10 % FL transcript, SMA severity is inversely correlated with 
SMN2 copy number. 
For a long time, SMN2 was the only known modifying gene and has therefore been target 
for the development of therapeutic strategies. The observation of SMN1-deleted patients with 
either extremely weakened or even absent symptoms in the presence of only a small number 
of SMN2 copies has in the past been associated with the existence of SMA-modifying genes. 
Finally, in 2008 the Actin-bundling protein Plastin 3 (PLS3) has been identified as a 
protective modifying gene showing high expression in asymptomatic homozygously SMN1-
deleted siblings of discordant SMA families in our group (Oprea et al., 2008). Cell culture as 
well as in vivo experiments in a zebrafish SMA model revealed that PLS3 overexpression 
rescues the axonal outgrowth phenotype. 
The goal of the present study was to address the question whether PLS3 overexpression 
is able to rescue the phenotype in an existing SMA mouse model. Furthermore, it was asked 
which effect PLS3 overexpression has on the development of neuromuscular junctions 
(NMJ) as well as muscle development and function. 
Using the Cre/loxP system, transgenic mice were generated expressing a V5-tagged 
version of human PLS3 (PLS3V5) either ubiquitously or motor neuron specifically (Hb9 
promoter). In a next step, PLS3V5 transgenic mice were crossed onto the SMA background 
using the Hung mouse model. All mice were crossed congenic onto clean C57BL/6N 
background to exclude any background modifying effects. Transgenic PLS3V5 mice on 
wildtype (wt) as well as on SMA background were histologically (Motor neurons, NMJs, 
muscle) and functionally (Motoric tests, weight, survival) analyzed in detail. 
Ubiquitous as well as motor neuron specific PLS3V5 expression was proven by qRT-PCR, 
Western blot analysis and immunohistochemistry. PLS3V5 transgenic mice on wt as well as 
on SMA background showed remarkable influence of PLS3 overexpression on motor neuron 
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and NMJ phenotype: The motor neuron and Acetylcholine receptor (AChR) cluster size was 
highly increased as compared to wt or SMA littermates. Time course measurements of 
presynaptic sprouting during the process of axonal pruning revealed highly improved axonal 
connectivity. These findings raised the question whether the increase of AChR cluster size in 
transgenic animals is an effect of pre- or postsynaptic PLS3V5 overexpression. To address 
this issue, motor neuron specific PLS3V5 overexpression was analyzed in wt mice. 
Strikingly, motor neuron specific overexpression of PLS3V5 was sufficient to increase AChR 
cluster and muscle fiber size, further strengthening the positive impact of neuronal PLS3V5 
expression on neurotransmission. Moreover, electrophysiological analyzes (NMJ quantal 
content measurements, Motor Unit Number Estimate (MUNE)) will be performed in the future 
and correlated with the recent findings.  
Despite this positive impact on axon biology, PLS3 overexpression neither increased 
survival nor improved motoric ability in the severe type I-like SMA mouse model used in this 
study. Therefore, it was hypothesized that a certain amount of SMN is required – similar to 
asymptomatic humans, who own at least 3 SMN2 copies – to rescue the SMA phenotype. To 
test this hypothesis, the PLS3V5 transgene is currently crossed onto a milder SMA 
background. Additionally, PLS3V5 was up to now only heterozygously overexpressed in 
SMA mice. Since also higher PLS3V5 levels might be necessary to finally improve SMA 
symptoms, PLS3V5 will be homozygously expressed in the SMA background in the future.  
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8 Zusammenfassung 
Die spinale Muskelatrophie (SMA) ist eine neurodegenerative Erkrankung und 
kennzeichnet sich durch den Verlust der α-Motoneurone in den ventralen Hörnern des 
Rückenmarks aus. Abhängig vom Schweregrad der SMA, für die es derzeit noch keine 
Heilmethode gibt, reicht das klinische Erscheinungsbild vom frühkindlichen Tod bis zu einer 
normalen Lebenserwartung in Begleitung einer milden Form der Muskelschwäche.  SMA 
wird durch den homozygoten Verlust des survival motor neuron Gens 1 (SMN1) verursacht. 
Neben SMN1 existiert beim Menschen noch ein weiteres, sehr ähnliches Gen: SMN2. Das 
SMN2 Gen besitzt eine C zu T Nukleotidtransition in Exon 7. Durch die Transition wird ein 
exonischer Spleißverstärker (engl. exonic splicing enhancer  (ESE)) in seiner Sequenz 
verändert, was zu alternativem Spleißen der SMN2 prä-mRNA und Verlust von Exon 7 in 90 
% der Gesamttranskriptmenge führt. Dennoch produziert auch SMN2 noch rund 10 % 
Vollängetranskripte. Durch Genkonversion bedingt, kommt SMN2 in der menschlichen 
Population in unterschiedlicher Kopienzahl vor, wobei die Anzahl zwischen null und maximal 
vier Kopien pro Allel schwanken kann. Da von SMN2 noch rund 10 % Volllängetranskripte 
gebildet werden, korreliert der Schweregrad der Erkrankung invers mit der Anzahl 
vorhandener SMN2 Kopien. 
Eine lange Zeit war SMN2 das einzige bekannte SMA-modifizierende Gen und daher Ziel 
zahlreicher Therapieansätze. Interessanterweise jedoch wurden in der Vergangenheit immer 
wieder SMN1-deletierte Patienten beschrieben, die trotz geringer SMN2 Kopienzahl eine nur 
sehr schwache bis gar nicht ausgeprägte Symptomatik zeigen. Diese Beobachtungen 
wurden auf das Vorhandensein anderer modifizierender Faktoren in nichtbetroffenen 
Patienten solcher sogenannten diskordanten Familien zurückgeführt. Im Jahr 2008 wurde in 
unserer Arbeitsgruppe schließlich das Aktinfilament bündelnde Protein Plastin 3 (PLS3) als 
stark hochreguliert und vor SMA schützend in asymptomatischen SMN1 homozygot 
deletierten Geschwistern diskordanter Familien identifiziert (Oprea et al., 2008). An 
neuronalen Zellkulturen und in einem Zabrafisch-SMA Modell wurde gezeigt, dass PLS3-
Überexpression Defekte im axonalen Auswachsen kompensieren kann.  
Im Sinne eines klassischen Rettungsexperiments war das Ziel der hier vorgelegten Arbeit 
die Untersuchung der Frage, ob die PLS3-Überexpression zu deutlicher Verbesserung der 
SMA-Symptomatik in einem bestehenden SMA-Mausmodell (Hung SMA Mäuse) führt. 
Weiterhin wurde untersucht, welchen Einfluss die PLS3-Überexpression auf die Entwicklung 
der neuromuskulären Endplatte (NME) sowie der Muskulatur und deren Funktion hat. 
Zur Beantwortung dieser Fragen wurden Im Rahmen dieser Arbeit unter Zuhilfenahme 
des Cre/loxP Systems transgene Mäuse hergestellt, die eine V5-markierte Version des 
humanen PLS3 entweder Motoneuronen-spezifisch (Hb9 Promotor), oder ubiquitär 
exprimieren. Im nächsten Schritt wurde das PLS3V5-Transgen dann auf den SMA-
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Hintergrund des Hung  Mausmodells gekreuzt. Um modifizierende Einflüsse des genetischen 
Hintergrunds auszuschließen, wurden alle Mäuse durch Rückkreuzung über mindestens 7 
Generationen auf einen reinen C57BL/6N-Hintergrund gebracht. Transgene PLS3V5-Mäuse 
auf wt und SMA Hintergrund wurden dann histologisch (Motoneuronen, NME, Muskel) und 
funktional (Motorische Tests, Gewichtsmessung, Überlebensdauer) detailliert analysiert. 
Zunächst wurde die Motoneuronen-spezifische sowie ubiquitäre PLS3V5-Expression 
mittels quantitativer reverser Trankskription (qRT) PCR, Western blot Analyse sowie 
Immunohistochemie bestätigt. Bei der anschließenden Untersuchung PLS3V5 transgener 
Mäuse auf wt und SMA Hintergrund wurde ein signifikanter Einfluss der PLS3 
Überexpression auf den Motoneuronen und NME Phänotyp festgestellt: Im Vergleich zu wt 
oder SMA Kontrolltieren waren Motoneurone und Acetylcholinrezeptoren (AChR) Cluster 
stark vergrößert. Die Untersuchung präsynaptischer Verästelungen zu unterschiedlichen 
Zeitpunkten während der axonalen Spezifizierung ergab eine stark verbesserte axonale 
Verknüpfung in PLS3V5 exprimierenden Tieren. Diese Ergebnisse ließen die Frage 
aufkommen, ob die beobachtete Vergrößerung der AChR Cluster auf prä- oder 
postsynaptische Effekte der PLS3V5 Expression zurückzuführen sei. Um diese Frage zu 
beantworten, wurde PLS3V5 im folgenden motoneuronenspezifisch im wt Hintergrund 
überexprimiert und die AChR Cluster Größe bestimmt. Dabei konnte festgestellt werden, 
dass die motoneuronenspezifische Überexpression von PLS3V5 ausreichend für die 
Vergrößerung der AChR Cluster ist. Darüber hinaus konnte in solchen Tieren sogar eine 
signifikante Zunahme des Muskelfibrillen-Durchmessers festgestellt werden. Diese 
Beobachtungen scheinen einen positiven Effekt der PLS3V5-Überexpression auf die 
neuronale Weiterleitung zu bestätigen. Dennoch müssen weitere elektrophysiologische 
Untersuchungen (z.B. Bestimmung des „quantal content“, Motor Unit Number Estimate 
(MUNE)) durchgeführt werden, um ein detaillierteres Bild der Auswirkungen einer PLS3V5-
Überexpression auf die Reizweiterleitung zu gewinnen.  
Trotz der genannten positiven Effekte auf die axonale Entwicklung konnte in PLS3V5 
exprimierenden SMA Tieren weder eine verlängerte Lebenszeit, noch eine verbesserte 
Motorik beobachtet werden. Darum wurde die Hypothese aufgestellt, dass PLS3V5 
möglicherweise nur in Gegenwart einer gewissen SMN Menge den SMA-Phänotyp 
verbessern oder retten kann, ähnlich der Situation in asymptomatischen Menschen, die 
immer mindestens 3 SMN2 Kopien trugen. Um diese Hypothese zu überprüfen, wird das 
PLS3V5-Transgen derzeit bereits auf einen milderen SMA-Hintergrund gebracht. Außer 
einer nicht ausreichenden SMN Menge könnte auch eine zu niedrige PLS3V5-Konzentration 
für das Ausbleiben von krankheitsverbessernden Effekten sein. Da in allen bisherigen 
Versuchen PLS3V5 lediglich heterozygot überexprimiert wurde, werden aktuell 
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Verpaarungen zur homozygoten Überexpression von PLS3V5 auf dem SMA Hintergrund 
durchgeführt. 
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11 Appendix 
Rosa26 targeting vector with PLS3V5 integrate 
 
SHORT HOMOLOGY ARM ccgcggcaggccctccgagcgtggtggagccgttctgtgagacagccgggtacgagt
cgtgacgctggaaggggcaagcgggtggtgggcaggaatgcggtccgccctgcagcaaccggagggggagggagaaggg
agcggaaaagtctccaccggacgcggccatggctcgggggggggggggcagcggaggacgcttccggccgacgtctcgtcg
ctgattggcttttttcctcccgccgtgtgtgaaaacacaaatggcgtgttttggttggcgtaaggcgcctgtcagttaacggcagccgg
agtgcgcagccgccggcagcctcgctctgcccactgggtggggcgggaggtaggtggggtgaggcgagctgacgtgcgggc
gcggtcggcctctggcggggcgggggaggggagggagggtcagcgaaagtagctcgcgcgcgagcggccgcccaccctcc
ccttcctctgggggagtcgttttacccgccgccggccgggcctcgtcgtctgattggctctcggggcccagaaaactggcccttgcc
attggctcgtgttcgtgcaagttgagtccatccgccggccagcgggggcggcgaggaggcgctcccaggttccggccctcccctc
ggccccgcgccgcagagtctggccgcgcgcccctgcgcaacgtggcaggaagcgcgcgctgggggcggggacgggcagt
agggctgagcggctgcggggcgggtgcaagcacgtttccgacttgagttgcctcaagaggggcgtgctgagccagacctccat
cgcgcactccggggagtggagggaaggagcgagggctcagttgggctgttttggaggcaggaagcacttgctctcccaaagtc
gctctgagttgttatcagtaagggagctgcagtggagtaggcggggagaaggccgcacccttctccggaggggggaggggagt
gttgcaatacctttctgggagttctctgctgcctcctggcttctgaggaccgccctgggcctgggagaatcccttgccccctcttcccct
cgtgatctgcaactccagtctttCTAGCATCTGTAGGGCGCAGTAGTCCAGGGTTTCCTTGATGATG
TCATACTTATCCTGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTGGTTAATT
AAAGTTATAATCGCTGAGGTAATATTTAAAATCATTTTCAAATGATTCACAGTTAATTTGC
GACAATATAATTTTATTTTCACATAAACTAGACGCCTTGTCGTCTTCTTCTTCGTATTCCT
TCTCTTTTTCATTTTTCTCTTCATAAAAATTAACATAGTTATTATCGTATCCATATATGTATC
TATCGTATAGAGTAAATTTTTTGTTGTCATAAATATATATGTCTTTTTTAATGGGGTGTATA
GTACCGCTGCGCATAGTTTTTCTGTAATTTACAACAGTGCTATTTTCTGGTAGTTCTTCG
GAGTGTGTTGCTTTAATTATTAAATTTATATAATCAATGAATTTGGGATCGTCGGTTTTGT
ACAATATGTTGCCGGCATAGTACGCAGCTTCTTCTAGTTCAATTACACCATTTTTTAGCA
GCACCGGATTAACATAACTTTCCAAAATGTTGTACGAACCGTTAAACAAAAACAGTTCAC
CTCCCTTTTCTATACTATTGTCTGCGAGCAGTTGTTTGTTGTTAAAAATAACAGCCATTGT
AATGAGACGCACAAACTAATATCACAAACTGGAAATGTCTATCAATATATAGTTGCTCTA
GTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCG
TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT
GACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGC
CAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCA
GTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTAT
TACCATGCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCC
TCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGG
GGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCG
GGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTT
CCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGG
GCGGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCG
CCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGG
CCCTTCTCCTTCGGGCTGTAATTAGCGCTTGGTTTAATGACGGCTTGTTTCTTTTCTGTG
GCTGCGTGAAAGCCTTGAGGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGAGCGGCTC
GGGGCTGTCCGCGGGGGGACGGCTGCCTTCGGGGGGGACGGGGCAGGGCGGGGTT
CGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCGCTAGCATCTGTAGGGCGCAGT
AGTCCAGGGTTTCCTTGATGATGTCATACTTATCCTGTCCCTTTTTTTTCCACAGCTCGC
GGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTGGTTAATTAAATAACTTCGTATAGCAT
ACATTATACGAAGTTATGGATCCGAACAAACGACCCAACACCCGTGCGTTTTATTCTGTC
TTTTTATTGCCGATCCCC NEOMYCIN: TCAGAAGAACTCGTCAAGAAGGCGATAGAAGG
CGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGCCC
ATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGG
TCCGCCACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCACCA
TGATATTCGGCAAGCAGGCATCGCCATGGGTCACGACGAGATCCTCGCCGTCGGGCAT
GCGCGCCTTGAGCCTGGCGAACAGTTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTC
CAGATCATCCTGATCGACAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCGAT
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GTTTCGCTTGGTGGTCGAATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGCAT
TGCATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCC
TGCCCCGGCACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAACGTCGA
GCACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGATAGCCGCGCTGCCTCGT
CCTGCAGTTCATTCAGGGCACCGGACAGGTCGGTCTTGACAAAAAGAACCGGGCGCCC
CTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCCAG
TCATAGCCGAATAGCCTCTCCACCCAAGCGGCCGGAGAACCTGCGTGCAATCCATCTT
GTTCAATGGCCGATCCCATATTGGCTGCAGGGTCGCTCGGTGTTCGAGGCCACACGCG
TCACCTTAATATGCGAAGTGGACCTGGGACCGCGCCGCCCCGACTGCATCTGCGTGTT
CGAATTCGCCAATGACAAGACGCTGGGCGGGGTTTGCTCGACATTGGGTGGAAACATT
CCAGGCCTGGGTGGAGAGGCTTTTTGCTTCCTCTTGCAAAACCACACTGCTCGACATTG
GGTGGAAACATTCCAGGCCTGGGTGGAGAGGCTTTTTGCTTCCTCTTGCAAAACCACAC
TGCTCGACTAGTGATTAAAGTCGACTCGGGGACACCAAATATGGCGATCTCGGCCTTTT
CGTTTCTTGGAGCTGGGACATGTTTGCCATCGATCCATCTACCACCAGAACGGCCGTTA
GATCTGCTGCCACCGTTGTTTCCACCGAAGAAACCACCGTTGCCGTAACCACCACGAC
GGTTGTTGCTAAAGAAGCTGCCACCGCCACGGCCACCGTTGTAGCCGCCGTTGTTGTT
ATTGTAGTTGCTCATGTTATTTCTGGCACTTCTTGGTTTTCCTCTTAAGTGAGGAGGAAC
ATAACCATTCTCGTTGTTGTCGTTGATGCTTAAATTTTGCACTTGTTCGCTCAGTTCAGC
CATAATATGAAATGCTTTTCTTGTTGTTCTTACGGAATACCACTTGCCACCTATCACCACA
ACTAACTTTTTCCCGTTCCTCCATCTCTTTTATATTTTTTTTCTCGAGGGATCTTTGTGAA
GGAACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCTC
TAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTG
TATTTTAGATTCCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAATG
AGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGAC
TCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTCCT
TCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTG
CTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATT
CTGTAACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTACTCC
ACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAGCTTT
TTAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGATCATA
ATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCC
CTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATA
ATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCA
TTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCTGACATGGT
AAGTAAGCTTATAACTTCGTATAGCATACATTATACGAAGTTATGGGCGCGCCACC PLS3
: ATGGATGAGATGGCTACCACTCAGATTTCCAAAGATGAGCTTGATGAACTCAAAGAGG
CCTTTGCAAAAGTTGATCTCAACAGCAACGGATTCATTTGTGACTATGAACTTCATGAGC
TCTTCAAGGAAGCTAATATGCCATTACCAGGATATAAAGTGAGAGAAATTATTCAGAAAC
TCATGCTGGATGGTGACAGGAATAAAGATGGGAAAATAAGTTTTGACGAATTTGTTTATA
TTTTTCAAGAGGTAAAAAGTAGTGATATTGCCAAGACCTTCCGCAAAGCAATCAACAGGA
AAGAAGGTATTTGTGCTCTGGGTGGAACTTCAGAGTTGTCCAGCGAAGGAACACAGCAT
TCTTACTCAGAGGAAGAAAAATATGCTTTTGTTAACTGGATAAACAAAGCTTTGGAAAAT
GATCCTGATTGTAGACATGTTATACCAATGAACCCTAACACCGATGACCTGTTCAAAGCT
GTTGGTGATGGAATTGTGCTTTGTAAAATGATTAACCTTTCAGTTCCTGATACCATTGAT
GAAAGAGCAATCAACAAGAAGAAACTTACACCCTTCATCATTCAGGAAAACTTGAACTTG
GCACTGAACTCTGCTTCTGCCATTGGGTGTCATGTTGTGAACATTGGTGCAGAAGATTT
GAGGGCTGGGAAACCTCATCTGGTTTTGGGACTGCTTTGGCAGATCATTAAGATCGGTT
TGTTCGCTGACATTGAATTAAGCAGGAATGAAGCCTTGGCTGCTTTACTCCGAGATGGT
GAGACTTTGGAGGAACTTATGAAATTGTCTCCAGAAGAGCTTCTGCTTAGATGGGCAAA
CTTTCATTTGGAAAACTCGGGCTGGCAAAAAATTAACAACTTTAGTGCTGACATCAAGGA
TTCCAAAGCCTATTTCCATCTTCTCAATCAAATCGCACCAAAAGGACAAAAGGAAGGTGA
ACCACGGATAGATATTAACATGTCAGGTTTCAATGAAACAGATGATTTGAAGAGAGCTGA
GAGTATGCTTCAACAAGCAGATAAATTAGGTTGCAGACAGTTTGTTACCCCTGCTGATGT
TGTCAGTGGAAACCCCAAACTCAACTTAGCTTTCGTGGCTAACCTGTTTAATAAATACCC
AGCACTAACTAAGCCAGAGAACCAGGATATTGACTGGACTCTATTAGAAGGAGAAACTC
GTGAAGAAAGAACCTTCCGTAACTGGATGAACTCTCTTGGTGTCAATCCTCACGTAAAC
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CATCTCTATGCTGACCTGCAAGATGCCCTGGTAATCTTACAGTTATATGAACGAATTAAA
GTTCCTGTTGACTGGAGTAAGGTTAATAAACCTCCATACCCGAAACTGGGAGCCAACAT
GAAAAAGCTAGAAAACTGCAACTATGCTGTTGAATTAGGGAAGCATCCTGCTAAATTCTC
CCTGGTTGGCATTGGAGGGCAAGACCTGAATGATGGGAACCAAACCCTGACTTTAGCTT
TAGTCTGGCAGCTGATGAGAAGATATACCCTCAATGTCCTGGAAGATCTTGGAGATGGT
CAGAAAGCCAATGACGACATCATTGTGAACTGGGTGAACAGAACGTTGAGTGAAGCTG
GAAAATCAACTTCCATTCAGAGTTTTAAGGACAAGACGATCAGCTCCAGTTTGGCAGTTG
TGGATTTAATTGATGCCATCCAGCCAGGCTGTATAAACTATGACCTTGTGAAGAGTGGC
AATCTAACAGAAGATGACAAGCACAATAATGCCAAGTATGCAGTGTCAATGGCTAGAAG
AATCGGAGCCAGAGTGTATGCTCTCCCTGAAGACCTTGTGGAAGTAAAGCCCAAGATG
GTCATGACTGTGTTTGCATGTTTGATGGGCAGGGGAATGAAGAGAGTG V5-TAG: AAGG
GCAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGCGGTT
CGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATC
ATCACCATCACCATTGAGGCGCGCCGCGGCCGCGATCAATTCGGTACCGAAGTTCCTA
TTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCCTCGAGGGTACCCCAATTCCGC
CCCCCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGT
TTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAAC
CTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATG
CAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAAC
AACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTC
TGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCC
ACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAAC
AAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTC
GGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCCGAACC
ACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACC GFP: ATGG
TGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACG
GCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCT
ACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCC
CACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCA
CCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAAC
ATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGA
CAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGC
AGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTG
CTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACG
AGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGG
CATGGACGAGCTGTACAAGTAATCCGGGATCCGGAGAGCTCCCAACGAAGTTCCTATTC
CGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCCTCGAGGTTGGATGCAGCCCGGGG
GATCCACTAGTTCTAGAGCGGCCGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCAT
CTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTC
CTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTG
GGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCA
TGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTC
GAGATCCACTAGTTCTAGCCTCGAGGCTAGAGCGGCCGCCGCGGATATCGAATTCG LO
NG HOMOLOGY ARM: ctagaagatgggcgggagtcttctgggcaggcttaaaggctaacctggtgtgtgggcgttgtc
ctgcaggggaattgaacaggtgtaaaattggagggacaagacttcccacagattttcggttttgtcgggaagttttttaataggggc
aaataggaaaatggaggatagggtcatctggggtttatgcagcaaaactacaggtatattgcttgtatccgcctcggagatttccat
gaggagataaagacatgtcacccgagtttatactctcctgcttagatcctactacagtatgaaatacagtgtgcgaggtagactatg
taagcagatttaatcattttaaagagcccagtacttcatatccatttctcccgctccttctgcagccttatcaaaaggtatttagaacact
cattttagccccattttcatttattatactggcttatccaacccctagacagagcattggcattttccctttcctgatcttagaagtctgatga
ctcatgaaaccagacagattagttacatacaccacaaatcgaggctgtagctggggcctcaacactgcagttcttttataactcctt
agtacactttttgttgatcctttgccttgatccttaattttcagtgtctatcacctctcccgtcaggtggtgttccacatttgggcctattctcag
tccagggagttttacaacaatagatgtattgagaatccaacctaaagcttaactttccactcccatgaatgcctctctcctttttctccatt
ataactgagctataccattaatggtttcaggtggatgtctcctcccccaatatacctgatgtatctacatattgccaggctgatattttaa
gacataaaggtatatttcattattgagccacatggtattgattactgctactaaaattttgtcattgtacacatctgtaaaaggtggttcctt
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ttggaatgcaaagttcaggtgtttgttgtctttcctgacctaaggtcttgtgagcttgtattttttctatttaagcagtgctttctcttggactgg
cttgactcatggcattctacacgttattgctggtctaaatgtgattttgccaagcttcttcaggacctataattttgcttgacttgtagccaa
acacaagtaaaatgattaagcaacaaatgtatttgtgaagcttggtttttaggttgttgtgttgtgtgtgcttgtgctctataataatactat
ccaggggctggagaggtggctcggagttcaagagcacagactgctcttccagaagtcctgagttcaattcccagcaaccacatg
gtggctcacaaccatctgtaatgggatctgatgccctcttctggtgtgtctgaagaccacaagtgtattcacattaaataaataatcct
ccttcttcttctttttttttttttaaagagaatctgtctccagtagaattactgaagtaatgaaatactttgtgtttgttccaatatggagccaat
aatcaaatactcttagcactggaaatgtaccaaggaactattttatttaagtgactgtggacagaggagccataactgcagacttgt
gggatacagaagaccaatgcagacttaatgtcttttctcttacactaagcaataaagaaataaaaattgaacttctagtatcctatttg
ttaaactgctagctttactaacttttgtgcttcatctatacaaagctgaaagctaagtctgcagccattactaaacatgaaagcaagta
atgataattttggatttcaaaaatgtagggccagagtttagccagccagtggtggtgcttgcctttatgccttaatcccagcactctgg
aggcagagacaggcagatctctgagtttgagcccagcctggtctacacatcaagttctatctaggatagccaggaatacacaca
gaaaccctgttggggaggggggctctgagatttcataaaattataattgaagcattccctaatgagccactatggatgtggctaaat
ccgtctacctttctgatgagatttgggtattattttttctgtctctgctgttggttgggtcttttgacactgtgggctttcttaaagcctccttccct
gccatgtggtctcttgtttgctactaacttcccatggcttaaatggcatggctttttgccttctaagggcagctgctgagtttgcagcctga
tttccagggtggggttgggaaatctttcaaacactaaaattgtcctttaatttttttttaaaaaatgggttatataataaacctcataaaat
agttatgaggagtgaggtggactaatattaatgagtccctcccctataaaagagctattaaggctttttgtcttatactaactttttttttaa
atgtggtatctttagaaccaagggtcttagagttttagtatacagaaactgttgcatcgcttaatcagattttctagtttcaaatccagag
aatccaaattcttcacagccaaagtcaaattaagaatttctgactttaatgttatttgctactgtgaatataaaatgatagcttttcctgag
gcagggtctcactatgtatctctgcctgatctgcaacaagatatgtagactaaagttctgcctgcttttgtctcctgaatactaaggttaa
aatgtagtaatacttttggaacttgcaggtcagattcttttataggggacacactaagggagcttgggtgatagttggtaaatgtgttta
agtgatgaaaacttgaattattatcaccgcaacctactttttaaaaaaaaaagccaggcctgttagagcatgctaagggatcccta
ggacttgctgagcacacaagagtagtacttggcaggctcctggtgagagcatatttcaaaaaacaaggcagacaaccaagaa
actacagtaaggttacctgtctttaaccatctgcatatacacagggatattaaaatattccaaataatatttcattcaagttttcccccat
caaattgggacatggatttctccggtgaataggcagagttggaaactaaacaaatgttggttttgtgatttgtgaaattgttttcaagtg
atagttaaagcccatgagatacagaacaaagctgctatttcgaggtctcttggttatactcagaagcacttctttgggtttccctgcact
atcctgatcatgtgctaggcctccttaggctgattgttgttcaaataacttaagtttcctgtcaggtgatgtcatatgatttcatatatcaag
gcaaaacatgttatatatgttaaacatttgacttaatgtgaaagttaggtctttgtgggttttgattttaatttcaaaacctgagctaaataa
gtcattttacatgtcttacatttggtgaattgtatattgtggtttgcaggcaagactctctgacctagtaaccctcctatagagcactttgct
gggtcacaagtctaggagtcaagcatttcaccttgaagttgagacgttttgttagtgtatactagttatatgttggaggacatgtttatcc
agaagatattcaggactatttttgactgggctaaggaattgattctgattagcactgttagtgagcattgagtggcctttaggcttgaatt
ggagtcacttgtatatctcaaataatgctggccttttttaaaagcccttgttctttatcaccctgttttctacataatttttgttcaaagaaata
cttgtttggatctccttttgacaacaatagcatgttttcaagccatattttttttcctttttttttttttttttggtttttcgagacagggtttctctgtata
gccctggctgtcctggaactcactttgtagaccaggctggcctcgaactcagaaatccgcctgcctctgcctcctgagtgccgggat
taaaggcgtgcaccaccacgcctggctaagttggatattttgtatataactataaccaatactaactccactgggtggatttttaattca
gtcagtagtcttaagtggtctttattggcccttattaaaatctactgttcactctaacagaggctgttggactagtggactaagcaacttc
ctacggatatactagcagataagggtcagggatagaaactagtctagcgttttgtatacctaccagcttatactaccttgttctgatag
aaatatttaggacatctagcttatcgatccgtcgacggtatcgataagcttgatatcgaattctaccgggtaggggaggcgcttttcc
aaggcagtctgagcatgcgcttagcagccccgctggcacttggcgctacacaagtggccttggcctcgcacacattccacatcca
ccggtaggcgccaaccggctccgttctttggtggccccttcgcgccaccttctctcctcccctagtcaggaagttcccccccgcccc
gcagctcgcgtcgtaggacgtgacaaatggaagtagcacgtctcactagtctcgtcagatggacagcaccgctgagcaatgga
agcgggtaggcctttggggcagcggccaatagcagctttgctccttcgctttctgggctcagaggctgggaaggggtgggtccgg
gggcgggctcaggggcgggctcaggggcggggcgggcgcccgaaggtcctccggaggcccggcattctgcacgcttcaaaa
gcgcacgtctgccgcgctgttctcctcttcctcatctccgggcctttcgacctgcaggtcctcgccatggatcctgatgatgttgttattct
tctaatcttttgtatggaaaacttttcttcgtaccacgggactaaacctggttatgtagattccattcaaaaaggtatacaaaagccaa
aatctggtacacaaggaaattatgacgatgattggaaagggttttatagtaccgacaataaatacgacgctgcgggatactctgta
gataatgaaaacccgctctctggaaaagctggaggcgtggtcaaagtgacgtatccaggactgacgaaggttctcgcactaaa
agtggataatgccgaaactattaagaaagagttaggtttaagtctcactgaaccgttgatggagcaagtcggaacggaagagttt
atcaaaaggttcggtgatggtgcttcgcgtgtagtgctcagccttcccttcgctgaggggagttctagcgttgaatatattaataactg
ggaacaggcgaaagcgttaagcgtagaacttgagattaattttgaaacccgtggaaaacgtggccaagatgcgatgtatgagta
tatggctcaagcctgtgcaggaaatcgtgtcaggcgatctctttgtgaaggaaccttacttctgtggtgtgacataattggacaaact
acctacagagatttaaagctctaaggtaaatataaaatttttaagtgtataatgtgttaaactactgattctaattgtttgtgtattttagatt
ccaacctatggaactgatgaatgggagcagtggtggaatgcagatcctagagctcgctgatcagcctcgactgtgccttctagttg
ccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaa
ttgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaagacaa
tagcaggcatgctggggatgcggtgggctctatggcttctgaggcggaaagaaccagctggggctcgacctcgagggggggcc
cgcggccgccctgcagggcgatcgctacgtacagcttttgttccctttagtgagggttaattgcgcgcttggcgtaatcatggtcata
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gctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgccta
atgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatc
ggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctg
cggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgag
caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcat
cacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccct
cgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacg
ctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctta
tccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagag
cgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctc
tgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgc
aagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaa
aactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatc
taaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatcca
tagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagac
ccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatc
cgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctac
aggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgt
tgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagc
actgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatg
cggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaa
aacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttc
agcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacac
ggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtat
ttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctaaattgtaagcgttaatattttgttaaaattcg
cgttaaatttttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatcccttataaatcaaaagaatagaccgagat
agggttgagtgttgttccagtttggaacaagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgtctat
cagggcgatggcccactacgtgaaccatcaccctaatcaagttttttggggtcgaggtgccgtaaagcactaaatcggaacccta
aagggagcccccgatttagagcttgacggggaaagccggcgaacgtggcgagaaaggaagggaagaaagcgaaaggag
cgggcgctagggcgctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatgcgccgctacaggg
cgcgtcccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctattacgccagctggcgaaa
gggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacgacgttgtaaaacgacggccagtgagcgc
gcgtaatacgactcactatagggcgaattggagct 
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